STATE OF MINNESOTA COUNTY OF HENNEPIN

DISTRICT COURT FOURTH JUDICIAL DISTRICT Medical Malpractice/Wrongful Death Court File No. 27-CV-07-1679 Judge John L. Holahan

Mary Weiss, on her own behalf, and as next of kin and Trustee of the estate of Dan Markingson, deceased, Plaintiff,
VS.

Board of Regents For the University of Minnesota; Dr. Stephen Olson; Dr. Charles Schultz; Institutional Review Board for the University of Minnesota; Astrazeneca Pharmaceuticals LP; Astrazeneca LP; and Zeneca, Defendants.

DEFENDANTS DR. STEPHEN OLSON'S AND DR. CHARLES SCHULZ'S AND THE UNIVERSITY OF MINNESOTA PHYSICIANS' DISCLOSURE OF FINDINGS AND OPINIONS OF EXPERT WITNESS IRA D. GLICK, M.D.

It is expected that Ira D. Glick, M.D., a medical doctor and psychiatrist duly licensed to practice medicine in the States of New York, California and Maryland, will be called to testify as an expert witness at the time of trial. A copy of his Curriculum Vitae is attached as Exhibit "A" which sets forth information pertaining to his background, education, training, hospital appointments, board certification, licensure, professional affiliations, honors/awards, publications and presentations. Dr. Glick has reviewed the following documents and case-related materials: 1. Copies of the medical charts and records of Dan Markingson, also known as Daniel Weiss, deceased, from the following healthcare providers: a. b. c. d. e. f. g. h. Fairview University Medical Center; Minnesota Regional Coroner's Office; Regions Hospital; Theodore I Residence/Boston Health Care Systems; Dr. Victor Amira; Children's Health of St. Paul; Group Health/HealthPartners; Dr. Joseph Gryskiewicz;

i. j. k. 1. m. 2.

University Health Service, Ann Arbor; University of Minnesota, Department of Psychiatry; Dakota County; Eagan Counseling Clinic; Pharmerica;

In addition to medical records, Dr. Glick has reviewed the following materials and information regarding this matter: n. o. P. q. r. s. t. u. v. w. x. y. z. aa. bb. cc. dd. ee. ff. gg. hh. 11. Deposition transcript of Dr. Olson; Deposition transcript of Dr. Schulz; Deposition transcript of Mary Weiss; Deposition transcript of Mike Howard; Deposition transcript of Dr. Arlow Andersen; Deposition transcript of David Pettit; Deposition transcript of Stacy Hohler; Deposition transcript of April Arnold; Deposition transcript of Daniel Buse; Expert Disclosures of James I. Hudson, M.D. and Harrison G. Pope, M.D., Keith A. Horton, M.D., Paul Root Wolpe, Ph.D., and Donald L. Frankenfeld, Economist. E-mails written by Dan Markingson to his mother, Mary Weiss; Investigative report of the Office of the Ombudsman; and Report of Department of Health & Human Services. July 22, 2005 Establishment and Inspection Report by the FDA written by Sharon L. Matson, Investigator. Informed Consent Document. Pre-petition Screening Team Recommendations dated November 14, 2003. Order to Confine, to Transport for Examination, Hearing, Appointment of Attorney, Examiner and Notice by Judge Edward Lynch dated November 17, 2003. Adult Consent Form for CAF Study Participation signed on November 21, 2003. Findings of Fact, Conclusions of Law, and Order for Stay of Commitment by Judge Robert F. Carolan dated November 20, 2003. Various correspondences written by Mary Weiss. Letters written back to Mary Weiss from a variety of individuals. Journals kept by Mr. Markingson. The American Journal of Psychiatry July 2007, published results on the Caf Study.

Dr. Glick is expected to testify at trial on issues of the standard of care, causation, damages, and the nature, extent and duration of Dan Markingson's medical condition. He will also respond to any and all findings and opinions expressed by each and every one of the Plaintiff's medical experts.

Dr. Glick's testimony will be based upon his education, training and experience, as well as his understanding of the medical teachings and practices which pertain to the issues presented in this case. In formulating his findings and opinions, he has reviewed and taken into consideration Mr. Markingson's medical records, information and additional discovery materials provided to him for his review as listed above. All of Dr. Glick's opinions will be stated to a reasonable degree of medical and psychiatric certainty, unless otherwise specified. Dr. Glick is expected to testify that that Dr. Stephen Olson and Dr. Charles Schulz both provided reasonable and appropriate care and treatment to Mr. Markingson. He will opine that each one of them satisfied the standard of care applied to them as physicians in their individual roles, as study investigators, and in the case of Dr. Schulz, as the head of the Department of Psychiatry at the University of Minnesota. Dr. Glick will testify that Mr. Markingson's participation in the CAFE Study in conjunction with all of the additional care and treatment he was receiving through Theodore I House, adult group therapy at the Fairview Day Treatment Center, individual therapy with Dr. Arlow Andersen, and monitoring by David Pettit of Dakota County was reasonable and appropriate care and treatment for Mr. Markingson. Dr. Glick is also expected to testify that the care and treatment rendered to Mr. Markingson by Dr. Olson and Dr. Schulz did not cause or contribute to Mr. Markingson's suicide and ultimate death.
Factual Background

Daniel Weiss was born on November 25, 1976. He was the only son of Mary Weiss and Tom Rosner, who never married. Ms. Weiss raised her son as a single parent. Mr. Markingson did not have a relationship with his biological father. It does not appear that Mr. Markingson had a strong male influence in his life during his formative years. Beginning in approximately 1983, Mr. Markingson was seen repeatedly throughout his childhood for complaints of headaches. His medical records reflect the fact that the source of his headaches may have been stress-related. On October 3, 1984, counseling was recommended to Ms. Weiss for her son's ongoing headache complaints. The same recommendation again occurred on January 29, 1985. It does not appear that Mr. Markingson received the counseling that was recommended. From April 1986 through 1992, Ms. Weiss had her son seen many times for headache complaints. He received neurology, relaxation therapy, chiropractic care, saw an ophthalmologist and also saw allergists to determine the source of the headaches. A neurologist suggested to Ms. Weiss that the source of the headaches were muscle contraction, i.e., stress. In August 1989, Mr. Markingson was placed on amitriptyline, brand name Elavil. Elavil is often prescribed for the relief of symptoms of mental depression. It is a member of the group of drugs called tricyclic antidepressants. It is unclear, based on the records, why Mr. Markingson was placed on this medication. It appears that Mr. Markingson may have remained on Elavil throughout his high school years.

Mr. Markingson completed his high school education and then took one year off to write a book and/or screenplay. Thereafter, he attended Hamline University for his freshman and sophomore years. He transferred to the University of Michigan where he completed his studies in 2000, and received a B.A. in English. In the late summer or early fall of 2000, Mr. Markingson moved to Los Angeles, California. The records reflect that Mr. Markingson's intended career path was to become an actor and/or writer. When he first arrived in Los Angeles, he worked a series of odd jobs, which included selling papers for the L.A. Times and doing office work in an accountant's office. The only steady job he held was at Star Line Tours as a tour guide. He was employed there from February 15, 2002 through August 2003. Initially, he worked full time at Star Line Tours, but changed his status to part time in early 2003. It is believed Mr. Markingson unexpectedly resigned from that position in August 2003. Ms. Weiss visited her son shortly after he moved to California in 2000. However, according to Ms. Weiss, their relationship completely changed after that visit. Ms. Weiss described the fact that her relationship with Mr. Markingson "totally deteriorated." He stopped calling her and he stopped writing to her. She described the fact that after that visit, coim-nunication between herself and her son completely ended. During Mr. Markingson's residency in California, he changed his last name from Weiss to Markingson. It is unknown why Mr. Markingson chose to change his last name. Ms. Weiss went to California in August 2003 to attempt to reconnect with her son. When she went out to Los Angeles, she had difficulty finding him and had to contact his employer to discern his whereabouts. Ultimately, Ms. Weiss was able to find her son and, after some time, convince him to return to Minnesota. Ms. Weiss testified that upon seeing her son during this initial visit to Los Angeles, she believed that he was mentally ill. He made comments about the fact that there would be an event that was going to occur, that people were watching him, and that there were aliens present in his home. He also commented that he may be called upon to harm people prior to his return to Minnesota Upon his return to Minnesota, Ms. Weiss arranged for her son to be seen at Group Health/HealtliPartners, This visit occurred on September 4, 2003. Prior to the visit, Ms. Weiss had called the office to report that her son had been experiencing memory loss and weight loss. A physical examination was conducted which appeared to be normal. Mr. Markingson also underwent laboratory tests. Those results showed a slightly underactive thyroid. Mr. Markingson's mental health was not specifically addressed at that visit. Mr. Markingson did not see a psychiatrist, psychologist, therapist, or any other mental healthcare provider at that time. The records reflect that on or about September 9, 2003, Mr. Markingson returned to California. After his return to California, Mr. Markingson began exchanging e-mails with "Guardian Angel Daisy@ hotmail.com " and "Michael the Archangell@hotmail.com ." These emails were exchanged from September 19 through September 23, 2003. Ms. Weiss assumed the identity of "Guardian Angel Daisy" and "Michael the Archangel" and exchanged these e-mails with Mr. Markingson. It is unknown whether or not Mr. Markingson knew that his mother was the author of these e-mails. In the context of these e-mails, Mr. Markingson discussed an event

that was purportedly going to occur in Duluth where he may be called upon to kill certain individuals. It was the promise of this "big event" that prompted Mr. Markingson to return to Minnesota. Mr. Markingson returned to Minnesota and moved into his mother's home, where she resided with a male companion. Purportedly, Mr. Markingson spent the majority of his days alone in his childhood room. According to his mother and her companion, he continued to exhibit what they believed to be delusional and paranoid behavior. He would repeatedly make reference to the "big event," "being the chosen one," and his belief that there were references being made about him on television. From the time of Mr. Markingson's return to Minnesota in late September 2003, up until November 12, 2003, he did not see a psychologist, psychiatrist, therapist, or a physician for his mental health condition. Purportedly, on November 12, 2003, Mr. Markingson told Ms. Weiss' companion, Michael Howard, that he intended to slit his mother's throat. This threat prompted Ms. Weiss and Mr. Howard to contact the police via 911. Mr. Markingson was transported in handcuffs from Ms. Weiss's home to Regions Hospital. The police report indicates that Mr. Markingson was aggressive verbally at his mother's home and indicated that he was unwilling to go to the hospital. However, Mr. Markingson calmed down prior to his arrival at Regions Hospital.
Hospitalization

Mr. Markingson was originally transported to Regions Hospital emergently. A history was taken from his mother by a social worker about Mr. Markingson's current mental health condition and history. She reported that Mr. Markingson had been discussing a "big event" that was satanic in nature. She reported that he had made threats to cause her harm on the day of his transport to the hospital. Mr. Markingson originally denied making these threats, but later acknowledged that he may be contacted in the future to do so as a result of the upcoming "big event." He stated that he would decide whether or not to follow through. He also denied any suicidal ideation or thoughts of harming others. The initial intake at Regions Hospital was done by Dr. Darren Manthey and Dr. Bradley Hernandez. They determined that Mr. Markingson was paranoid, delusional, grandiose and threatening to harm others. Due to a space issue and a stated family preference, Mr. Markingson was transferred to Fairview University Medical Center ("FUMC"). Mr. Markingson was admitted to FUMC on a 72-hour hold by resident, Dr. John Darling. Prior to his admission to the psychiatric ward at FUMC, Drs. Darling and Olson took a history and performed an examination of Mr. Markingson. Dr. Olson verified Dr. Darling's findings and signed off on them as the attending psychiatrist. Drs. Darling and Olson found that the patient's eye contact was good, but intense at times. His mood was noted to be "good," and his affect was bright, and at times expansive. Drs. Darling and Olson found that his thought process was coherent and linear. Drs. Darling and Olson also found that the patient's thought content was positive for delusions, paranoia and ideas of reference. Mr. Markingson's insight and judgment were noted to be impaired by his significant delusional framework. Drs. Darling's and Olson's initial impression was that Mr. Markingson had a recent onset of multiple delusions and psychotic symptoms that had been developing in recent months. Drs. Darling's and Olson's

diagnosis was psychosis and mood disorder, to rule out bipolar affective disorder, psychosis and schizophrenia. On November 13, 2003, Dr. Olson wrote his admission note for Mr. Markingson. The basis of the information contained in that note came from both Mr. Markingson himself, as well as his mother. Mr. Markingson acknowledged at that time that he did have some unusual beliefs, but attributed them to a lack of sleep and anxiety. Ms. Weiss advised Dr. Olson that she had had very little contact with her son over the last year and a half Ms. Weiss also informed Dr. Olson she recently exchanged e-mails with her son using false identities. Dr. Olson's notes reflect that Mr. Markingson appeared to be downplaying his psychosis and trying to present himself in the best possible light. Dr. Olson's diagnosis for Axis I. was Psychosis NOS, and a differential diagnosis to include paranoid schizophrenia, schizoaffective disorder, and bipolar disorder with manic psychosis. Dr. Olson noted that the patient had an extended period of deterioration and elaborate, disorganized and fragmentary delusional thinking suggestive of paranoid schizophrenia. However, Dr. Olson could not rule out bipolar disorder given the patient's claim of a sleep disorder and increased level of self-esteem. The 72-hour hold was to remain in place and Dr. Olson prescribed Risperdal for the patient. Mr. Markingson initially refused to take Risperdal. On November 14, 2003, Mr. Markingson met with the pre-petition screening team. At that point in time, it was noted that the patient did not have the capacity to make decisions regarding neuroleptic medication, and a Jarvis petition was being considered. During the interview, Mr. Markingson advised the screening team that he would be willing to be a voluntary patient and follow his physician's recommendations, but that he did not want to take any neuroleptic medication. Dr. Olson also spoke to the pre-petition screening team, and advised them that the patient had bizarre beliefs and lacked insight into the cause of those beliefs. There was also concern about whether the patient would follow through without patient care or whether an admission to an inpatient facility would be necessary. Commitment was ultimately recommended by the screening team and Dr. Olson. In conjunction with the recommendation of the screening team for commitment, Dr. Olson wrote an examiner's statement in support of the petition for commitment. This was written on November 14, 2003. Dr. Olson described the history of the bizarre thinking of the patient and his threats to harm his mother. Dr. Olson advised the court that the development of the delusional thinking appeared to have occurred in the last 6-18 months and that the patient lacked a prior history of psychosis. He also reported to the court that the patient lacked insight into the causation of his delusional thinking. Dr. Olson advised the court that his diagnostic impressions and conclusions were that the patient had psychosis NOS; paranoid schizophrenia versus psychiatric mania versus psychosis due to a medical condition. In Dr. Olson's opinion at that time, Mr. Markingson was at high risk for acting on his delusions. This was submitted to the court, along with the pre-petition screening team's recommendation for commitment. According to a progress note written by Dr. Olson at 5:00 p.m. on November 14, he met with Mr. Markingson and filled out the examiner's statement in support of the petition for commitment. This note reflects that on the evening of November 13, 2003, Mr. Markingson agreed to take the prescribed anti-psychotic medication Risperdal. Thus, his medication use

started at that time. Also, during Dr. Olson's meeting with Mr. Markingson, he admitted that his unusual beliefs had gone on longer than he had originally acknowledged, but would not reveal for how long. He also continued to deny some of the history that had been reported by his mother. However, he did admit that he had been concerned about a satanic cult, his mother's identity, being "the one," and having Angelina Jolie as his sister. Overall, Dr. Olson noted that the patient appeared to be minimizing his past thoughts, and that his insight and judgment were impaired. Dr. Olson questioned whether or not Mr. Markingson was sincere about voluntarily agreeing to seek treatment. Thus, he was of the opinion that going forward with the commitment would be appropriate and that a Jarvis hearing may be necessary if the patient did not continue to be medication compliant. On November 17, 2003, a Dakota County District Court Judge set forth an Order to Confine, to Transport for Examination, Hearing, Appointment of Attorney, Examiner and Notice. The petition was brought by Kathryn Knight for judicial commitment of Daniel Markingson as a mentally ill person. The judge ordered that FUMC was to retain custody of Mr. Markingson for observation, evaluation, diagnosis and emergency treatment. A Jarvis petition was not sought because Mr. Markingson had remained compliant and was taking his Risperdal as prescribed. After taking the medication for several days, Mr. Markingson's case manager and therapist, Kathleen Bernhaft, wrote the treating physician's recommendations to the court. The recommendation of FUMC and Dr. Olson was that a stay of commitment would be appropriate. The reason being that Mr. Markingson had been cooperative with his inpatient treatment and was in the process of developing an aftercare plan. Further, Mr. Markingson had been medication compliant. The diagnosis at that time was psychosis NOS, mood disorder NOS, rule out bipolar affective disorder with psychosis and schizophrenia. Erin Holker, Ph.D. LP at FUMC performed a neuropsychological evaluation of Mr. Markingson on November 18, 2003. Testing was done to determine Mr. Markingson's intellectual functioning level and his cognitive impairment, if any. The testing revealed that Mr. Markingson's overall intellectual functioning was in the superior range. Moreover, no cognitive difficulties were noted which could potentially interfere with Mr. Markingson's ability to actively participate in his own care and treatment. Mr. Markingson told Dr. Holker of his desire to continue the use of Risperdal and that he was committed to participating in his care and treatment. On November 19, 2003, Dr. Olson discussed the CAFE Study with Mr. Markingson and his mother. According to his November 19 note, both Mr. Markingson and his mother were interested in the Study. Dr. Olson provided them both with materials for their review and consideration. Assessment of informed consent was not limited to this single session. This was an ongoing process during Mr. Markingson's hospitalization. Dr. Olson continued to assess his ability to understand the information presented to him. Dr. Olson also continued to present information to Mr. Markingson about alternative care options. Dr. James Jacobson conducted an examination of Mr. Markingson on November 19, 2003, pursuant to the court's order. Dr. Jacobson's diagnosis for Axis I of Markingson was

psychosis, NOS, rule out mood disorder, NOS, rule out bipolar disorder with psychosis versus rule out schizophrenia. Dr. Jacobson took a history and performed an exam on Mr. Markingson. Dr. Jacobson found that Mr. Markingson was fully oriented and that his thinking was logical and goal directed. He did not appear to be delusional, but did admit having peculiar thoughts in the past. He expressed to Dr. Jacobson his consent to the stay of commitment. Dr. Jacobson's recommendation to the court was that Mr. Markingson remain hospitalized for continued evaluation to ensure that his recent mental health improvements continued. He also recommended that a commitment or a stay of commitment would be appropriate for Mr. Markingson. A Jarvis hearing was not recommended by Dr. Jacobson because Mr. Markingson was compliant with his medication and he agreed to continue to take his medication. On November 20, 2003, Mr. Markingson appeared in court. During this proceeding, he was represented by an attorney. At that time, Mr. Markingson indicated that he voluntarily was agreeing to a stay of commitment. He admitted to being mentally ill and in need of treatment. The commitment was to be stayed for six months with a list of terms that included: "(a) that the respondent remain hospitalized, cooperative with the treatment plan at Fairview University Medical Center until medically discharged, and follow all of the aftercare recommendations of the treatment team; (b) that the respondent enter, participate in and satisfactorily complete the inpatient/outpatient treatment program and aftercare recommendations as determined by his social worker; (c) that the respondent cooperate with the treatment plan and follow the rules at any living facility as arranged by his social worker; (d) that the respondent consent to admission or re-admission to a hospital or other appropriate care facility as determined by the respondent's social worker in the event of a relapse; (e) that the respondent take drugs or medications only as prescribed, and abstain from the use of any non-prescribed drugs or alcohol; (f) that the respondent see a psychiatrist and/or therapist as frequently as recommended; (g) that the respondent engage in no behavior which is threatening or injurious to self or others; (h) that the respondent participate in any day treatment program or community support services; (i) that the respondent participate in family therapy if recommended; (j) that the respondent sign releases of information authorizing his social worker and the various service providers to exchange information; and (k) that the respondent cooperate with his social worker as determined." On November 21, 2003, Mr. Markingson agreed to participate in the Cafe Study. Prior to signing the informed consent, he underwent an evaluation with Jeanne Kenny, a Study coordinator, and Liz Lemke, an assistant working on the Study. Mr. Markingson passed the evaluation and was able to provide information about potential side effects, things expected of him, and his right to withdraw from the Study at any point in time. Thereafter, Mr. Markingson read the consent form, had the consent form read to him, and signed the consent form in the presence of Dr. Olson and Ms. Kenney. The informed consent set forth the purpose of the Study, the Study sponsor, Mr. Markingson's right to withdraw from the Study at any time, and alternative care and treatment available to Mr. Markingson, Mr. Markingson had the opportunity to ask any questions and raise any concerns prior to signing the information consent. Ultimately, he agreed to participate and signed. Despite signing the informed consent to participate in the CAF Study, Mr. Markingson did not begin the medication for that Study until December 5, 2003. He continued on Risperdal. He was slowly tapered off the Risperdal after December 5, 2003.

Mr. Markingson's first screening visit for the CAF Study occurred on November 24, 2003. A history of Mr. Markingson's onset of his mental illness was taken at that point in time. It was noted that the medication he was taking at the time of that visit was Risperdal and Ativan pm. The diagnosis was schizophrenia paranoid type, to rule out psychosis NOS and schizophreniform. It was noted that the patient did in fact meet the criteria for schizophrenia, and therefore did meet the diagnostic criteria for the trial. By November 25, 2005, Mr. Markingson was noted to be tolerating his Risperdal without difficulty. He also appeared to be gaining more insight into his prior delusional and paranoid behavior. Mr. Markingson reported at that point in time that he was having tension with his mother and was noted to be upset with her for her decision to not allow him to reside in her home post discharge. On November 26, 2003, Mr. Markingson met for the first time with his case manager and/or assigned social worker from Dakota County, David Pettit. During this meeting, Mr. Pettit met with Dr. Olson, Ms. Weiss and Mr. Markingson. At that point in time, Dr. Olson presented the CAFE Study to Mr. Pettit for his review and consideration. Mr. Pettit acknowledged that he believed that the care and treatment provided in the CAFE Study was reasonable and appropriate. He also stated that in his opinion, this provided Mr. Markingson with more interaction with his medical care providers than if he was discharged in the normal fashion. Ultimately, Mr. Pettit agreed to allow Mr. Markingson to participate in the CAFE Study. On December 3, 2003, Dr. Olson did an additional assessment of Mr. Markingson for the CAFE Study. Mr. Markingson indicated that he was working on being comfortable with the fact that he had psychosis. He also indicated a willingness to move to a group home. Once again, Mr. Markingson consented to treatment and to his participation in the CAFE Study. On December 8, 2003, Mr. Markingson was discharged from FUMC. He was being transferred to Theodore I House run by Boston Health Care Systems. The Theodore I House ("Theo House") at the time was a Rule 36 facility with around-the-clock staff. The decision to have Mr. Markingson at this facility was based upon the recommendations of Mr. Pettit. Dr. Olson's discharge diagnosis on December 8, 2003, was psychosis NOS, probable schizophrenia, and questionable history of alcohol abuse versus dependence. Mr. Markingson was noted to have mild hypothyroidism and had been placed on Synthroid. Over the course of Mr. Markingson's hospitalization, Dr. Olson became aware of the fact that he and his mother had a stressful relationship. Further, according to the history provided by Ms. Weiss, she and her son had not had contact for a substantial period of time. Dr. Olson noted that throughout Mr. Markingson's hospitalization, he remained guarded and superficial, although he did admit to having unusual and delusional thoughts. Dr. Olson also noted that Mr. Markingson continued to minimize his mental illness and the events leading up to his hospitalization.

CAF Study

The CAF Study was a 52 week randomized, double-blind, flexible dose multicenter study to evaluate the overall effectiveness, as measured by discontinuation rates of Olanzapine, Quetiapine and Risperidone in patients early in the course of psychotic illness. There were 24 sites throughout the United States where the CAFE Study was conducted. Joseph P. McEvoy and Jeffrey Lieberman served as the head research physicians of the Study. The Study was sponsored by Astrazeneca Pharmaceutical Company. A total of 400 patients were randomly assigned to treatment with one of the three drugs. The University of Minnesota was one of the site locations. Dr. Olson served as the principal investigator at the University of Minnesota site, with Dr. S. Charles Schulz and Dr. John Vuchetich serving as co-investigators. The CAF Study was modeled after the CATIE Study that had been conducted by the National Institute of Mental Health (NIMH). That Study was conducted to determine the longterms effects and usefulness of antipsychotic medications in persons with schizophrenia. The Study tested the anti-psychotic medications Olanzapine, Quetiapine, Risperidone, Clozapine and Ziprasidone, as well as Perphenazine and Fluphenazine Decanoate. The CATIE Study lasted for approximately 18 months. The majority of sites which conducted the CAFE Study, also participated in the CATIE Study. The CAFE Study was set up to mimic real-world clinical care. That is a distinct difference in the CAFE Study from other types of clinical research. Mr. Markingson attended 11 visits during his participation in the Caf Study. The summary of assessment ratings for the CAFE visits, was as follows:
SUMMARY OF ASSESSMENT RA
Date and Visit # Screen 11/24/03 Baseline 12/5/03 Visit 1 12/11/03 Visit 2 12/19/03 Visit 3 12124103 Visit 4 12/31/03 Visit 5 1/8/04 Visit 6 1/16/04 Visit 7 1/30/04 Visit 8 2/13/04 Visit 9 3/2/04 Visit 10 3/31/04 Visit 11 4/28/04

PANSS Positive Symptoms Negative Symptoms Calgary Depression Rating Scale * Suicide Sub-rating Positive and Negative Syndrome Scale Clinical Global Impressions Adverse Event/Side Effects Abnormal Involuntary Movement Scale Barnes Rating for Drug Induced Akathisia Simpson Angus Abbrev Medication Adherence Alcohol/Drug Use Scale Health Care Service Utilization Heinrich Carpenter Quality of Life Insight and Treatment Attitude 23 not complete 5 44 4 None 0 0 0 1abstinent 32 98 16 13 11 10 7 11 9 - absent I 40 3 None 0 0 0 9 12 10 9 1 45 3 None 0 0 0 8 9 2 3sleepiness 10 7 9 1 40 3sleepiness 0 0 0 8 1abstinent 30 9 2 None 7 9 9 I 35 2 None 0 0 0 8 2alcohol 32 7 7 9 1 32 2 2 sleepiness 2- insomnia 0 0 0 9 8 8 1 abstinent 30 92 22 7 9 9 1 35 2 None 7 10 9 1 36 2 None 0 13 20 9 1 52 4 None 0 0 0 8 1abstinent 34 10 18 9 1 55 3 None 0 0 1 8 2 alcohol 27

10

These rating scales demonstrate an improvement in the positive symptoms of schizophrenia seen with treatment and the low level of schizophrenia and depressive symptoms throughout the duration of the Study. The positive and negative scales have 30 items grouped into positive, negative and general subscales. The November 24, 2003 screening retrospective rating of 5 selected positive symptom items totaled 23, indicative of moderately severe symptomology (23/5 = 4.6; 4 = moderate, 5=moderate severe). However, by the time of the baseline ratings, Mr. Markingson's score on the full 7-item subscale had dropped to 13 and remained in the range of 7-13 for the entire six months prior to his death. His scores of 7-13 represent a near total resolution of psychosis showing a marked improvement. Further, these scores reflect that Mr. Markingson's delusional thoughts, hallucinations and paranoia were nearly totally absent. The PANSS Ratings had minimum scores of 7 for positive and negative subscales and 16 for the general symptom subscale. Mr. Markingson's negative subscales scores increased from 11 at his baseline visit to 18-20 by visits 10 and 11; his general scores went from 20 at baseline to 26-28 at visits 10 and 11. These scores are in the minimal to mild range, and as reflected in the clinical notes, a moderate deterioration in self-care and grooming. In general, antipsychotic medications exert their therapeutic benefit almost exclusively on positive symptoms, and there is no requirement to change medication due to an increase in negative symptoms. The medication that Mr. Markingson was assigned in the Study was learned after his death to be Seroquel, also known as Quetiapine. Each capsule of the Study medication contained 100 mg of Quetiapine. The maximal dose was 8 capsules per day, corresponding to a total maximum dose of 800 mg. From December 5, 2003 to December 10, 2003, Mr. Markingson was taking two pills per day. From December 11, 2003 to December 13, 2003, he was taking a total of four pills per day. From December 14, 2003 to December 19, 2003, he was taking a total of five pills per day. From December 20, 2003 through March 31, 2004, Mr. Markingson was taking a total of 7 pills per day. From April 1, 2004 onward, he was taking a total of 8 pills per day. At that point, he reached the maximum dose of 800 mg. of Seroquel.
1. Dr. Olson

Dr. Olson provided care and treatment to Mr. Markingson throughout the course of his hospitalization. In addition, Dr. Olson saw Mr. Markingson after his discharge. His documented visits with Mr. Markingson occurred on December 11 and 19, March 2 and 31, and April 9. All of these visits were very lengthy; 30 minutes to one hour. Dr. Olson also recalled speaking with Mr. Markingson at his January 30, 2004 visit. This meeting lasted 15 minutes to one-half hour. Therein, Dr. Olson addressed concerns about Mr. Markingson's medication compliance. He advised Mr. Markingson about the importance of medication and what could happen if he stopped. In addition, Dr. Olson was present at several visits that were conducted by Jeanne Kenney. Ms. Kenney was the Study coordinator who had been trained to do the necessary testing for the Study. At those visits where Mr. Markingson was evaluated by Ms. Kenney, she performed symptom ratings, side effect assessments, psychosocial education sessions, and other components of the Study. Dr. Olson testified that he often came in midway through those visits

11

with Ms. Kenney and Mr. Markingson. When this occurred, Dr. Olson would examine Mr. Markingson and assess his condition. He would provide appropriate direction to Ms. Kenney about Mr. Markingson's assessment, medication and ongoing needs. In addition, Dr. Olson and Ms. Kenney would discuss all of her findings and the progress of Mr. Markingson. This would occur while Mr. Markingson was still at FUMC/ARC. Ms. Kenney and Dr. Olson would discuss whether or not Mr. Markingson was showing signs of relapse, possible side effects, or if there was any other major problem that had presented. Dr. Olson noted that he was available at all times to see Mr. Markingson if such a problem arose. Mr. Markingson was also participating in a day treatment program at FUMC. The multidisciplinary team at the day treatment facility met monthly to discuss clients. Dr. Olson participated in those monthly meetings. During those monthly meetings, Dr. Olson and the day treatment team would discuss Mr. Markingson's behavior and progress. Dr. Olson also recalls having 2-3 private conversations with Dan Buse, Mr. Markingson's primary therapist in the day treatment program, regarding Mr. Markingson's mental state, progress and his mother's concern about his ongoing alleged psychosis.
2.

Dr. Charles Schulz

Dr. Schulz saw Dr. Markingson on one occasion during his hospitalization at FUMC. That visit occurred on November 29, 2003. Dr. Schulz had reviewed Mr. Markingson' s medical chart and interviewed him. Mr. Markingson was also examined by Dr. Schulz. Dr. Schulz found that the patient's thought process was logical, his mood was pleasant, and that his affect was appropriate. Dr. Schulz, as a co-investigator in the CAF Study, did not have any one-on-one visits or evaluations with Mr. Markingson. He received one letter from the patient's mother, Mary Weiss, although she claims to have sent him a total of three letters. After receiving that letter from Ms. Weiss, Dr. Schulz investigated her concerns. Dr. Schulz met with Dr. Olson and Jeanne Kenney to discuss Mr. Markingson's involvement in the CAFE Study. That conversation included a review of Mr. Markingson's progress, medication use, and overall mental health. Dr. Schulz then crafted a response to Ms. Weiss addressing each of her concerns. Dr. Schulz, as a co-investigator on the Study, gave 10% of his overall time to the project. In addition to serving as a co-investigator on the Study, Dr. Schulz is also the head of the Department of Psychiatry at the University of Minnesota. His role as a co-investigator was to be available as a backup rater for Dr. Olson if that was necessary. In addition, he was always available to Dr. Olson to answer any questions he might have, to discuss the progress of the study, or to discuss individual patients participating in the Study. As previously indicated, Dr. Schulz is also the head of the Department of Psychiatry at the University of Minnesota. The majority of his duties are administrative in nature. He also does clinical work each year for 2-4 weeks working as an attending psychiatrist in the inpatient service. He also sees outpatients for about four hours per week. During that timeframe, he will be teaching residents and conducting supervision over his entire staff. Dr. Schulz also monitors

12

all of the physicians, fellows, residents, and other staff members working in the Department of Psychiatry at the University of Minnesota.
3. Eakan Counselink Center

For individual therapy, Mr. Markingson was seen by Dr. Arlow Andersen, Ph.D. LP, of the Eagan Counseling Clinic located in Eagan, Minnesota. Dr. Andersen saw Mr. Markingson on December 11, 2003, January 12, 2004, February 16, 2004, March 29, 2004, and April 26, 2004. Each of Dr. Andersen's visits with Mr. Markingson lasted approximately one hour. This one-on-one therapy was a part of Mr. Markingson's discharge plan from the hospital. It was also part of the outpatient work suggested by Mr. Pettit as a part of Mr. Markingson's stay of commitment. Dr. Andersen was aware of Mr. Markingson's participation in the CAF Study. That information was learned from Mr. Markingson. In each of Dr. Andersen's visits, he found Mr. Markingson's thought process to be logical and coherent. Dr. Andersen also found Mr. Markingson to have good insight and good judgment. In each of Dr. Andersen's visits, he assessed whether or not IVIr. Markingson was showing signs of harm to himself or others. In each of his visits, he noted that this was either low without plan or absent. In fact, on his last visit with Mr. Markingson on April 26, 2004, he noted that any risk to self was absent. Dr. Andersen testified that he did not believe that Mr. Markingson showed signs of being suicidal during their last visit. They also discussed the fact that Mr. Markingson's stay of commitment had been extended at his last visit. Mr. Markingson reported to Dr. Anderson that he did not object to the extension because he realized he was not prepared to return to California.
4. Day Treatment

Mr. Markingson participated in adult mental health day treatment at FUMC. This program was recommended by his social worker, David Pettit, as well as Dr. Olson. His participation was from January 14, 2004 through May 5, 2004. He was seen by Daniel Buse, HSW LLCSW, and Len I3ennati, OTR/L. Mr. Markingson attended day treatment on Monday, Wednesday and Friday each week for three hours per day. Two hours of the visits were in group therapy, and one hour was dedicated to occupational group therapy. Mr. Markingson had been referred to day treatment to provide structure, support and education about his mental illness. The medical records of Mr. Buse indicate that throughout Mr. Markingson's stay in day treatment, he presented as stable and denied any psychotic symptoms. Mr. Markingson also willingly acknowledged past delusional thoughts, and recognized that his thoughts were bizarre in nature and content. Mr. Buse acknowledged that on occasion, Mr. Markingson presented with some negative symptoms which included some effect flattening, social withdrawal and avoidance. Mr. Buse noted that Mr. Markingson had excellent attendance throughout the course of his participation in day treatment. Mr. Buse noted in his discharge summary that Mr. Markingson indicated a willingness to be discharged from day treatment as of May 5, 2004. Similarly, Mr. Bennati, in charge of his

13

occupational therapy, found that Mr. Markingson acknowledged his diagnosis of schizophrenia and was receptive to continuing his medication use. Mr. Markingson's presentation in occupational therapy was noted throughout to be reserved and quiet. Some negative symptoms noted by Mr. Bennati were that Mr. Markingson had a blunted affect, on occasion appeared disheveled in his appearance, and at times was withdrawn. However, Mr. Buse and Mr. Bennati both thought Mr. Markingson was mentally stable enough to be discharged from day treatment. Mr. Markingson graduated from his day treatment program on or about May 5, 2004. He rarely missed his scheduled appointments. The records from all of his providers seemed to indicate that he was ready for his transition into independent living, and that he was committed to seeking further care and treatment for his ongoing mental illness.
5. Theodore I House

After being discharged from FUMC, Mr. Markingson resided in a group home. This home was a Rule 36 facility known as Theodore I House ("Theo House") run by Boston Health Care. This facility was comprised of clients who were mentally ill, but not developmentally disabled. The group home provided 24 hours a day, 7 days a week staff care and mondtoring. The staff notes and depositions from staff members indicate that Mr. Markingson was quiet, reserved, but never exhibited delusions, hallucinations, or paranoid thinking. Mr. Markingson was a resident of Theo House from December 8, 2003 until the time of his death on the very early morning hours of May 8, 2004. On or about January 23, 2004, the staff at Theo House became somewhat suspicious that Mr. Markingson may be cheeking or palming his medication. In an effort to stop that behavior, the staff put into a place a protocol where Mr. Markingson was required to take his medication straight from a cup, not allowing him to place it in his hand; he had to consume his medication in staff presence, and had to stay in the presence of staff for several minutes to ensure that he swallowed the medication. This protocol began shortly after January 23, 2005, and persisted up until the time of Mr. Markingson's death. Staff believed Mr. Markingson continued to take his medication as prescribed up until the time of his death. According to the staff notes from Theo House, Mr. Markingson accepted extension of his stay of commitment. Further, the staff notes reflect that Mr. Markingson was looking forward to transitioning into his own apartment and living independently. Staff notes and depositions indicate that no one had any reason to believe that Mr. Markingson was considering suicide or exhibiting behavior which would demonstrate he had suicidal ideation.
Assessment and Opinions 1.

Dr. Stephen Olson

In the opinion of Dr. Glick, Dr. Olson did not violate the standard of care by having three simultaneous roles in regard to the care and treatment he rendered to Dan Markingson. Based upon the training, experience, and knowledge of Dr. Glick, it is reasonable and appropriate for an individual to serve as a principal investigator in a clinical trial, to be the personal psychiatrist of a

14

clinical trial, and also to be the primary care psychiatrist for a patient. However, Dr. Glick will clarify that there are truly only two roles that Dr. Olson assumed in this case. Those two roles are principal investigator and treating clinician. According to Dr. Glick, it is standard practice in clinical research for one psychiatrist to assume these roles. Dr. Glick believes Dr. Olson was aware of a potential conflict and undertook necessary steps to avoid these conflicts. Therefore, Dr. Olson satisfied the standard of care in each of these roles according to Dr. Glick. Dr. Olson in no way violated the ethical code of conduct nor did he violate the applicable standard of care according to Dr. Glick. Dr. Glick will opine that regardless of his role, Dr. Olson's primary concern throughout was providing care that was in the best interests of his patient, Dan Markingson. Dr. Glick will acknowledge that some may view a conflict of interest amongst these roles. However, the only time these potential conflicts become concerning, is if the best interests of a patient are lost sight of, or if a psychiatrist does something wrong. Dr. Glick will testify that Dr. Olson never lost sight of the best interests of Dan Markingson, nor did he do anything wrong. In Dr. Glick's opinion, Dr. Olson also made the appropriate efforts to safeguard against conflicts of interests interfering with his care. Dr. Glick will also offer the opinion that it is a standard practice when doing clinical research in the psychiatric research community for a psychiatrist to assume all three roles. It is more common than not that a psychiatrist will serve as the principal investigator of the study, the primary research psychiatrist of the study, and the primary care psychiatrist for the patient. Dr. Glick will testify this is the accepted method of doing clinical research and results in better care for patients. It is the opinion of Dr. Glick that the Nuremburg Code, Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice Guideline, and FDA Regulations and Guidelines are guidelines. These guidelines do not set forth the standard of care by which to judge clinical care. These guides set forth ethical considerations which, in some instances, must be reviewed and accounted for in clinical trials. However, these guidelines caimot be conclusively considered the standard of care required for clinical care. Dr. Glick will opine that in obtaining informed consent from Mr. Markingson to participate in the CAFE Study, reasonable and appropriate methods were utilized. In his opinion, the standard of care was satisfied when obtaining informed consent from Mr. Markingson. Informed consent is a process and is not limited to the signature on a single document. Dr. Olson followed all of the steps necessary to ensure that Mr. Markingson was not only competent to give informed consent, but actually willingly agreed to participate in the CAFE Study. As previously indicated, Mr. Markingson had been hospitalized since November 12, 2003. On or about November 13, Mr. Markingson began taking Risperdal. The notes reflect that the Risperdal had the desired effect on Mr. Markingson by helping him control his psychotic symptoms. Risperdal was an appropriate antipsychotic medication for Dr. Olson to prescribe. He remained on Risperdal from November 13 until December 5, 2003, when he began to taper off of the Risperdal and began the CAFE Study medication, later learned to be Seroquel. During

15

that timeframe, Mr. Markingson's psychotic symptoms began to stabilize, he was no longer having active hallucinations or delusions, and his thought processes were described to be reactive and organized. Further, he had coherent and clear thoughts. In the opinion of Dr. Glick, Mr. Markingson's medical records revealed that he was competent to give informed consent on November 21, 2003. A neuropsychological examination performed by Erin Holker, Ph.D. LP on November 18, 2003, indicates that by that date Mr. Markingson did not have cognitive impairments. Specifically, Dr. Holker's report indicates that Mr. Markingson's overall intellectual functioning was in the superior range. Further, Dr. Holker noted that Mr. Markingson did not have cognitive difficulties that would interfere with his ability to actively participate in his own treatment. In the opinion of Dr. Glick, Mr. Markingson was able to provide informed consent. The informed consent form was signed by Mr. Markingson on November 21, 2003 ; In the opinion of Dr. Glick, Mr. Markingson was competent and able to understand the CAFE Study, and also to understand the informed consent process at that time. Mr. Markingson remained competent throughout his participation in the CAFE Study, and according to Dr. Glick, was able to give ongoing informed consent which satisfied the applicable standard of care. Dr. Glick will testify that it was reasonable and appropriate to have Jeanne Kenney and Liz Lemke participate in the informed consent process. They had been adequately trained through the CAFE Study on competence as well as doing the competency evaluation. Further, Ms. Kenney had extensive knowledge about the CAFE Study, and therefore, was a reasonable and appropriate person to participate in the informed consent process. Dr. Glick will also opine that Dr. Olson's participation in obtaining informed consent from Mr. Markingson was reasonable, appropriate and was within accepted standard medical care. Dr. Olson followed every precaution to ensure that Mr. Markingson was competent to participate in giving informed consent. Further, Dr. Glick will opine that Dr. Olson reasonably presented the CAFE Study as alternative care and treatment and did not coerce Mr. Markingson into participating. In the opinion of Dr. Glick, the informed consent process in no way caused or contributed to Mr. Markingson's death. Dr. Glick will testify that there was nothing about Mr. Markingson's being under a stay of commitment which barred his participation in the CAFE Study. Dr. Glick will opine that having Mr. Markingson placed under a stay of commitment, demonstrated Dr. Olson's commitment to putting Mr. Markingson's best interests at the forefront of his care. There were no legal limits that would have prohibited Dr. Olson from having a person under a stay of commitment participate in a clinical trial. Dr. Glick will opine it was reasonable and appropriate for Dr. Olson to ask Mr. Markingson to voluntarily participate in the CAFE Study. Dr. Olson's actions were within accepted standards of medical practice. Dr. Glick will testify that Mr. Markingson was not coerced into participating in the CAF Study. Further, Dr. Glick will testify that the stay of commitment did not order Mr. Markingson to participate in the CAFE Study. Rather, Dr. Olson simply presented the CAFE Study as alternative care and treatment for Mr. Markingson. Ultimately, it was up to Mr. Markingson and

16

his county case manager to determine if they wanted to participate in the Study. They both voluntarily concluded it was appropriate for Mr. r Markingson to participate. Dr. Glick will opine that Mr. Markingson's participation in the CAFE Study was reasonable and appropriate care, and that Mr. Markingson was not in any way forced or coerced into participating in the Study. Dr. Glick is also supportive of the informed consent document utilized in the CAF Study. In his opinion, this document reasonably set forth the risks and benefits of participating in the CAFE Study. It stated the names and roles of all of the study investigators. It also set forth the study sponsor, Astrazeneca. More importantly, it set forth information that Mr. Markingson's participation in the Study was voluntary and that he could withdraw from the Study at any point in time. Dr. Glick will opine that the document set forth a reasonable and appropriate amount of alternative care which Mr. Markingson could have sought. Dr. Glick will also testify that the document did not exaggerate nor unduly emphasize any benefits of Mr. Markingson's participation in the Study. Thus, in the opinion of Dr. Glick, the informed consent document in and of itself was reasonable and appropriate and satisfied the standard of care. Dr. Glick will testify that it was reasonable and appropriate for Mr. Markingson to participate in the CAFE Study. The CAFE Study utilized three FDA-approved antipsychotic medications. No placebo was involved in the Study. In the opinion of Dr. Glick, this is an exceptionally important aspect of the CAFE Study. At no point in time was Mr. Markingson at risk of having his psychotic symptoms go unmedicated. Instead, the CAFE Study involved three antipsychotic medication which have a marked impact on the positive symptoms, some negative symptoms, and cognition. Thus, in the opinion of Dr. Glick, Mr. Markingson's participation in the CAFE Study was reasonable, appropriate and satisfied the standard of care. In Dr. Glick's opinion, it is absolutely clear that Mr. Markingson suffered from schizophrenia. The medical records also reflect that Mr. Markingson appeared to have a substance abuse issue. There is absolutely no basis to deduce any other diagnosis of the patient. Dr. Glick believes that Dr. Olson took the appropriate amount of time to assess the patient and to determine his diagnosis. Dr. Glick is supportive of the diagnosis reached by Dr. Olson for Mr. Markingson. Dr. Glick will opine that there is no evidence that Mr. Markingson was bipolar or suffered from any other mental illness. He will concede that it was appropriate to rule out bipolar as a potential diagnosis for Mr. Markingson. However, in his opinion, under no uncertain terms, Mr. Markingson was not bipolar. Thus, Mr. Markingson met the Study inclusion/exclusion criteria and was appropriately enrolled in the Study. Dr. Glick will also opine that Mr. Markingson had substantially more monitoring and involvement with mental healthcare professionals than he would have received had he been seen in the standard method. The standard method of care called for antipsychotic medication and some support, i.e., one-on-one psychiatric visits or some form of therapy. In a standard care setting, Mr. Markingson would have had long periods of time without being seen by his psychiatrist. Further, he would have been responsible for taking his own medication with very limited monitoring. Due to Mr. Markingson's involvement in the CAFE Study, he was receiving substantially more monitoring that he would have received in standard private practice.

17

In addition to the greater amount of monitoring he was receiving because of his participation in the CAFE Study, he was also receiving a great deal of care through his participation in the adult day treatment program at FUMC, by being seen by an individual therapist one time a month, living at Theo House and having 24 hour around the clock care, and the additional monitoring of his county case manager. According to Dr. Glick, the standard of care and level of monitoring Mr. Markingson received, was above and beyond reasonable and appropriate care. Dr. Glick will opine that the level of monitoring involvement with mental healthcare professionals Mr. Markingson had, did not in any way cause or contribute to his death. The evidence throughout the medical records indicate that Mr. Markingson was made well aware of his opportunity to seek alternative care and treatment, to seek a second opinion, and to withdraw from the CAFE Study. Providing Mr. Markingson with this vital information was reasonable and appropriate according to Dr. Glick. Mr. Markingson was a competent adult and was the only one who could make that decision. Further, his county case manager never requested alternative care for him. Dr. Glick will opine that providing Mr. Markingson with all of this information satisfied the standard of care. This did not cause or contribute to his death. Dr. Olson also testified that he provided information to Mr. Markingson about alternatives to his participation in the CAFE Study. According to Dr. Olson, he described for Mr. Markingson his right to seek standard medical care. Providing verbal information, in addition to the written information received by Mr. Markingson, was reasonable and appropriate according to Dr. Glick. Dr. Glick will testify that providing this information to Mr. Markingson in no way caused or contributed to Mr. Markingson's cause of death. Dr. Glick is of the opinion that it was reasonable and appropriate to seek an extension of Mr. Markingson's stay of commitment in May 2004. According to the medical records, as well as the deposition testimony, in March and April 2004, Mr. Markingson began to comment upon his desire to return to California. He indicated that he was going to travel there without any realistic financial planning to get there, and he did not have in place any healthcare system which could continue to address and assist him with his ongoing mental illness. Dr. Glick will opine that there is absolutely no evidence that the stay of commitment was sought for any other reason than to ensure appropriate care and treatment for Mr. Markingson. There is absolutely no evidence that the stay of commitment was sought based upon a desire to retain Mr. Markingson in the CAFE Study. Further, Dr. Glick will opine that there was no coercion by Dr. Olson to have Mr. Markingson continue to participate in the stay of commitment. The decision to extend the stay of commitment was reasonable and appropriate and satisfied the standard of care according to Dr. Glick. Dr. Glick will opine that based upon his review of the PANS S scores and records, in his opinion, Mr. Markingson was experiencing sporadic signs of demoralization. However, Dr. Glick does not believe that there was a gradual deterioration over time that ultimately led to Mr. Markingson's death. Dr. Glick believes that Mr. Markingson experienced sporadic ups and downs which would be typical for a person suffering from schizophrenia and dealing with that

18

mental health disorder. Dr. Glick does not agree that Mr. Markingson was in a gradual spiral down in his mental health condition which caused or contributed to his death. Therefore, Dr. Glick will opine that Dr. Olson reasonably and appropriately monitored Mr. Markingson. Therefore, Dr. Olson's care and treatment to Mr. Markingson was in accord with accepted standards of medical practice. Dr. Glick is also prepared to address the assertion that Dr. Olson should have placed Mr. Markingson on a different antipsychotic medication. The use of Seroquel, or any of the antipsychotic medication in the Study, was reasonable and appropriate care and treatment. In the opinion of Dr. Glick, the use of Seroquel did stabilize Mr. Markingson and substantially reduced and minimized his psychotic symptoms. The ongoing problems experienced by Mr. Markingson were negative symptoms from his underlying condition. Dr. Glick will testify and explain that negative symptoms generally are not easily treated through the use of medication. Dr. Olson did provide good clinical care both as Mr. Markingson's inpatient psychiatrist, as well as the principal investigator and Study physician for the CAFE Study, according to Dr. Glick. Dr. Olson saw Mr. Markingson on a consistent and regular basis throughout his hospitalization at FUMC. Further, Dr. Olson saw Mr. Markingson on December 11 and 19, 2003. Thereafter, he saw him on January 30, March 2 and 31, and April 9. Dr. Olson testified that there were several visits from December through Febmary where he saw Mr. Markingson at the end of his CAFE visits during which time he met with Mr. Markingson and evaluated him In addition, Dr. Olson was meeting once a month with the day treatment staff to discuss Mr. Markingson's progress and overall wellbeing. Dr. Olson would also have regular interaction with Jeanne Kenney and would discuss her observations of Mx. Markingson, as well as her assessments of his progress. Dr. Olson interacted with Mr. Markingson and evaluated him a substantial amount according to Dr. Glick. The care and treatment rendered by Dr. Olson was reasonable and appropriate care. By taking the additional steps to interact with other persons providing care to Mr. Markingson, Dr. Olson took an additional step above and beyond the necessary standard of care. In the opinion of Dr. Glick, in no way did his care and treatment cause or contribute to Mr. Markingson's death. According to Dr. Glick, there is absolutely no validity to the allegation that Dr. Olson was a "absent" principal investigator, Study psychiatrist, or individual psychiatrist. Dr. Olson took his role as Mr. Markingson's primary care psychiatrist, the principal investigator of the CAFE Study, and the psychiatrist for the CAFE Study very seriously. The care and treatment he provided to Mr. Markingson was at all times reasonable and appropriate. In no way did the care and treatment rendered by Dr. Olson as the principal investigator of the Study, the Study physician, nor as Mr. Markingson's primary caregiver, in any way cause or contribute to Mr. Markingson's death. Dr. Glick will also opine that it was reasonable and appropriate to have Jeanne Kenney participate in the evaluations and diagnostic interviews with Mr. Markingson. Ms. Kenney received the appropriate training and experience to do that testing. Further, she consulted with Dr. Olson on each of her visits with Mr. Markingson. According to Dr. Glick, this was a reasonable and appropriate method of assessing this patient. Further, he is of the opinion that

19

this satisfied the standard of care and in no way caused or contributed to Mr. Markingson's death. Dr. Olson also reasonably and appropriately considered the concerns being raised by Ms. Weiss. The record reflects that Ms. Weiss sent Dr. Olson two letters in November 2003. Those letters set forth some concerns she had about her son's participation in the CAFE Study, and alleged ongoing psychotic symptoms. He also on occasion received messages from Ms. Weiss raising her concerns. Dr. Olson took into consideration these concerns. He would consider that information against the presentation that Mr. Markingson made at his CAFE Study visits. In addition, he would weigh these concerns against information being received from the Theo House and the observations of Mr. Markingson being made during adult day treatment. In all instances, Mr. Markingson presented as being stable and no one could verify the concerns raised by Ms. Weiss. Thus, Dr. Olson reasonably and appropriately assessed and evaluated the concerns raised by Ms. Weiss. When those were determined to be without verification from other sources, Dr. Olson did not disregard those comments, but continued to consider them as a part of his ongoing care and treatment of IVIr. Markingson. These assessments were reasonable, appropriate and satisfied the applicable standard of care. In no way did this cause or contribute to Mr. Markingson's cause of death. Dr. Glick will opine that it takes anywhere between six to eighteen months of psychiatric care and consistent antipsychotic medication use before the symptoms of first episodes of psychosis fully stabilize. Mr. Markingson was still in the early stages of receiving care for his disease, and was continuing to have ongoing problematic symptoms. According to Dr. Glick, this was expected and appropriately accounted for by Dr. Olson and the rest of Mr. Markingson's treatment team. Dr. Glick will testify that in his opinion there was a significant amount of conflict and turmoil between Mr. Markingson and Ms. Weiss. Ms. Weiss was Mr. Markingson's only close relative as he had no father in his life and no siblings. Thus, his only source of family support was someone who did not understand his disease, was not being patient with his recovery, and with whom he had trust issues. These factors created a great deal of stress for Mr. Markingson and hindered his ability to work toward stabilization of his disease. Dr. Glick will also offer the opinion that the majority of persons diagnosed with schizophrenia have difficulty accepting care. Approximately 80% will either decline care or fail to follow through with the prescribed care in the first few months. In this case, Mr. Markingson had been compliant with all of his care for almost six months at the time of his death. In the opinion of Dr. Glick, this demonstrates what excellent care and monitoring Mr. Markingson was receiving in the CAFE Study. Dr. Glick will testify there was no reason for Dr. Olson to withdraw Mr. Markingson from the Study. Dr. Glick will opine there were no clear warning signs that Mr. Markingson was potentially suicidal. He was not exhibiting signs of psychosis nor was he deteriorating. The behavioral assessment of suicide ideation consistently showed no evidence of suicide.

20

Furthermore, none of his multiple clinicians, staff at Theo House, or apparently, residents at Theo House were aware of Mr. Markingson's being suicidal. Dr. Glick ,will opine that it was reasonable and appropriate to have Mr. Markingson remain in the CAFE Study. The CAFE Study provided reasonable and appropriate care and was within the accepted standards of medical practice. Remaining in the CAFE Study did not in any way cause or contribute to Mr. Markingson's cause of death. Dr. Glick will testify that those with schizophrenia have a greater rate of suicide than the average population. Individuals who are schizophrenic have the capability of committing suicide even if they are hospitalized in a locked ward. In the case of Mr. Markingson, he was receiving an exceptional amount of care and close monitoring. His decision to take his own life was not caused or contributed to by the care and treatment rendered by Dr. Olson as the principal investigator of the CAFE Study, Dr. Olson as primary care psychiatrist of the CAFE Study, nor as Mr. Markingson's individual primary care psychiatrist. According to Dr. Glick the toxicology report indicated Mr. Markingson had stopped taking his Caf Study medication (quetiapine). The fact that there was no presence of the medication in his blood indicates that Mr. Markingson had not been taking his medication for a few days prior to his suicide. The ability to follow through with care and medication compliance is a significant concern for people diagnosed with schizophrenia. Despite all efforts to ensure Mr. Markingson took his medication, it appears he did stop taking it. Mr. Markingson's nonadherence to treatment in the few days prior to his death likely caused or contributed to his suicide. Dr. Glick will testify that he did review the Department of Health and Human Services report regarding their review of the death of Mr. Markingson. In his opinion, there were absolutely no adverse findings related to Dr. Olson, the University of Minnesota, the CAFE Study, nor Dr. Schulz. Dr. Glick has also reviewed the investigation conducted by the Food and Drug Administration by Sharon L. Matson, Investigator, in January of 2005. Dr. Glick will testify that the investigation conducted by the FDA found no adverse care and treatment by Dr. Olson, Dr. Schulz, or any other person involved in Mr. Markingson's care and treatment. The FDA found that Mr. Markingson's diagnosis of schizophrenia was reasonable and appropriate. Dr. Glick also noted that the FDA found that the court order did not require Mr. Markingson's participation in the CAFE Study. Thus, there was no evidence of inappropriate coercion. The FDA investigator found that Mr. Markingson received more care than he would have received in standard medical care by his participation in the CAFE Study. The FDA also found that Mr. Markingson was in a state to give voluntary, informed consent on November 21, 2003. The FDA also noted in their report that Mr. Markingson's continued participation in the Caf Study was appropriate and there was no clinical evidence of deterioration. According to Dr. Glick, the FDA report is proof of the excellent care and treatment Dr. Olson and the CAFE Study afforded to Mr. Markingson.

21

Dr. Glick will point out that not one of the other care providers involved in Mr. Markingson's care and treatment ever attempted to contact Dr. Olson. Dr. Glick will opine that if Dr. Andersen, Mr. Pettit, the Theo House staff, or the day treatment staff, had any questions or concerns about Mr. Markingson's progress or stability in the CAFE Study, it would have been incumbent upon them to contact Dr. Olson. According to Dr. Glick, it is very telling that at no point in time did any of these care providers contact Dr. Olson with concerns about Mr. Markingson. Instead, individuals from each one of these facilities have indicated that they believed that Mr. Markingson was stable and did not need additional assessment by Dr. Olson. This reiterates that the care and treatment received by Mr. Markingson was reasonable and appropriate. Dr. Glick is of the opinion that the standard of care did not call for Dr. Olson to obtain blood tests to verify Mr. Markingson's medication level. According to Dr. Glick it is highly unusual almost never clinically done - for blood tests to be obtained. It appeared that Mr. Markingson was compliant with taking his Caf medication. Mr. Markingson was regularly attending all of his appointments with his various medical providers. He was not reporting having any active hallucinations or delusions. Mr. Markingson also did appear to exhibit any signs of significant deterioration. Given these circumstances, Dr. Glick does not believe this type of case would call for an extreme measure like blood testing. Thus, the standard of care did not require Dr. Olson to acquire blood tests, urine tests or other laboratory testing to determine Mr. Markingson's medication level. In the opinion of Dr. Glick, Dr. Olson at all times provided reasonable and appropriate care and treatment to Mr. Markingson. In his role as principal investigator of the CAFE Study, CAFE Study physician, and primary care psychiatrist to Mr. Markingson, he provided reasonable and appropriate care and treatment, all of which satisfied the standard of care. Further, in his opinion, in no way did the care and treatment provided by Dr. Olson cause or contribute to Mr. Markingson's death. Dr. Glick will opine that the care provided by Dr. Olson, Dr. Schulz, the University of Minnesota Physicians, nurses, all other physicians, psychiatrists, psychologists, social workers, day treatment personnel, and Theo I staff was reasonable and appropriate. In his opinion, none of their care caused or contributed to Mr. Markingson's death.
2.

Dr. S. Charles Schulz

During Mr. Markingson's hospitalization, he saw Dr. Schulz on one occasion on or about November 29, 2003. Dr. Schulz was covering rounds at the hospital for Dr. Olson during that timeframe. Dr. Schulz performed a history and examination of Mr. Markingson during this visit. Dr. Schulz found Mr. Markingson's thought process to be logical and that his mood was pleasant and his affect was appropriate. He was noted to be on Risperdal at that time and Dr. Schulz continued the patient's use of that medication. In the opinion of Dr. Glick, the care and treatment rendered by Dr. Schulz to Mr. Markingson on this single visit was reasonable, appropriate, and satisfied the standard of care. His examination and assessment of this patient, along with the continuation of Mr. Markingson's medication, was appropriate care. Dr. Glick will opine that Dr. Schulz's care and treatment of this patient did not cause or contribute to his death.

22

Dr. Glick is also expected to testify and opine that Dr. Schulz did not violate the standard of care for a co-investigator of a clinical trial, nor as the head of the Department of Psychiatry. Dr. Glick will opine that Dr. Schulz's activities in those capacities was within accepted medical practice. Further, Dr. Glick will provide the opinion that Dr. Schulz neither caused nor contributed to Mr. Markingson's death. According to Dr. Glick, the evidence will show that Dr. Olson and the CAF Study treatment team were involved in obtaining informed consent from Mr. Markingson. Dr. Schulz did not interact with Mr. Markingson after his single visit with him, in the hospital. Dr. Schulz did not present to Mr. Markingson any information about the CAFE Study. Dr. Schulz did not make an assessment of Mr. Markingson's competence at any point in time during his hospitalization. Further, all of the evidence will show that Dr. Schulz in no way participated in the informed consent process conducted on November 21, 2003. In the opinion of Dr. Glick, Dr. Schulz could not have violated the standard of care requirements for obtaining informed consent when he was not in any way involved in that process. Thus, Dr. Schulz's lack of involvement in the informed consent process, could not have been a component or a causal factor in Mr. Markingson's death. Dr. Glick will testify that the standard of care did not require Dr. Schulz to participate in the informed consent process. As a co-investigator of the CAF Study, Dr. Schulz was aware of the information contained in the informed consent document. That document had been reviewed by the Institutional Review Board at the University of Minnesota. That Board took into consideration the reasonableness and appropriateness of that document for use amongst human subjects. After making several changes to the document, the Institutional Review Board approved the use of that document which had been utilized to enroll other subjects in the CAFE Study for the year or more that it had been conducted at the University of Minnesota site prior to Mr. Markingson's involvement. Dr. Glick is of the opinion that the information contained in the CAFE Study informed consent document was reasonable and appropriate. It is his opinion that that document fully set forth information about Mr. Markingson's right to withdraw from the Study, alternative treatment, the risks of the Study, and the benefits. To a reasonable degree of psychiatric and medical certainty, Dr. Glick will opine that this document was reasonable, appropriate and satisfied the standard of care. In no way was the document exploitive nor coercive. Dr. Glick will also testify that as a co-investigator on the Study, Dr. Schulz was only responsible for the care provided to those patients he was seeing. Only the principal investigator on a study is responsible for the care of all of the patients. Dr. Schulz never saw Mr. Markingson as a participant in the CAFE Study. Dr. Glick will also opine that Dr. Schulz was not involved in Mr. Markingson's stay of commitment. Nevertheless, Dr. Glick will opine that regardless of Mr. Markingson's stay of commitment, he was still a reasonable and appropriate candidate to participate in the CAFE Study. Further, regardless of the fact that he was functioning under a stay of commitment, did not negate the fact that , Mr. Markingson was competent and able to voluntarily agree to participate in the CAFE Study. Dr. Glick will opine that it was reasonable and appropriate for Dr. Schulz, as a co-investigator of the CAFE Study and as the head of the Department of

23

Psychiatry at the University of Minnesota, to allow Mr. Markingson to participate in the CAF Study given his competence, voluntary choice to participate in the study, and approval of Mr. Markingson's case manager/social worker, David Pettit. Dr. Glick will opine that given his role in Mr. Markingson's care and treatment, Dr. Schulz was not obligated to ensure that Mr. Markingson obtained a second opinion. The medical records reflect that Mr. Markingson was satisfied with the care he was receiving from Dr. Olson and in the CAFE Study. The records also reflect that Dr. Olson, on several occasions, expressed to Mr. Markingson that he had the right to seek a second opinion, yet each time Mr. Markingson refused. The standard of care did not require Dr. Schulz to force or even suggest to Mr. Markingson that a second opinion was necessary. As previously stated in his opinions on Dr. Olson, Dr. Glick will opine that acquiring a blood test to discern the level of antipsychotic medication in Mr. Markingson's blood was not required. Dr. Schulz had no reason to personally conduct such a test or to request that Dr. Olson or the CAFE Study staff perform such testing. Dr. Glick will opine that blood level testing is done in the rarest of circumstances and certainly would not have been called for in this case. Dr. Schulz's position as co-investigator and department head did not require him to seek blood level testing for Mr. Markingson. Dr. Schulz did not violate the standard of care and did not cause or contribute to Mr. Markingson's death in this regard. Dr. Glick will also address the suggestion that there was a conflict of interest based upon an alleged financial gain that Dr. Schulz would receive as a result of Mr. Markingson's participation in the CAFE Study. Dr. Glick will opine that he has reviewed the records and does not see any evidence of a financial motivation which would have in any way impaired or hindered Dr. Schulz's judgment in regard to the care and treatment provided to Mr. Markingson. Further, there is no evidence of any financial misconduct in how Astrazeneca paid for the performance of the Study. Dr. Schulz took very seriously his role as the head of the Department of Psychiatry and as a co-investigator of the CAFE Study to ensure that all staff, including Dr. Olson, provided appropriate care to all patients and/or Study subjects. In the opinion of Dr. Glick, Dr. Schulz reasonably and appropriately monitored the CAFE Study and was available to assist in any manner necessary if issues arose. He allowed Dr. Olson, a seasoned, skilled and highly knowledgeable member of his staff, to serve as the principal investigator of the CAFE Study. Dr. Glick will opine that Dr. Olson's skill and knowledge level called for Dr. Schulz to allow Dr. Olson to conduct this Study independently. Dr. Schulz was, in the opinion of Dr. Glick, right in that assessment as Dr. Olson did provide appropriate care. Therefore, Dr. Schulz satisfied the standard of care by allowing the CAFE Study to be conducted in the manner in which it was at the University of Minnesota. There is nothing about the way the CAFE Study was conducted that caused or contributed to Mr. Markingson's death. The way the Study was implemented at the University of Minnesota by Dr. Schulz and Dr. Olson under the direction of the IRB was reasonable and appropriate.

24

According to Dr. Glick, Dr. Schulz knew that Dr. Olson was a conscientious principal investigator, CAFE Study physician, and primary caregiver. Further, he knew he would do whatever was necessary to provide reasonable and appropriate care to Mr. Markingson. Dr. Olson did have reasonable and appropriate contact with Mr. Markingson throughout the course of his hospitalization, and his aftercare prior to his death. Dr. Schulz reasonably and r appropriately monitored Dr. Olson's contact with Mr. Markingson, and all of the CAFE Study participants, both as a co-investigator and as the head of the Department of Psychiatry at the University of Minnesota. Dr. Glick is of the opinion that Dr. Schulz did reasonably and appropriately investigate and consider the information he received from Ms. Weiss. Further, Dr. Glick will opine that Dr. Schulz's investigation of the subject matter was reasonable, appropriate and satisfied the standard of care. Dr. Glick will also testify that the timely response by Dr. Schulz to Ms. Weiss's concerns about her son's participation in the CAFE Study satisfied the standard of care and did not in any way cause or contribute to Mr. Markingson's death. When Dr. Schulz received Ms. Weiss's correspondence, he contacted Jeanne Kenney and Dr. Olson to review Mr. Markingson's participation in the CAFE Study. Dr. Schulz testified that he spent more than one hour talking to them to discern whether or not there was any validity to the concerns she was making about Mr. Markingson's behavior, progress, and continued participation in the CAFE Study. Dr. Schulz extensively questioned both Ms. Kenney and Dr. Olson about her concerns, and after investigating that matter, felt satisfied that Mr. Markingson was progressing appropriately, his condition had stabilized, and that he was an appropriate candidate to be a participant in the CAFE Study. Dr. Schulz addressed each and every one of Ms. Weiss's concerns. He discussed Mr. Markingson's change in behavior and improvement in his condition since his participation in the CAFE Study. He also reiterated to Ms. Weiss that if Mr. Markingson was not responding to the CAFE medication or indicated a desire to withdraw, he could do so. Dr. Schulz advised Ms. Weiss that Mr. Markingson had not asked to be removed from the Study, and that his medication appeared to be helping with his symptoms. Further, Dr. Schulz reiterated to Ms. Weiss that Mr. Markingson had the right to seek a second opinion, but that decision was Mr. Markingson's alone. Finally, Dr. Schulz addressed Mr. Markingson's living situation and indicated to her that a trial run in a local apartment would certainly be better than Mr. Markingson's desire to return to California without supervision. The letter written by Dr. Schulz, in the opinion of Dr. Glick, was reasonable, appropriate and satisfied the standard of care. Dr. Glick will testify that in no way did Dr. Schulz's actions cause or contribute to Mr. Markingson's death. Dr. Glick will testify that there was absolutely no evidence which would have indicated to Dr. Schulz that Dr. Olson was an absent physician or principal investigator. To the contrary, in the opinion of Dr. Glick, Dr. Schulz investigated and appropriately reached the conclusion that Ms. Markingson was receiving reasonable and appropriate care in the clinical trial. There was absolutely no basis for Dr. Schulz to intervene into the care of Mr. Markingson nor discontinue his participation in the Study. Dr. Schulz satisfied the standard of care and did not cause or contribute to Mr. Markingson's death.

25

The only concerns about Mr. Markingson's care and treatment in the CAFE Study came from Ms. Weiss. Federal requirements indicate that an Institutional Review Board is to receive information about concerns received from investigators conducting the Study. However, those are the concerns that are registered by the participants. Ms. Weiss was not a participant in the CAFE Study. It was not required that either Dr. Olson or Dr. Schulz report this information to the Institutional Review Board, Quintiles nor Astrazeneca. Mr. Markingson did not personally lodge any complaints about his participation in the CAFE Study, the medication, nor any adverse effect he may have been experiencing. The standard of care did not call for Dr. Olson nor Dr. Schulz to advise the Institutional Review Board, Quintiles, nor Astrazeneca Pharmaceuticals. Dr. Glick will also opine that Dr. Schulz did not have a duty to disclose to Ms. Weiss that he was a co-investigator on the CAFE Study in his response to her. That information had nothing to do with Mr. Markingson's care. Further, there is no proof it would have changed the care Mr. Markingson received. The standard of care did not require Dr. Schulz to disclose that information to her. Ms. Weiss was not a participant in the CAFE Study, was not a monitor of the CAFE Study, and was simply a person presenting concerns about a patient. Thus, Dr. Schulz's care and treatment did not cause or contribute to Mr. Markingson's death. Dr. Glick will also opine that the fact that the Office of the Ombudsman, the Department of Health and Human Services, and the FDA all conducted investigations and studies into the outcome of this case. In the opinion of Dr. Glick, each one of these investigating entities found that the standard of care had been satisfied and in no way did the care and treatment rendered by Dr. Olson, Dr. Schulz, or any person affiliated with the CAFE Study cause or contribute to Mr. Markingson's death. Instead, each of these entities found that the care and treatment provided to Mr. Markingson was reasonable and appropriate. Dr. Glick will also point out that in each one of these investigations conducted, Dr. Schulz was not named nor was he indicated as a person whose actions were being investigated. Dr. Glick will indicate that this information is striking because it demonstratively shows Dr. Schulz's role as both a co-investigator and the head of the Department of Psychiatry was not at any point in time questioned by these institutions. Further, not one entity believed that Dr. Schulz's role as a co-investigator, nor as the head of the Department of Psychiatry, caused or contributed to Mr. Markingson's death. In the opinion of Dr. Glick, Dr. Schulz satisfied the standard of care both as a coinvestigator of the CAFE Study and as the head of the Department of Psychiatry at the University of Minnesota. Dr. Schulz's activities in each of those roles, was reasonable and appropriate. There is not any evidence, in the opinion of Dr. Glick, as either a co-investigator or as the head of the Department of Psychiatry Dr. Schulz in any way caused or contributed to Mr. Markingson's death. Dr. Glick will also opine that there was no evidence of bias or unethical judgment by Dr. Olson or Dr. Schulz as a result of Astrazenca's sponsorship of the study. According to Dr. Glick, there is absolutely no evidence of unlawful payment to Dr. Olson or Dr. Schulz directly by Astrazeneca. The method of payment to the University of Minnesota was reasonable and appropriate. Further, there was nothing that violated the standard of care by having payments

26

m.acle lo the University even if a portion of these payments went to support Dr. Olson's or Dr. Schulz's salaries. Dr_ Glick will also offer opinions about the emplo schizophrenia. In his opinion, schizophrenia is a life long schizophrenia must be medioine compliant throughout th stability. As a result of the disease process, the majority have difficulty remaining medication compliant. Further, schizophrenia often experience several relapses througho hospitalized on at least one occasion in their life, All of th with schizophrenia from the ability to obtain aad retain sta experience,, regardless of ideation level, most Will be unab reliant upon social security disability benefits as their sole bility of a patient sufferin.g from isease. People diagnosed with life in order to maintain mental people diagnosed with schizophrenia MODS with a diagnosis of their life, and most are rese factors inhibit persons diagnosed lc, fun time employment. In his to maintain employment and are cans of support.
-

CERTIFICATIO
I certify that the tbregoing statements and opinions are true and correct to the best of my knowledge and belief. I further certify that the above opi ons are rendered to a reasonable degree of medical and psychiatric certainty. These opinio i may be supplemented or revised should there be additional discovery and/or information su mined or brought to my attention for

TeVieW.

Ira D. Glick, Subscribed and sworn to before me this _ day of .2007.

-

.D.

Notary Public

Dated:
(-

MPLJB305611, I

David D. sop #120434-' Angela M Nelson #03066l 7 GISLAS N flt HUNTER LLP Attorneys for Stephen Olson, M.D., and Charles Schulz, MD. 701 Xeni Avenue South, Suite 500 Minneapo s, MN 55416 Pbone: 7 3-225-6000

27

CALIFORNIA JURAT WITH AFFIANT STATEMENT

2&SitiGM= State of California County of

Sc,0
curnent signer[s],

See Attached Document (Notary to cross out lines 1-6 belo 0 See Statement Below (Lines 1-5 to be completed only by

not Notary)

Signature of Document Signer N. 1

Signature ot Doodment Signer No. 2 II arty)

Subscribed a d ewerft-te-ior affirmed) before me on this

tC11
Date (1 )

da of
Month

, 2061 , by
Year
Mame of Signer

<7.

NANCY CHEUNG COMM. *1644065

"y(Proved to me on the basis of satisfactory evidence to be the rson who appeared before me (.) (7)Pt

-fend"
(2)
of Signer

MY Cann. Esp. Feti 9, 2410

5AN,FRANasco couKrr
s
ss

Notary Pubit-caltorris
s

rrt

E Personally known to me
Proved to me asis of satisfactory to be th on who appeared before me.)
Signature or Notary Pub

Place Notary Seal Above

OPTIONAL
Though the information below Is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document
RIGHT TI1UMBPRitIT OF SIGNER ,t1 PIGHT T IqUIVIEPRINT OF. SIGNER' a2

of Any Attached Docurnzs,t,, cuicot_ ri)-isaoS we-42- ,>cTitle or Type of Doeurnentk-P 11/41'1 0 c tArtk ckc-,
Further Description
Decurneni Date:

1\3 0 Dafre--

Number of Pages:

7:1

Signer(s) Other Than Named Above: 10

tY11/142Ar- S.7 131,A,f2.ArS

30ZAMOIN
C2004 National NotaryAssocialion 9350 De Soto Ave., P.O. Box 2402 Chatsrvorth, OA 91313-2402*

NationelNoteryiorg Item #5910 Reorder: call Toll- Freet -Soo-876-e827

Ira D. Glick, M.D.

Curriculum Vitae Ira David Glick, MD

Professor of Psychiatry, Dept. of Psychiatry & Behavioral Sciences Stanford University School of Medicine; 401 Quarry Road, #2122 Stanford, CA 94305-5546 (650) 723-3519 <iraglick@stanford.edu >

Date of Birth: Education:

October 15, 1935

Place of Birth: Brooklyn, New York

SS# 161-32-7428

1957 1961

B.S., Dickinson College, Carlisle, Pennsylvania M.D., New York Medical College

Postgraduate Education:

1961-1962 1962-1966

1965-1966

Rotating Internship, Beth Israel Hospital, New York, NY Psychiatry Residency 1962-63 - First Year Resident, Hillside Hospital, Glen Oaks, New York 1963-64 - Second Year Resident, Mt. Zion Hospital, San Francisco, California 1964-65 - Chief Resident, Hillside Hospital Candidate, New York Psychoanalytic Institute, New York, NY

Licensure & Certification:

1962 1963 1963 1968 1980 1988

New York State Medical License Diplomate of the National Board of Medical Examiners California State Medical License - (G 9084) Diplomate of the American Board of Psychiatry and Neurology Mental Health Administrator, Commission on Certification in Administrative Psychiatry of the American Psychiatric Association Maryland Medical License

Academic Appointments:

1965-1968

Instructor & Assistant Attending Psychiatrist, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University Assistant Clinical Professor of Psychiatry, Medical College of Georgia School of Medicine, University of California, San Francisco (UCSF): 1968-72 Assistant Clinical Professor of Psychiatry and of Obstetrics & Gynecology 1971-73 Career Teacher in Psychiatry of the National Institute of Mental Health at Langley Porter Neuropsychiatric Institute 1972-76 Associate Clinical Professor 1976-78 Professor of Psychiatry in Residence, School of Medicine Professor of Psychiatry, Cornell University Medical College, New York, NY

1966-1968 1968-1978

1978-1993

Ira D. Glick, M.D.

1993Positions:

Professor of Psychiatry & Behavioral Sciences, Stanford University School of Medicine

1965-1966 1966-1968

Staff Psychiatrist and Research Associate, Hillside Hospital, Glen Oaks, New York Service Record: Captain, Army of the United States, Chief, Psychiatry Service, U.S.Army Hospital Specialized Treatment Center, Fort Gordon, Georgia Langley Porter Neuropsychiatric Institute and Dept. of Psychiatry, School of Medicine, University of California, San Francisco 1968-78 Chief, Clinical Research Ward (renamed the In patient Treatment & Research Service, 5/1/75) 1975-78 Director, Medical Student Education Associate Medical Director, Payne Whitney Clinic, Dept. of Psychiatry, The New York HospitalCornell Medical Center 1978-88 - Director, Inpatient Services 1978-93 - Director of the Family Therapy Program 1990-93 - Director, Outpatient Dept. Senior Science Advisor to the Director, National Institute of Mental Health, Rockville, MD, 80% Stanford University School of Medicine & Stanford University Hospital 1993 - 2000 - Director of Inpatient & Partial Hospitalization Services, 1995 - 96 - Acting Deputy Chief of Staff and Chief of Psychiatry, Palo Alto Veterans Administration Hospital 1993 present - Director, Schizophrenia Research Clinic

1968-1978

1978-1993

1988-1990 1993-

Other Training:

1965-1966 1968-1969

Dept. of Research, Hillside Hospital: Seminar on Research Methods in Psychiatry, D. Klein, MD J. Starkweather, PhD, Dept. of Information Systems, UCSF: An Introduction to Computer Programming PL-1 Dept. of Psychiatry, UCSF: Seminar on Supervision, R. Wallerstein, MD Dept. of Psychiatry, UCSF: Seminars on Models in Psychiatry, J. Ruesch, MD Dept. of Psychology, Langley Porter Neuropsychiatric Institute: Course on Advanced Statistics, W. Hargreaves, PhD Dept. of Psychology, Langley Porter Neuropsychiatric Institute: Advanced Statistics 226- A & B, R. Elashoff, PhD and W. Hargreaves, PhD UCSF: Health Sciences Education Seminar, E. Rosinski, PhD Dept. of Anatomy, UCSF: Course on Cell Structure & Function, R. Long, PhD Dept. of Physiology, UCSF: Course, Endocrinology 101, C. Kragt, PhD Dept. of Business Administration, Philosophy of Management University of California, Berkeley Science, C. Churchman, PhD

1968-1969 1968-1969 1969-1970

1971-1972

1971-1972 1972 1972 1972

Ira D. Glick, M.D.

1973 1978-1979

Cardiovascular Research Institute, UCSF: Group Practice in the Art of Teaching, N. Staub, MD Dept. of Psychiatry, Albert Einstein College of Medicine: Administrative Psychiatry & Mental Health Planning, S. R. Kaplan, MD

Honors and Awards: 1953-1954 1959

Skull & Key Award: Dickinson College. Given yearly to College's most outstanding freshman National Foundation Medical Student Fellowship, Dept. of Physical Medicine & Rehabilitation,

New York Medical College (Summer) 1960

National Institute of Mental Health Research Training Grant , Dept. of Psychiatry, New York

Medical College (Summer) 1961

Stephen P. Jewett Award : Dept. of Psychiatry, New York Medical College. One award given each year for proficiency in psychiatry to a fourth year medical student Army Commendation Medal : U.S. Army Hospital, Ft. Gordon, Georgia Career Teacher in Psychiatry: National Institute of Mental Health, MH-12450

1968 1971-1973 1974-1975

Dept. of Psychiatry Nominee for the Kaiser Award for Excellence in Teaching, and the UCSF Budget Committee Award for Special Recognition of Distinction in Teaching
American Journal of Nursing, 1979, Books of the Year Award, presented for "Psychiatric

1979

Hospital Treatment for the 1980's" 1974-1978 1979-1980

Consultant, Psychiatric Education Branch of the National Institute of Mental Health

Ad Hoc Reviewer for the Psychosocial & Biobehavioral Treatments Subcommittee of the Treatment Development and Assessment Research Review Committee, NIMH Member, Special Review Committee on Depression, ADAMHA, NIMH (July)
Fulbright Research Scholar, Japan, (January through July). Research Fellowship, the Japanese National Institute of Mental Health, Itchikawa, Japan, (January through July) The American Psychiatric Association and PIA Award for Hospital Psychiatric Research, awarded

1982 1987 1987

1987

annually for research in the field of hospital psychiatric treatment. 1986-1997 1990
The Best Doctors in America The Seymour D. Vestermark Award, awarded annually "to recognize leadership & creativity in psychiatric education, "by the American Psychiatric Association, (given to the ACNP for a Model Curriculum in Psychopharmacology developed by a subcommittee which I co-chaired with David

Janowsky, MD) 1990

Director's Award, National Institute of Mental Health

1991

The Association for Academic Psychiatry Psychiatric Education Award, Honorable Mention,
3

Ira D. Glick, M.D.

awarded biannually for Innovative Educational Materials and Techniques, for the Model Curriculum in Psychobharmacology 1991 1991 1991-1994 1993 One of three recipients of Alumni Achievement Awards from New York Medical College Runner-up for The American Academy of Clinical Psychiatrists Clinical Research Award MacArthur Foundation Research Network on Depression The Van Ameringen Award in Psychiatric Rehabilitation, awarded annually by American Psychiatric Association, in recognition of outstanding and sustained contributions to field of psychiatric rehabilitation in areas of research, service and education (in 1992, I was given "Honorable Mention" for this same award) The Gralnick Award, given annually by the American Psychological Foundation to a researcher "whose work covers the psychosocial aspects of schizophrenia with an emphasis on the early stages of the disorder" Association for Academic Psychiatry Annual 1997 Education Award for "outstanding contributions as an educator, both in curriculum development and in presentation" Annual Outstanding Achievement Award of the Northern California Psychiatric Society (NCPS) of the APA, "recognizes a member of NCPS who has made significant and exceptional contributions to the field of psychiatry." Distinguished Contribution to Family Systems Research Award. This annual AFTA award recognizes an individual for outstanding research on subjects central to the field of family therapy. Rockefeller Foundation Award for Residence at Bellagio, Italy, Summer 2002. Metzger-Conway Fellow, Clarke Center, Dickinson College, Carlisle, PA Fulbright Lecturing Award, India Excellence in Teaching Award, Stanford University School of Medicine, Stanford, CA. In recognition of contributions to the educational mission of the school. Nominee for Franklin G. Ebaugh, Jr. Award for excellence in teaching, SUSM First Annual Irma Bland Award for Excellence in Teaching Residents, given annually by the American Psychiatric Association to Departments of Psychiatry for outstanding and sustaining contributions made as a faculty. Dickinson College Distinguished Alumni Award for Professional Achievement. This yearly award names alumni who have demonstrated outstanding accomplishment, as well as strength of character, in their professional and civic lives. Member, NIMH Review Committee concerned with clinical trials of pharmacotherapeutic, psychotherapeutic and combination treatments.

1994

1996

2000

2001

2002 2003 2003 2004

2004 2005

2006

2005-2009

Visiting Professorships (VP) & Endowed Lectures: 1972 VP: Dept. of Psychiatry, School of Medicine, University of San Marcos, Lima, Peru, (August) 1) Teaching of Psychiatry to Medical Students 2) Family Therapy Today
4

Ira D. Glick, M.D.

1978-1988 1979

Distinguished Lecturer, Lederle Pharmaceutical Co

VP: Dept. of Psychiatry, College of Medicine, University of Arizona, Health Science Center, Tucson, Arizona
Gary N. Spero Community Mental Health Memorial Lecture Series, "The Family Model in

1980

Inpatient and Day Hospital Settings," Maimonides Medical Center, Brooklyn 1980 1981 VP: Dept. of Psychiatry, University of Connecticut Health Center, Farmington, Connecticut VP: Maudsley Hospital, Tavistock Clinic and Hospital for Sick Children, London 1) "The Family Model in an Inpatient Setting", Seminar on Hospital Psychiatry, Mental Health Workers, Great Britain 2) "Family Therapy and Hospitalization", Tavistock Clinic 3) "Family Research", Marlborough Hospital 4) "Family Research", Grand Rounds, Hospital for Sick Children 5) "Indications and Contraindications for Family Therapy", The Family Institute of London
Keynote Address, "Guidelines for Family Therapy," as part of a continuing education course entitled "Clinical Techniques for the Practice of Family Therapy," sponsored by the Dept. of Psychiatry, Long Island Jewish- Hillside Medical Center Visiting Faculty Program, Mead Johnson Pharmaceutical Co.

1982

1982-1989 1983 1983

VP: Dept. of Psychiatry, University of California, San Diego VP: Dept. of Psychiatry, College of Medicine, University of Arizona Health Sciences Center, Tucson
Schweppes Visiting Professor, The Menninger Clinic, Topeka

1984 1985

VP: Dept. of Psychiatry, University of Wisconsin Medical School, Madison, "The Shrinking of Hospital Psychiatry" VP, Dept. of Psychiatry, Medical University of South Carolina, Charleston 1) Grand Rounds, "Inpatient Family Intervention - A Controlled Study" 2) Inge Taylor Memorial Lecture, "Why Don't Patients Receive Appropriate Psychiatric Treatment?" 3) All Day Seminar with Psychiatry Residents, "Theory & Practice of Integrative Psychiatry" VP: Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Dept. of Psychiatry, "The Family Model: Does It Have Anything to Offer for the Treatment of Affective Disorders?" VP: Fairfield Hills Hospital, Newtown, Connecticut, "Treating the Hospitalized Patient and Their Family" VP: Dept. of Psychiatry, School of Medicine, University of Verona, Italy, Jan-Jun
Visiting Lecturer Series, "Effectiveness in Psychiatric Care," New Jersey College of Medicine

1985

1985

1985

1986 1990

and Dentistry, Newark

Ira D. Glick, M.D.

1990

Invited Speaker, "What a Psychiatric Hospital Can and Cannot Do: A Review of Efficacy Studies." at a conference, "The Role of the Mental Hospital in the 21st Century," sponsored by the London Psychiatric Hospital, Ontario, Canada Invited Lecture, "New Wine in New Bottles: The Changing Role of Psychiatric Hospitals for Patients and Their Families," at The Sheppard Pratt National Symposium on Schizophrenia, Baltimore Academic Lecture: "New Models for the Treatment of the Chronically Mentally III," Annual Meeting of the Ontario Psychiatric Association, Toronto (February) Invited Lecture: "A Survival Guide for the Family of the Borderline Patient (and Vice Versa)," New Approaches to the "Borderline Syndrome," Sixth Tokyo Institute of Psychiatry International Symposium, Tokyo, Japan (November) VP & Invited Lecture: University Institutions of Psychiatry, Geneva, School of Medicine, University of Geneva, Switzerland and Invited Lecture, "Effectiveness in Psychiatric Care: A Followup Study of the Treatment of Hospitalized Patients with Major Affective Disorder seen in Europe, Asia and the U.S. United States" (April) VP: Institute of Clinical Psychiatry, School of Medicine, University of Pisa, Pisa, Italy, with Invited Lecture, "Effectiveness in Psychiatric Care: A Followup Study of the Treatment of Hospitalized Patients with Major Affective Disorder in Europe, Asia and the United States" Invited Lecture, "Effectiveness in Psychiatric Care: A Followup Study of the Treatment of Hospitalized Patients with Major Affective Disorder in Europe, Asia and the United States," Dept. of Psychiatry, Second School of Medicine, Naples, Italy (April) Invited Lecture, "Effectiveness in Psychiatric Care: A Followup Study of the Treatment of Hospitalized Patients with Major Affective Disorder in Europe, Asia and the United States," Institute of Clinical Psychiatry and the Dept. of Psychiatry, School of Medicine, Verona, Italy. Academic Lecture: "Combining Medications with Psychosocial and Rehabilitation Strategies for the 1990's," 2nd Annual Psychopharmacology Clinical Day, Department of Psychiatry, University of Toronto, Toronto (October). Distinguished Lecturer, Professors of Psychiatry Series: New Strategies of Treatment for Axis I Disorders, 1995. VP, Department of Psychiatry, School of Medicine and Surgery, University of Bari, Italy, June. Keynote Speaker, Strategies of Intervention in Family Psychotherapy, First National Congress, Italian Society for Research and Interventions on the Family, Subsection of the Italian Psychiatric Society.. Keynote Address, Combination Therapy for the Treatment of Psychosis, Third Annual STEP Symposium, Improving the Prognosis of Psychotic Disorders (Schizophrenia Treatment & Evaluation Program), University of North Carolina at Chapel Hill, June, 1996, Keynote Address, Combination Therapy for the Treatment of Axis I Disorders, 1996 Taipai Mental Health Conference, Taipai, Taiwan, December 1996. VP, Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, March 1997. Award Lecture, Through the Golden Chalkboard: Reflections on the Teaching-Learning Process in Psychiatry, 1997 Annual Meeting of the Association of Academic Psychiatry, March, 1997.

1990

1991

1991

1993

1993

1993

1993

1994

1995

1995

1996

1996

1997 1997

Ira D. Glick, M.D.

1998

VP, Department of Psychiatry & Internal Medicine, St. Francis Medical Center, Pittsburgh, PA, 1998.
Principal Speaker, "Lone Star : Society, The Familly and Individual Identity," as part of the film series of the New Orleans Museum of Art and Department of Psychiatry LSU, entitled: Lights, Camera - Analysis, " New Orleans, October, 1998. Keynote Speaker, "New Treatments for Schizophrenia and Other Psychoses," at the National Satellite Symposium for the Argentine Psychiatric Society, "Time for Change in the Treatment of Psychosis, " Buenos Aires, Argentina, November, 1998. Principal Speaker, at the National Conference organized by the Uruguayan Ministry of Health,

1998

1998

1998

Uruguayan Society of Psychiatry and the Psychiatric Department of the School of Medicine in the National University, Montevideo, Uruguay, November 1998: "New Atypical Antipsychotics and Their Indications" 'Combining Medication and Psychotherapy for Axis I Disorders" 1999 1999
Visiting Professor, University Hospital Utrecht, The Netherlands, Summer 1999. Plenary lectures at the Schizophrenia Symposium, Eastern Idaho Regional Medical Center, Idaho

Falls, ID, June, 1999: "New Strategies for the Treatment of Axis I Disorders" "New Treatments for Schizophrenia" 1999
Plenary Lecture, "New Diagnositic Methods and Treatments for Schizophrenia: Turning the Treatment Corner" at the Annual Meeting of the Canadian Psychopharmacologic Association, Halifax, June, 1999 Guest Lecture, "The New Atypical Antipsychotics for New Indications," Annual Meeting, Korean

2000

Psychopharmacology Association, Korea, April, 2000. 2000 2002

Visiting Professor, EPPIC Program, University of Melbourne, Melbourne, Australia, August, 2000. Invited Lecture, "Novel Antipsychotics: What We've Learned; What We Need to Know." CME

course on Novel Antipsychotics, Case Western Reserve University School of Medicine, Cleveland, September, 2002. 2004
Visiting Professor, Family Studies Unit, National Institute Mental Health and Health Series

(NIMHANS), Bangalore, India "Combining Medication and Psychotherapy" "The New Model of Inpatient Psychiatry" 2004
Inaugural Lecture, "Gary N. Spero Memorial Lectureship, "Schizophrenia and Psychosis: New

Data, New (Combined) Treatments & New Controversies." Department of Psychiatry, Weill Medical College of Cornell University, New York, March, 2004. 2004
Visiting Professor, School of Medicine, University of Iowa

Combining Medication and Psychotherapy for Axis I Disorders Schizophrenia: New Data and New Controversies 2005
At the Indonesian Society for Biological Psychiatry, Psychopharmacology and Sleep Medicine,

Jakarta, Indonesia, February, 2005. Educational Symposia, "The Teaching of Psychopharmacology: Circa 2005"

Ira D. Glick, M.D.

Opening Plenary Lecture: "Developing a Curriculum in Psychopharmacology" 2005

Lecture: "Developing a Curriculum in Psychopharmacology." Teaching Psychopharmacology: Substance, Methods, Science. Pre-Meeting: American Association of Directors of Psychiatric Residency Training, Tucson, AZ, March, 2005 Invited Lecture, "Collaboration With Big Pharma," as part of the Stanford Summer Research

2005

Institute, entitled Careers in Geriatric Psychopharmacology. Stanford, CA, July, 2005

Funded Research Activities:

1965-66 G.D. Searle Research Grant for the study
Pseudopregnancy Treatment of Periodic Psychiatric Illness

1971-75

National Institute of Mental Health Grant for the project MH-20593

Short vs. Long Psychiatric Hospitalization: A Controlled Study

$133,000 $ 25,484

Supplement 1975-77 Lederle Research Grant for the study

Loxitane Treatment in Schizophrenia

1977-1978

Endo Research Grant for the study

Molidone Hydrochloride vs. Haloperiodol: Double Blind Investigation of the Treatment of Acute Schizophrenia

1977-1982

National Institute of Mental Health Grant for

Medical Student Psychiatric Education, MH-10569

$395,280

1977-1978

Vice Chancellor's Advisory Committee on Instructional Improvements Grant, UCSF, for project Effectiveness and Efficiency in Small Group Teaching with Mary Malloy, MD

1,400 1982-1983 National Institute of Mental Health - Biomedical Research Support Grant for the study Inpatient Family Intervention: A Controlled Study National Institute of Mental Health Contract -to develop a Model
Psychopharmacology Curriculum for Psychiatric Residency Training Programs 83K055987501D (with David Janowsky MD) under the

$ 15,000

1982-1983

auspices of the American College of Neuropsychopharmacology . 1984-1986 National Institute of Mental Health Grant for project
Inpatient Family Intervention: Evaluation of Practice, MH-34466

$ 4,290

$180,000

1984-1993

National Institute of Mental Health, Cooperative Clinical Agreement Award for the project, Treatment Strategies in Schizophrenia, MH-40007 $863,000 1987-89 Supplement $104,000 1989-92 Competitive Renewal $688,581 1992-93 Supplement $ 30,000 Fulbright Research Award for the project, 8

1987

Ira D. Glick, M.D.

Delivery and Compliance to Good Medical Treatment

$ 20,000

1991

Janssen Research Grant for the study, Risperidone in the

Treatment of the Negative Symptoms of Schizophrenia

1992-1995

National Institute of Mental Health Grant, Marital Treatment for Bipolar Disorder Patients, MH-45528-01A3, Co-Principal Investigator with John Clarkin, PhD, P.I. $520,000
Depakote in the

1992 (Cornell) Abbott Laboratories Research Grant for the study:

Prevention of Mania

1993 (Stanford) 1992 Pfizer Research Grant for the study: CP-88 for the Treatment of Schizophrenia and Schizoaffective Disorder

1992 (Cornell) Abbott Laboratories Research Grant for the study: The Safety
and Efficacy of Sertindole in Schizophrenic Patients:

1993 (Stanford) A Double-Blind, HaIdol-Referenced, Placebo-Controlled Study 1993

Pharmacoloqic Medication Discovery & Development Project (PMDDP) Supported by SmithKline Beecham, Lilly & Abbott Laboratories

$10,000

1993

Pfizer Research Grant for the study, Treatment of Adolescent Depression

with Sertraline

1993

Abbott Laboratories Research Grant for the study, Safety and Efficacy
of Depakote in the Prevention of Mania in Patients With Bipolar Disorder

1995

Eli Lily unrestricted grant to develop a Model Psychopharmacoloqy Curriculum for Residents (Committee Chair) under the auspices of the American Society of Clinical Psychopharmacology

1995

Eli Lily Research Grant for the study, Olanzapine versus Risperidone
in the Treatment of Schizophrenia and other Psychotic Disorders

1995

Upjohn Research Grant for the study, Dose-response Study in the Treatment of Negative Symptoms of Schizophrenia with Pramipexole Abbott Laboratories Research Grant for the study, A Comparative Cost
Effectiveness Study of Depakote and Usual Care versus Lithium and Usual Care in the Treatment of Bipolar Disorder

$50,000

1995

1996

Zeneca Pharmaceuticals Research Grant for the study, A Multicenter,

Open, Randomized Comparison of Seroquel and Usual Care on Health Outcomes in Subjects with Schizophrenia and Schizoaffective Disorder

1997

Hoechst Marion Roussel Research Grant for the study, A Multicenter,

Randomized, Double-Blind, Placebo and Active Controlled Study of MDL 100,907 in Schizophrenic and Schizoaffective Patients

1997

Otsuka America Pharmaceutical, Inc. Research Grant for the study,

A Phase III Double-Blind Placebo-Controlled Study of Aripiprazole

Ira D. Glick, M.D.

in the Treatment of Psychosis, with Risperidone as Active Control

1998

Novartis Pharmaceuticals Corporation, A Prospective, Randomized, International,

Parallel-group Comparison of Clozaril/Leponex vs. Zyprexa in the Reduction of Suicidality in Patients with Schizophrenia or Schizoaffective Disorder Who Are At Risk for Suicide

1998

Zeneca Pharmaceuticals Research Grant for the investigator initiated study, Quetiapine vs Haloperidol Decanoate for the Long-Term
Treatment of Schizophrenia and Schizoaffective Disorder

$100,000

with Marder S. 1998 Lilly Research Labs, The Acute and Long-Term Efficacy of Olanzapine
in First-Episode Psychotic Disorders: A Randomized Double-Blind Comparison w/Haloperidol

1998

Pfizer Pharmaceuticals, A Multi-Center, Placebo Controlled Double Blind Study Comparing the Safety and Efficacy of Ziprasidone and Olanzapine in Subjects with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care. Janssen Pharmaceutica, Risperidone Depot vs. Placebo in the Treatment of
Subjects with Schizophrenia or Schizoaffective Disorder

1999

1999

Development of a Model Psychopharmacology Curriculum for Psychiatric Residents. (through the American Society of Clinical Psychopharmacology)

$15,000

Supported in part by Lilly, Janssen and Zeneca Pharmaceuticals. 2000 Bristol-Myers Squibb, Aripiprazole vs. Perphenazine in the Treatment of
Patients with Acute Schizophrenia.

2000 National Institute of Mental Health, sub-contract (MH90001), Comparative

$550,000

Effectiveness of Antipsychotic Medications in Patients with Schizophrenia CATIE.

Human Genetics Initiative 2001 Bristol-Myers Squibb, A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Flexible Doses of Aripiprazole Versus Perphenazine In the Treatment of Patients with Treatment-Resistant Schizophrenia. Pfizer, Zodiac International Schizophrenia Study to Compare the Cardiovascular Safety of Ziprasidone and Olanzapine. Pfizer, A 12 Week Multicenter, Randomized, Double-Blind, Placebo Controlled
Evaluation of Donepezil Hydrochloride as Adjunctive Therapy in the Treatment

2003

2003

of Cognitive Impairment in Patient with Schizophrenia or Schizoeffective Disorder 2004 2004 2004 Oshima Education Fund Astra-Zeneca, Comparison of Atypicals for First Episode (CAFE) Bristol-Myers Squibb, The Treatment of Schizophrenia and OCD Symptomatology with Aripirazole (investigator initiated study). Bristol-Myers Squibb, Efficacy and Weight Reduction Effects of Aripiprazole in Stabilized Patients with Schizophrenia and Weight Associated $80,000 $30,000

2004

$105,000
10

Ira D. Glick, M.D.

with Atypical Antipsychotics (investigator initiated study). 2005 AmericanCollege of Neuropsycopharmacology, ACNP Public Outreach Program GlaxoSmithKline, Lamictal vs Depakote Double Blind. (investigator initiated study) Solvay Pharmaceuticals, Parallel-Group Efficacy and Safety Study of Two Fixed Doses of Bifeprunox in the Treatment of Schizophrenia. Co-Investigator of a Harman Clinic Endowment Grant for a project $145,000 Fostering Collaboration Through Clinical Education: A Clinical Neurosciences Seminar, Clinic and Curriculum Series in Child Psychiatry and Pediatric Neurology (with Joshi SV, Chang KD and Hahn J). $ 5,000

2005

$120,000

2005

2005

Regional and National Professional Societies:

1965-1970 1965-

American Medical Association American Psychiatric Association 1971 Fellow 1985-92 Foundations' Fund Board for Research in Psychiatry (Chair, 1985-92) 1999 Life Fellow 1999 Member, Committee on Research on Psychiatric Treatments 2003 Sub-committee on Antipsychotic Drugs & Diabetes Mellitus 2004 Committee on Awards, Northern California Psychiatric Society American College of Psychiatrists 1990 Fellow 1996 Committee on Honorary Fellowships Society of Biological Psychiatry 1991-93 Resource Development Committee 1997Task Force on the Future of SBP 2001 George N. Thompson Award Committee, Society of Biological Psychiatry American College of Neuropsychopharmacology 1973Scientific Associate 1978 Member 1980-84 Education and Training Committee, (Chair, 1982-84) 1984 Fellow 1984-90 Co-Chair, Committee to Develop a Model Curriculum in Psychopharmacology 1987-89 Committee on Problems of Public Concern 1989-91 Task Force on Coordinating Academic Industry & Government Efforts in Psychopharmacology 1989 & '96-98 Task Force on Psychotropic Drug Prescribing Privileges for Non-physicians 1988-92 Task Force on Scientific Misconduct 1994Mentor, NIMH/Mead Johnson Minority Award Program 1995-97 Finance Committee (Chair, 1997-98)
11

1970-1974 & 1990-

1970-

1973-

Ira D. Glick, M.D.

2000-03 2006-07 1973

Constitution and Rules Committee (Chair, 2002-2004) Co-Chair of the Education and Training Committee

Association for Academic Psychiatry, Charter Member 1978-80 Secretary 1983 Co-Chairman and Founder, Section on Residency Training 1983-84 Fellowship Committee The Hastings Center-Institute of Society, Ethics and the Life Sciences American Family Therapy Academy 1982-84 Board of Trustees 1985 Committee on History of AFTA American Association of Psychiatric Administrators Association for Clinical Psychosocial Research, Founding Member 1982-85 Steering Committee 1988 Fellow Group for the Advancement of Psychiatry, Committee on the Family 1991 Program Committee 1992 Ad hoc Committee to Develop Practice Guidelines Psychiatric Research Society Collegium Internationale Neuro-Psychopharmacologicum (C.I.N.P.) 2002 CINP Regional Committee for North America Academia, Medicine & Psychiatria Foundation 1992 Fellow American Society of Clinical Psychopharmacology, Founding Member 1993 Model Curriculum Committee, Chair 1995Work Group, Interface with Government & Industry, Clinical Trials Committee 1998 Scientific Advisory Board 2001-04 Treasurer 2005Co-chair, Joint ASCP-AADPRT Curriculum Project (with David Goldberg, MD) International Society for Sports Psychiatry, Founding Member 1993Chair, Scientific Program 1993 Executive Board 2004 Chair, Nomination Committee West Coast College of Biological Psychiatry, Fellow 1998 Program Chair Pacific Rim College of Psychiatrists, Fellow ACNP, Co-Chair of he Education and Training Committee

1978 1978

1980 1982

1984-94

1989 1990

1992-

1993-

1993-

1997

1998 2006-2007

Editorial and Advisory Boards:

12

Ira D. Glick, M.D.

1970-1981 1981 1981 1982 1982-1995 1984-1997 1984-1987 1989 1990 -2 1993 1993 1995-1997 1996 1997- 9 1997- 9 1997 1998

Family Process Journal of Clinical Psychopharmacology Contemporary Family Therapy - An International Journal The Journal of Family Therapy (England) Board of Advisors, Dickinson College The Journal of Family Psychotherapy National Council of Advisors on Development and External Affairs, UCSF Progress in Neuropsychology and Biological Psychiatry Advisory Board, MultiMedia Reviews in Psychiatry,, Massachusetts General Hospital. Board Member, The National Mental Health Project Sertindole Advisory Board Neuroscience Venture, Abbott Laboratories Gralnick Foundation Awards Committee CNS Science Advisory Board, Wyeth Ayerst Pharmaceutical Advisory Board, Janssen Pharmaceutica and Research Foundation Advisory Board, Institute for Healthcare Quality, Minneapolis Advisory Board, Zeneca Pharmaceuticals Advisory Board, Otsuka Pharmaceuticals

1999Advisory Board, Hoechst Marion Roussel (Aventis) 1999Advisory Board, NPSP Pharmaceuticals Bipolar Clinical Advisory Board, Boca Raton 2001, 5 2001 2002, 4,5 2002, 3,4,5 2005 Advisory Board, Pfizer (Geodon) Pharmaceuticals Board of Directors, National Foundation for Depressive Illness, Inc. Advisory Board, Shire Pharmaceuticals Advisory Board, Bristol-Myers Squibb California Neuroscience Advisory Board Editorial Board, The Journal of Clinical Psychiatry

PUBLICATIONS Books, Monographs, Bibliographies:

1.

Haley J, Glick ID: Psychiatry and the Family, An Annotated Bibliography of Articles Published 1960-64. Palo Alto, California, Family Process, 1965.
13

Ira D. Glick, M.D.

2.

Glick ID, Haley J: Family Therapy and Research: An Annotated Bibliography of Articles and Books Published 1960-1970. New York, Grune and Stratton, 1971. Glick ID, Kessler DR: Marital and Family Therapy. New York, Grune and Stratton, 1974 1976 - Summarized in Foote C, Levy RJ, Sander FEA, Cases and materials on family law, second edition, Boston, Little, Brown, 1976, pp. 1153-1145 1980 - Second Edition. 1985 - Translated into Japanese by Koji Suzuki, MD; 2nd printing, 1989 1986 - Translated into Chinese by Xiang De-Zhao, MD 1987 - Third Edition, with Clarkin JF & Kessler DR. Published by American Psychiatric Press, Inc., Washington, D.C. 2000 - Fourth Edition, with Berman E, Clarkin JF & Raft D. American Psychiatric Press, Inc., Washington, D.C. 2002 Spanish Edition, translated by Raquel Martin Lanas, Madrid, Grupo Medica, Glick ID, Hargreaves WA: Psychiatric Hospital Treatment for the 1980s: A Controlled Study of Short Versus Long Hospitalization. Lexington, Mass., Lexington Press, 1979.

3.

4.

5. Glick ID, Weber D, Rubinstein D, Patten J: Family Therapy and Research: An Annotated Bibliography of Articles, Books, Videotapes and Films Published 1950-1979, 2nd Edition, New York, Grune and Stratton, 1982. 6, Glick ID, Janowsky DS, Salzman C, Shader RI: A Model Psychopharmacology Curriculum for Psychiatric Residents. Nashville, TN, The American College of Neuropsychopharmacology, 1984 a) Translated into Japanese, Japanese Journal of Psychopharmacology, 6:335-452, 1986 b) Reprinted in Psychopharmacology: The Third Generation of Progress, edited by Herbert Y. Meltzer. Raven Press, New York, 1313-1321, 1987 c) Translated into Japanese for the Lectures on Clinical Psychiatric Issues, Part II, edited by Yamaguchi T, Tajima S. Chugoku-shikoku Psychotherapy Workshops, Hiroshima and Nichidai Seishin-shinkeika Workshops, Tokyo 1994 Grunebaum H, Beavers WR, Berman E, Combrinck-Graham L, Glick ID, et al: (Formulated by the Committee on the Family, Group for the Advancement of Psychiatry), The Family, the Patient, and the Psychiatric Hospital: Toward a New Model. New York, Brunner/Mazel, 1985. Clarkin JF, Haas GL, Glick ID (eds): Affective Disorders and the Family: Assessment and Treatment, New York, Guilford Press, 1988. Glick ID (ed): Treating Depression, San Francisco, Jossey-Bass, 1995. DeBattista C, Glick ID (ed.). The Medical Management of Depression. Essential Medical Information Systems, Inc. Durant, OK: 1996. 1998 - Second Edition 2002 Third Edition Glick ID, Doraiswarmy PM, Halper J, et al: 2001 - Second Edition 2004- Third Edition Glick ID, Ellison J, Halper J, et al: The ASCP Model Psychopharmacology Curriculum, for Psychiatric Residency Programs, Training Directors, and Teachers of Psychopharmacology. The American Society of Clinical Psychopharmacology, Inc. New York, 2004. Ritvo EC, Glick ID: The Concise Guide to Marriage and Family Therapy. American Psychiatric Press, Inc. Washington, DC, 2002.
14

7.

8.

9. 10.

11.

12.

Ira D. Glick, M.D.

2005 13.

Spanish Edition translated by Jose Luis Nunez Herrejon, Madrid, Manual Moderno pubs.

Tandon R, Glick ID, Goldman M, Jibson MD, Marder SR, Mel!man TA: Managing Schizophrenia, A Comprehensive Primer 2005. McMahon Publishing Group, New York, 2005.

Journal Articles: 1. Glick ID, Singer B: Follow-up of patients discharged from the rehabilitation service of a hospital for treatment of chronic disease. Arch Phys Med Rehab 44:29-36, 1963. Greenberg IM, Glick ID, Match S, Riback SS: Family therapy: Indications and rationale. Arch Gen
Psychiat 10:7-24, 1964.

2.

3.

Glick ID, Grauber DN: Kartagener's syndrome and schizophrenia: Report of a case with chromosomal studies, Am J Psychiatry 121:603-605, 1954 Glick ID, Salerno LF, Royce JR: Psychophysiologic factors in etiology of preeclampsia. Arch Gen Psychiat 12:260-266, 1965. Glick ID: Mood and behavioral changes associated with the use of the oral contraceptive agents: A review of the literature. Psychopharmacol 10:363-374, 1967. Glick ID, Setleis H, Woerner MH, Pollack M: Schizophrenia in siblings reared apart: A case report. Am J Psychiatry 124:236-240, 1967. Glick ID: The "sick" family and schizophrenia - cause and effect? Supplement, Dis New Syst 29:129132, May 1968. Hauptman B, Glick ID: Auditory hallucinations with imipramine. J Hillside Hosp 17:32-34, 1968 Mardikian B, Glick ID: Patient-staff meetings: A study of some aspects of content, tone and speakers. Ment Hygiene 53:303-305, 1969. Glick ID, Sternberg D: Performance IQ as a predictor of hospital treatment Comprehen Psychiat 10:365368, 1969. Goldfield MD, Glick ID: Self-mutilation of the female genitalia. J Nerv Ment Dis 31:843-845, 1970. Glick ID, Hauptman B, Klein DF: Pseudopregnancy treatment of periodic psychiatric illness: A pilot study. Psychiat Quart 44:403-407, 1970. Chastko HE, Glick ID, Gould E, Hargreaves WA: Patients' posthospital evaluation of psychiatric nursing treatment. Nurs Res 20:333-338, 1971. Glick ID, Winstead D: Childhood a sociality in the differential diagnosis of schizophrenia with drug abuse vs. psychosis with drug intoxication. Psychiat Quart 47:208-217, 1973. O'Hanrahan T, Glick ID: Drug abuse and function in graduate students. Comprehen Psychiat 14:235240, 1973. Langee H, Glick ID, Hoffman B, Silver LB, Morrison AP: The requirements of a residency training program, circa 1972. Am J Psychiatry 130:1151-1152, 1973. Glick ID, Goldfield MD, Kovnat P: Recognition and management of psychosis associated with hemodialysis. Calif Med 119:56-59, 1973.
15

4.

5.

6.

7.

8. 9.

10.

11. 12.

13,

14.

15.

16.

17.

Ire D. Glick, M.D.

18.

Glick ID, Hargreaves WA, Goldfield MD: Short versus long hospitalization: A prospective controlled study. 1. Preliminary results of a one year followup of schizophrenics. Arch Gen Psychiat 30:363-369, 1974. Glick ID, Hargreaves WA, Raskin M, Kutner SJ: Short versus long hospitalization: A prospective controlled study. II. Inpatient results for schizophrenics. Am J Psychiat 132:385-390, 1975. Glick ID, Hargreaves WA, Drues J, Showstack JA: Short versus long hospitalization: A prospective controlled study. Ill. Inpatient results for non-schizophrenics. Arch Gen Psychiatr 33:78-83, 1976. Gould E, Glick ID: Patient-staff judgments of treatment program helpfulness on a psychiatric ward. Med Psychol 49:23-33, 1976.
Br J

19.

20.

21.

22.

Glick ID, Hargreaves WA, Drues J, Showstack JA: Short or long hospitalization for psychiatric disorders? Psychopharm Bull 11(4):35-37, 1975 (abstract). Glick ID, Hargreaves WA, Drues J, Showstack JA: Short versus long hospitalization: A prospective controlled study. IV. One-year followup results for schizophrenics. Am J Psychiatry 133:509-514, 1976. Glick ID, Hargreaves WA, Drues J, Showstack JA: Short versus long hospitalization: A prospective controlled study. V. One year followup results for nonschizophrenics. Am J Psychiatry 133:515-517, 1976. Leib AC, Underwood PR, Glick ID: The staff nurse as primary therapist: A pilot study. J Psychiatric Nurs
Ment Health Services 14:11-17, 1976.

23.

24.

25.

26.

Hargreaves WA, Glick ID, Drues J, Showstack JA, Feigenbaum E: Short versus long hospitalization: A prospective controlled study. VI. Two year followup results for schizophrenics. Arch Gen Psychiatry 34:305-311, 1977. Glick ID, Hargreaves WA, Drues J, Showstack JA: Short versus long hospitalization: A prospective controlled study, VII. Two year followup results for non-schizophrenics. Arch Gen Psychiatry 34:314-317, 1977. Gould E, Glick ID: The effects of family presence and family therapy on outcome of hospitalized schizophrenic patients. Family Process 16:503-510, 1977. Glick ID, Epstein LJ: Increasing learning during the psychiatric residency. 550, 1977.
Comprehen Psychiatry 18:545-

27.

28.

29.

30.

Dinaburg D, Glick ID, Feigenbaum E: Use of marital therapy in the treatment of female alcoholism. Studies Alcohol 38:1247-1258, 1977.

31.

Showstack JA, Hargreaves WA, Glick ID, O'Brien RS: Psychiatric followup studies: Practical procedures and ethical concerns. J New & Ment Dis 166:34-43, 1978. Glick ID, Bennett SE: Psychiatric complications of progesterone and oral contraceptives. J Clin Psychopharmacology 1:350-365, 1981. Glick ID: Short-term intensive psychiatric hospital treatment: Which treatment and for whom? J Nat'l
Assoc Private Psychiatr Hosp 9:8-11, 1977.

32.

33.

34.

Young RD, Glick ID, Hargreaves WA, Braff D, Drues J: Therapists A-B score and treatment outcome with psychiatric inpatients: A table of random numbers. Br J Med Psychol 52:119-122, 1979.

16

Ira D. Glick, M.D.

35.

Braff D, Stone C, Callaway E, Geyer M, Glick ID, Bali L: Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15:339-343, 1978. Drues J, Hargreaves WA, Glick ID, Klein DF: Premorbid asocial adjustment and outcome in schizophrenia. J Nerv & Ment Dis 166:881-884, 1978. Braff DL, Bachman J, Glick ID, Jones R: The therapeutic community as a research ward: Myths and facts. Arch Gen Psychiat 36:355-360, 1979. Kessler DR, Glick ID: Brief family therapy. Psychiatric Clinics of North America, 2:75-84, 1979. (Reprinted in Advances in Family Psychiatry, Vol. III, Howells J (Ed), NY Int. Press). Glick ID, Hargreaves WA: Hospitals in the 1980s: Service, training and research. Hosp & Comm Psychiatr 30:125-128, 1979. Davis C, Glick ID, Rosow I: The architectural design of a psychotherapeutic milieu. Hosp & Comm
Psychiatr 30:453-460, 1979.

36.

37.

38.

39.

40.

41.

Glick ID, Kessler DR: Family Therapy, in the American Psychiatric Association's Syllabus for SelfAssessment Program (PKSAP=IV), 1979, pp 131-1. Glick ID, Stewart D: A new drug treatment for premenstrual exacerbation of schizophrenia. Comprehensive Psychiatry 21:281-287, 1980 Glick ID, Marcotte DB: Psychiatric aspects of basketball. Psychiatric Annals 10:3, 1980. Clarkin JF, Glick ID: Duration of hospitalization as a variable in outcome. The Psychiatric Hospital 13:5054, 1982. Young RC, Gould E, Glick ID, Hargreaves WA: Personality inventory correlates of outcome in a followup study of psychiatric hospitalization. Psychological Reports 46:903-906, 1980. Binder R, Glick ID, Rice M: A comparative study of parenteral molindone and haloperidol in the acutely psychotic patient. J Clin Psychol 42:203-206, 1981. Johnson GR, Glick ID, Young R: Length of stay of patients in sheltered care and physical space: A comparative study. Psychological Reports 47:703-708, 1980. Glick ID, Braff DL, Johnson J, Showstack JA: Outcome of irregularly discharged psychiatric patients. Am
J Psychiatry 138:1472-1476, 1981, (French translation, Medecine et Hygiene, 44:3320-3328, 1986).

42.

43. 44.

45.

46.

47.

48.

49. 50.

Glick ID: A family therapist in the People's Republic of China. Intl J Family Therapy, 4:177-183, 1982 Pynoos RS, Glick ID: The use of joint consultations in inpatient psychiatry. Am J Psychiatry, 140:596-598, 1983. Clarkin JF, Glick ID: Recent developments in family therapy: A review. Hosp Comm Psychiatry, 33:550556, 1982. Reprinted in Psychotherapies (French). Glick ID, Showstack JA, Klar HM: Toward the definition and delivery of appropriate care. Am J Psychiatry 139:908-909, 1982. Braff DL, Glick ID, Griffin P: Thought disorder and depression in psychiatric patients. Comp Psychiatry, 24:57-64, 1983.
17

51.

52.

53.

Ira D. Glick, M.D.

54.

Frosch WA, Glick ID, Talbott JA: The teacher as impediment to learning: The problem of focal conviction. Arch Gen Psychiatry, 40:1257, 1983. Glick ID, Borus JF: Marital and family therapy for troubled physicians and their families. JAMA, 251:18551858, 1984. 1. Translated into Japanese, JAMA, pp 27-32, 1984 Brown R, Kocsis J, Glick ID: Efficacy and feasibility of high dose tricyclic antidepressant treatment in elderly delusional depressives. J Clin Psychopharm, 4:311-315, 1984. Glick ID, Klar HM, Braff DL: Guidelines for hospitalization of chronic psychiatric patients. Hosp & Comm Psychiatry, 35:934-936, 1984. Chen C, Glick ID: Core tasks in the resident's mastery of psychiatric administration. Admin in Mental Health, 12:207-211, 1985. Glick ID, Clarkin JF, Spencer JH, et al: Inpatient family intervention. A controlled evaluation of practice: I. Preliminary results of the six-months follow-up. Arch Gen Psychiatry, 42:882-886, 1985. Reprinted in the Sixth Edition of the Psychiatric Knowledge and Skills Self-Assessment Program VI of the American Psychiatric Association Roy-Byrne P, Pynoos RS, Glick ID: The inpatient psychiatric unit as consultation service. Can J Psychiatry, 31:54-58, 1986. Glick ID, Spencer J: Inpatient family therapy: On the boundary between past and present. Fam Proc, 24:349-352, 1985.61. Janowsky DS, Glick ID, Lash L, et al: Psychobiology and psychopharmacology: Issues in clinical research training. J Clin Psychopharmacol, 6:1-7, 1986. Gruenke LD, Craig JC, Klein FK, Glick ID, et al: Determination of chlorpromazine and its major metabolites by gas chromatography/mass spectrometry: Application to biological fluids. Biomedical Mass Spectrometry, 12:707-713, 1985. Glick ID, Fleming L, DeChillo N, et al: A controlled study of transitional day care for non-chronically-ill patients. Am J Psychiatry, 143:1551-1556, 1986. Glick ID: Treating the new American couple. J of Sex & Marital Therapy, 12:297-306, 1986. Translated into Japanese for the Journal of the Japanese Association of Group Psychotherapy, 1988. Haas GL, Glick ID, Spencer JH: The patient, the family, and compliance with posthospital treatment for affective disorders. Psychopharmacology Bulletin, 22:999-1005, 1986. Talbott JA, Glick ID: The inpatient care of the chronically mentally ill. Schizophrenia Bulletin, 12:129-140, 1986. Haas GL, Glick ID, Clarkin JF, et al: Inpatient family intervention: A randomized clinical trial II. Results at hospital discharge. Arch Gen Psychiatry, 45:217-225, 1988. Braff DL, Glick ID, Johnson MH, Zisook S: The clinical significance of thought disorder across time in psychiatric patients. J Nerv Ment Dis, 176:213-220, 1988. Glick ID, Marcotte DB: Psychiatric aspects of basketball. JSports Medicine & Physical Fitness, 29:104112, 1989.
18

55.

56.

57.

58.

59.

60.

61.

62.

63.

64.

65.

66.

67.

68.

69.

70.

Ira D. Glick, M.D.

71.

Greenberg L, Fine SB, Cohen C, Larson K, Michaelson A, Rubinton P, Glick, ID: An interdisciplinary psychoeducation program for schizophrenic patients and their families in an acute care setting. Hospital & Community Psychiatry, 39:277-282, 1988. Andreason NC, Glick ID: Bipolar affective disorder and creativity: Implications and clinical management. Comprehensive Psychiatry, 29:207-217, 1988. Spencer JH, Glick ID, Haas GL: A randomized clinical trial of inpatient family intervention, Ill. Overall effects at followup for the entire sample. Am J Psychiatry, 145:1115-1121, 1988. Burti L, Glick ID, Tansella M: Measuring the Treatment Environment of a Psychiatric Ward and a Community Mental Health Center After the Italian Reform. Community Mental Health Journal, 26:193201, 1990. Glick ID, Showstack JA, Cohen C, Klar HM: Between Patient and Doctor: Improving the Quality of Care for Serious Mental Illness. Bulletin of the Menninger Clinic, 53:193-202, 1989. Glick ID, Spencer JH, Clarkin JF, et al: A Randomized Clinical Trial of Inpatient Family Intervention IV. Followup Results for Subjects with Schizophrenia. Schizophrenia Research, 3:187-200, 1990. Glick ID, Jacobs M, Lieberman J, et al: Prediction of Short Term Outcome in Schizophrenia: Depressive Symptoms, Negative Symptoms, and Extrapyramidal Signs. Psychopharmacology Bulletin, 25:344-347, 1989. Clarkin JF, Glick ID, Haas GL, et al: A randomized clinical trial of inpatient family intervention, V. Results for affective disorders. J Affective Disorders, 18:17-28, 1990. Glick ID, Burti L, Suzuki K, Sacks WI: Effectiveness in psychiatric care: I. A cross-national study of the process of treatment and outcomes of major depressive disorder. J Nerv Ment Disease, 179:55-63, 1991. Glick ID, Clarkin JF, Haas G, et al: A randomized clinical trial of inpatient family intervention: VI. Mediating variables and outcome. Family Process, 30:85-99, 1991. Haas GL, Glick ID, Clarkin JF, et al: Gender and schizophrenia outcome: A clinical trial of an inpatient family intervention. Schizophr Bull, 16:277-292, 1990. Glick ID: Improving treatment for the severely mentally ill: Implications of the decade-long Italian psychiatric reform. Psychiatry, 53:316-323, 1990. Glick ID, Burti L, Minakawa K, Maehara K, Sacks M: Effectiveness in psychiatric care: II. Outcome for the family after hospital treatment for major affective disorder. Annals of Clinical Psychiatry, 3:187-198, 1991. Glick ID, Janowsky DS, Salzman C, Shader RI: A proposal for a model psychopharmacology curriculum for psychiatric residents. Neuropsychopharmacology, 8:1-5, 1993. Glick ID, Burti L, Suzuki K, Sacks M: Effectiveness in psychiatric care: IV. Achieving effective medication management for major affective disorder. Psychopharmacology Bulletin 28:257-259, 1992. Glick ID: Medication and family therapy for schizophrenia and mood disorder. Psychopharmacology Bulletin, 28:223-225, 1992. Olfson M, Glick ID and Mechanic D: Inpatient treatment of schizophrenia in general hospitals. Hospital & Community Psychiatry, 44:40-44, 1993.

72.

73.

74.

75.

76.

77.

78.

79.

80.

81.

82.

83.

84.

85.

86.

87.

19

Ira D. Glick, M.D.

88.

Glick ID, Burti L, Okonogi K, Sacks M: Effectiveness in psychiatric care: Ill. Psychoeducation and outcome for patients with major affective disorder and their families. British Journal of Psychiatry, 164: 104-106, 1994. Glick ID, Clarkin JF, Haas GL, Spencer JH: Clinical significance of inpatient family intervention: VII. Conclusions from the clinical trial. Hospital and Community Psychiatry, 44:869-873, 1993. Glick ID, Dulit RA, Wachter E, Clarkin JF: The family, family therapy & borderline personality disorder. Psychotherapy Practice and Research , 4:237-246,1995. Carpenter D, Clarkin JF, Wilner PJ, Glick ID: Personality pathology among married adults with bipolar disorder. Journal of Affective Disorders, 34:269-274, 1995. Guttman HA, Beavers WR, Berman E, Combrinck-Graham L, Glick ID, et al: A model for the classification and diagnosis of relational disorders. J Psychiatric Services, 46:926-932, 1995. Hanrahan M, Glick ID: Improving outpatient treatment for severely mentally ill persons: doing the right thing. Administration Policy in Mental Health, 23:459-463, 1996. Schooler NR, Severe JB, Glick ID, Hargreaves WA, Keith SJ: Transition From Acute To Maintenance Treatment: Prediction of Stabilization. Internat'l Clin Psychopharm, 11 (suppl2):85-91, 1996. Glick ID, Lecrubier Y, Montgomery S, Vinar 0, Klein DF: Efficacious and safe psychotropics not available in the United States. Psych Annals, 26:354-361, 1996. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID: Relapse and rehospitalization during maintenance treatment of schizophrenia: The effects of dose reduction and family treatment. Archives of Gen Psych, 54:453-463, 1997. Guttman HA, Beavers WR, Berman E, Combrinck-Graham L, Glick ID, et al: (Group for the Advancement of Psychiatry Committee on the Family): Global assessment of relational functioning scale (GARF): I. Background and Rationale, Family Proc, 35:155-172, 1996. Clarkin JF, Carpenter D, Hull J, Winer P, Glick ID: Effects of psychoeducational intervention for married bipolar patients and their spouses. Psychiatric Services, 49:531-533, 1998. Glick ID: The inpatient family intervention (IFI) experience. Italian J Psych Behav Sci, 1:1-9, 1997. Pearsall R, Glick ID, Pickar D, Suppes T, Tauscher J, Jobson KO: A new algorithm for treating schizophrenia. Psychopharmacology Bulletin, 34:349-353, 1998. Schultz SC, Thompson P, Jacobs M, Ninnan PT, Robinson D, Weiden P, Yadalam K, Glick ID: Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry, 60:366-372, 1999. Mordacai D, Glick ID: Divalproex for the treatment of geriatric bipolar disorder. In J Geriatric Psychiatry, 14:494-496, 1999. Ambrosini PJ, Wagner KD, Biederman J, Glick I: Multicenter open-label sertraline study in adolescent oupatients with major depression. J Am Child Adolesc Psychiatry, 38:566-572, 1999. Jeste DV, Glick ID: Editors' Introduction: "Intervention research in psychosis: past, present, and future." Schizophrenia Bulletin, 26:527-531, 2000. J

89.

90.

91.

92.

93.

94.

95.

96.

97.

98.

99. 100.

101.

102.

103.

104.

20

Ira D. Glick, M.D.

105.

Mueser KT, Sengupta A, Schooler NR, Bellack AS, Xie H, Glick ID, Keith SJ: Family treatment and medication dosage reduction in schizophrenia: effects on patient social functioning, family attitudes, and burden. J Consulting & Clinical Psychology; 69:3-12, 2001. Glick ID, Suppes T, DeBattista C, Hu R, Marder S: Clinical update: psychopharmacological treatment strategies for depression, bipolar disorder and schizophrenia. Annals Internal Medicine 134:47-60, 2001. Glick ID, Janowsky DS, Zisook S, Lydiard RB, Oesterheld J, Ward NG, Ellison J, Shear MK, Doraiswamy PM, Preven DW, Ross P, Klein DF: Teaching psychopharmacology in the 1990s: the first year experience with The American Society of Clinical Psychopharmacology model psychopharmacology curriculum. Academic Psychiatry, 25:1-8, 2001. Glick ID, Horsfall JL: Psychiatric conditions in sports: diagnosis, treatment, and quality of life. The Physician and Sportsmedicine, 29: 45-55, 2001. Glick ID, Lemmens P, Vester-Blokland E: Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. International Clinical Psychopharmacology, 16:265-274, 2001. Klein DF, Glick ID et al: Improving clinical trials: American Society of Clinical Psychopharmacology recommendations. Archives of General Psychiatry, 59:72-278, 2002. Glick ID, Murray SF, Vasudevan P Marder SR, Hu RJ: Treatment with atypical antipsychotics: new indications and new populations. J Psychiatric Research 35:187-191, 2001. Glick ID, Berg PH: Time to study discontinuation, relapse and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. International Clin Psychopharm 17:65-68, 2002. Glick ID, Dixon L: Patient and family support organization services should be included as part of treatment for chronic psychiatric illness. J Psychiatric Practice, 8:63-69, 2002. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Archives
of General Psychiatry 60:553-564, 2003.

106.

107.

108.

109.

110,

111.

112.

113.

114.

115.

Stroup TS, McEvoy JP, Swartz MS, Byerly M, Glick ID, et al: The NIMH antipsychotic trials of intervention effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophrenia Bulletin 29:15-32, 2003. Jibson MD, Glick ID, Tandon RT: Schizophrenia and other psychotic disorders. Focus 2:17-30, 2004. Glick ID, Carter WG, Tandon R: A paradigm for treatment of inpatient psychiatric disorders: from asylum to intensive care. J Psychiatric Practice 9:1-5, 2003. Glick ID, Zaninelli R, Hsu C, et al: Patterns of concomitant psychotropic medication use during a two year study comparing clozapine and olanzapine for the prevention of suicidal behavior. J Clinical Psychiatry 65:679-685, 2004. Glick ID: Adding psychotherapy to pharmacotherapy: data, benefits, and guidelines for integration. Am J Psychotherapy 58:186-208, 2004. Zisook S, Benjamin S, Balon R, Glick ID, et al: Alternate methods of teaching psychopharmacology. Academic Psychiatry 29:141-154, 2005. Glick ID: Undiagnosed bipolar disorder: new syndromes and new treatments. The Primary Care Companion to the J Clin Psychiatry 6:27-33, 2004.
21

116. 117.

118.

119.

120.

121.

Ira D. Glick, M.D.

122.

Glick ID, Zisook S: The challenge of teaching psychopharmacology in the new millennium: the role of curricula. Academic Psychiatry 29: 134-140, 2005. Green Al, Tohen MF, Hamer RM, et al: First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research 66:125-135, 2004. Glick ID: Psychosis: new perspectives and strategies: l'Encephale 37:49-50, 2001. Glick ID: Atypical antipsychotics: new data and new controversies. Japanese J Clin Psychopharmacology 6:500-512, 2003. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO: Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161:1837-1847, 2004. Glick ID, Marder SR: Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clinical Psychiatry 66:638-641, 2005. Ritvo EC, Glick ID: Family problems and sports performance. Physician & Sportsmedicine 33:37-41, 2005. Glick ID, Duggal V, Hodulik C: Aripiprazole as a dopamine partial agonist: positive and negative effects. J Clinical Psychopharmacology (in press).

123.

124. 125.

126.

127.

128. 129.

Book Chapters & Columns:

1.

Glick ID, Bennett SE. Psychiatric effects of progesterone and oral contraceptives. In: Shader R (ed) Psychiatric Complications of Medical Drugs. New York, Raven Press, 1972, pp 295-331. Glick ID. Psychotropic action of oral contraceptives. In: RH TM (ed), Psychotropic Action of Hormones. White Lake, NY, Spectrum Publications, Inc., 1976, pp 155-167. Glick ID. The quality of delivery of mental health services to the community. In: Serban G (ed) New Trends of Psychiatry in the Community. Cambridge, Ballinger Publishing Co., 1977, pp 203-206. Kessler DR, Glick ID. Family therapy. In: Ostwald P, Ruesch J (eds) Communication and Human Interaction. New York, Grune and Stratton, Inc., 1977. Glick ID. Practical considerations (Discussions of "The effects of social class on parental values and practices" by Kohn ML and of "The development of children in mother-headed families" by Hetherington EM, Cox M, Cox R), In: Reiss D, Hoffman H (eds) The American Family: Dying or Developing. New York, Plenum Press, 1979, pp 73-78, 147-150. Glick ID, Kessler DR, Clarkin JF. Approaches to family therapy. In: Arieti S, Brodie HKH (eds), American Handbook of Psychiatry, Volume VII, New York, Basic Books, 1981, pp 388-407. Glick ID, Clarkin JF. The effects of family presence and brief family intervention for hospitalized schizophrenic patients: A review, In: Harbin HT (ed) The Psychiatric Hospital and the Family. Spectrum, Inc., 1982, pp 157-171. Clarkin JF, Frances AJ, Glick ID. The decision to treat the family: Selection criteria and enabling factors. In: Aronson ML, Wolberg LW (eds) Group and Family Therapy. New York, Brunner/Mazel, 1981, pp 149167.

2.

3.

4.

5.

6.

7.

8.

22

Ira D. Glick, M.D.

9.

Glick ID, Clarkin JF. Family therapy when an affective disorder is diagnosed. In: Gurman AS (ed) Questions & Answers in the Practice of Family Therapy, New York, Brunner/Mazel, 1981, pp 250-253. Glick ID, Bennett SE. Oral contraceptives and the menstrual cycle. In: Friedman RD (ed) Behavior and the Menstrual Cycle. New York, Marcel Dekker, Inc, 1982, pp 345-365. Glick ID, Borus J. Family therapy for the impaired physician. In: Scheiber SC, Doyle BD (eds) The Impaired Physician. New York, Plenum Press, 1983, pp 97-108. Clarkin JF, Glick ID. Supervision of family therapy. In: Blumenfield M (ed) Applied Supervision in Psychotherapy. Grune and Stratton, 1982, pp 87-106. Grunebaum H, Glick ID. The basics of family treatment. In: Grinspoon L (Ed): Psychiatry Update, Vol II. Washington APA Press, 1983, pp 185-203. Magaro PA, Talbott JA, Glick ID. The inpatient care of chronic schizophrenia. In: Bellack AS (ed), Schizophrenia - Treatment, Management, and Rehabilitation. Orlando, FI, Grune and Stratton, 1984, pp 193-218. Haas GL, Clarkin JF, Glick ID. Marital and family treatment of depression. In: Beckham EE, Leber WR (eds), Handbook of Depression: Treatment, Assessment, and Research. Homewood Illinois, The Dorsey Press, 1985, pp 151-183. Glick ID. Treatment of premenstrual syndrome in psychiatric practice. In: Osofsky HJ, Blumenthal SJ (eds) Premenstrual Syndrome: Current Findings & Future Directions, Progress in Psychiatry. Washington, D.C., American Psychiatric Press, 1985, pp 57-65. Glick ID, Clarkin JF. The family model of intervention. In: Sederer L (ed) Inpatient Psychiatry: Diagnosis and Treatment, Second edition. Baltimore, Williams and Wilkins, 1986, pp 296 -307 (third edition, 1991, pp 255-276). Stewart TJ, Bjorksten OJ, Glick ID. Sociodemographic aspects of contemporary American marriage. In: Bjorksten OJ (ed) New Clinical Concepts in Marital Therapy. Washington, D.C., American Psychiatric Press, Inc. 1985. Glick ID, Haas GL, Clarkin JF: The family and posthospital treatment compliance among affective disorders. In: Halbreich U, Feinberg SS (eds) Psychosocial Aspects of Nonresponse to Antidepressant Drugs, Washington, D,C., American Psychiatric Press, 1986. Glick ID, Quitkin FM, Bennett SE: The influence of estrogens, progestins and oral contraceptives on depression, In: Halbreich U, Rose R, (eds) Hormones and Depression, New York, Raven Press, 1987, pp 339-356. Talbott JA, Glick ID: The inpatient care of the chronic mentally ill. In: Lion JR, Adler WN, Webb WL (eds) Modern Hospital Psychiatry. New York, Norton & Company, 1988, pp 352-370. Craig JC, Gruenke LD, Klein FD, Glick ID, et al. Development of a method for the determination of chlorpromazine and its major metabolites by gas chromatography/mass spectrometry, and application to biological fluids, Perspectives in Psychopharmacology: A Collection of Papers in Honor of Earl Usdin, Edited by W. Bunney and R. Barchas, New York, Alan R. Liss, Inc., 1988, pp 375-389.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

Glick ID, Clarkin JF, Haas GL. Family and Couple Therapies, in Treatments of Psychiatric Disorders (Karasu, T. Byram, (ed) A Task Force Report of the American Psychiatric Association, Washington, D.C. APPI, 1989.

23

Ira D. Glick, M.D.

24.

Clarkin JF, Glick ID, Haas GL, Spencer, JH Jr. Inpatient Family Intervention for Affective Disorders . In: Keitner, GI (ed) Depression and Families: Impact and Treatment, Progress in Psychiatry Series, American Psychiatric Press, Wash. DC, 1990. Clarkin JF, Haas GL, and Glick ID: Inpatient Family Intervention. In: Clarkin JF, Haas GL and Glick ID (eds) Affective Disorders and the Family: Assessment and Treatment, New York, Guilford Press, 1988, pp 134-152. Clarkin JF and Glick ID: Instruments for the Assessment of Family Malfunction. In: Wetzler S, (ed), Measuring Mental Illness: Psychometric Assessment for Clinicians, American Psychiatric Press, Washington, D.C. 1989, pp 211-227. Glick I D, Dulit RA, Wachter E, Clarkin JF: A Survival Guide for Patients with Borderline Personality Disorder and Their Families. In: Minakawa K (ed) New Approaches to the Borderline Syndrome, Toyko, Iwasaki Gakujutsu Shuppan , 1991, pp 158-168. Glick ID, Freund NY and Olfson M: What a Psychiatric Hospitalization Can and Cannot Do: A Review of Efficacy Studies. In: Persad E, Kazarian SS and Joseph LW (eds) The Mental Hospital in the 21st Century. Toronto, Canada, Wall & Emerson, Inc., 1992, pp 191-204. Clarkin JF, Haas GL and Glick ID: Family and Marital Therapy. In: Paykel, ES. (ed) Handbook of Affective Disorders, 2nd edition. New York, Churchill Livingstone, 1992, pp 487-500. Glick ID, Clarkin JF and Goldsmith SJ: Combining Medication with Family Psychotherapy. In: Beitman B (ed), Combined Treatments, the American Psychiatric Press Review of Psychiatry, Vol. 12. Washington, D.C. American Psychiatric Press, Inc., 1993, pp 585-610. Klerman GL, Weissman MW, Markowitz J, Glick ID, Wilner PJ, Mason B, Shear MK: Medication and Psychotherapy. In: Bergen, AE and Garfield, SL (eds), Handbook of Psychotherapy and Behavioral Change, 1994, John Wiley, New York. fourth edition, pp 734-781. Glick ID, Braff D, Janowsky D: Short and Long-Term Psychopharmacological Treatment Strategies. In: Psychopharmacology: The Fourth Generation of Progress, Bloom FE, Kupfer DJ (eds). Raven Press, New York, 1995, pp 839-848. Revised: Glick ID, Marder S, Janowsky D, Suppes T, DeBattista C: New short- and long-term
psychopharmacologic treatment strategies for schizophrenia, bipolar disorder and depressive disorder. In: Watson SJ, Deutch A (eds), Psychopharmacology: The Fourth Generation of Progress

25.

26.

27.

28.

29.

30.

31.

32.

CD-ROM, Philadelphia, PA, Lippincott-Raven, 1998. 33. DeBattista C, Glick ID: The applicability of pharmacotherapy for neurosis and personality disorder: In: Current Opinion in Psychiatry, 1995, pp. 102-105. Glick ID: Unbundling the Function of an Inpatient Unit: In: JP Docherty (ed), Inpatient Psychiatry in the 1990's: New Directions in Mental Health Services. San Francisco: Josey Bass, 1994, pp. 35-43. Glick ID: Neuroleptic-psychosocial interactions and prediction of outcome. In: Gaebel W, Awad AG (eds): Prediction of Neuroleptic Treatment Outcome in Schizophrenia - Concepts and Methods. New York, Springer-Verlag, 1994: pp 65-70. Thase ME, Glick ID: Combined Treatment. In: Glick ID (ed), Treating Depression. San Francisco, Jossey-Bass, 1995, pp 183-208. Sholevar GP, Glick ID, Sholevar EH: Family Intervention and Psychiatric Hospitalization. In: Textbook of Family and Couples Therapy. Edited by GP Sholevar and LD Schwoeri. Washington, DC, American Psychiatric Publishing, Inc., 2003, pp 637-655.
24

34.

35.

36.

37.

Ira D. Glick, M.D.

38.

Glick ID, Lecrubier Y, Montgomery SA, Vinar 0, Klein D. Promising Psychopharmacological Agents *Available in Europe. In: Schatzberg AF, Nemeroff CB (eds), Textbook of Psychopharmacology. Washington, DC, American Psychiatric Press,1995: pp 839-846. Glick ID, Clarkin JF: Family In: Sacks MFI, Sledge WH, Waren C (Eds) Core Readings in Psychiatry: An Annotated Guide to the Literature, Washington, APPI, 1995: pp. 63-70. Clarkin JK, Glick ID: Family and Marital Therapy In: Sacks MH, Sledge WH, Waren C (Eds) Core Readings in Psychiatry: An Annotated Guide to the Literature, Washington, APPI, 1995: pp. 553-560. Glick ID, Clarkin JF: Family Support and Intervention. In: Sederer LI and Rothschild AJ, Acute Care Psychiatry: Diagnosis and Treatment, Baltimore, Williams & Wilkins, 1997: pp. 337-354. Glick ID: Familiy Associations and Family Therapy: from Conflict to Collaboration. In: Clerici M, Bertrando P (Eds) Psychoeducation and Self-Help in Major Psychiatric Disorders, Torino, Italy, Boringhieri Editore, (in press) Belanoff JK, Glick ID: New Psychotropic Drugs for Axis I Disorders: Recently Arrived, in Development and Never Arrived. In: Schatzberg AF, Nemeroff CB (eds), Textbook of Psychopharmacology, Second Edition. Washington, DC, American Psychiatric Press, 1998, pp 1015-1026. Glick ID: Family therapies: efficacy, indications and treatment outcomes. In: Janowsky DF (ed), Psychotherapy: Indications and Outcomes, American Psychiatric Press, 1999, pp 303-321. Jeste DV, Glick ID: Editors' introduction: intervention research in psychosis: past, present, and future. In: NIMH Schizophrenia Bulletin, 26:527-531, 2000. Belanoff JK, Glick ID: New Psychotropic Drugs for Axis I Disorders. In: The Essentials of Clinical Psychopharmacology. Edited by AF Schatzberg and CB Nemeroff. Washington, DC, American Psychiatric Press, 2001, pp 701-714. Tandon R, Glick ID: Introduction. In: Managing Schizophrenia: A Comprehensive Primer. New York, McMahon Publishing, 2002, pp. 6-9. Glick ID, Loraas EL: Family Treatment of Borderline Personality Disorder, In: Family Therapy and Mental Health. Edited by MacFarlane MM. New York, NY, The Haworth Press, 2001, pp 135-150. Ritvo EC, Glick ID: Couples Therapy, for the text, Textbook of Psychiatry, Second Edition, Edited by Tasman A, Lieberman J, Kay J. England, John Wiley & Sons, Ltd, 2003, pp 1792-1806. Glick ID, Mullen B: Family Intervention in the Treatment of Personality Disorder and Issues of Compliance. In: Personality Disorder and the Family (in press). Liberman RP, Glick ID: Drug and psychosocial curriculum for psychiatric residents in the treatment of schizophrenia. Psychiatric Services 55:1217-1219, 2004 Glick ID, Horsfall JL: Diagnosis and Psychiatric Treatment of Athletes. In: Clinics in Sports Medicine. Edited by Tofler IR and Morse ED, Elsevier, NY, 2005, pp. 771-781. Glick ID, Mullen B: Family Intervention in the Treatment of Personality Disorder and Issues of Compliance. In: Personality Disorder: Current Research and Treatments. Edited by Reich J, Routledge, Taylor & Francis Group, New York, 2005, pp.185-201.

39.

40.

41.

42.

43.

44.

45.

46.

47.

48.

49.

50.

51.

52.

53.

Editorials:
25

Ira D. Glick, M.D.

1.

Glick ID, Showstack JA, Klar HM: Toward the definition and delivery of appropriate care. Am J Psychiatry 139:908-909, 1982. GAP Committee on the Family: The challenge of relational diagnoses: Applying the biopsychosocial mood in DSM-IV. Am J Psychiat, 146:1492-1494, 1989. Judd LL, Glick ID: The National Institute of Mental Health: prospects and promises. Biol Psychiatry, 26:545-546, 1989. Glick ID, Zisook S, Schader RI: The challenge of teaching psychopharmacology and improving Clinical practice. J Clin Psychopharmacology, 25:203-205, 2005 Zisook S, Glick ID, Goldberg DA: Challenges and opportunities in teaching psychopharmacology during residency training. J Clin Psychiatry 66:948, 2005.

2.

3.

4.

5,

Book Reviews:

1.

Glick ID: Treating the Treatment Failures by Arnold M. Ludwig, Grune & Stratton, Inc. 1971, 235 pp. California Medicine 177: 104, July 1972. Glick ID: Mom's House, Dad's House by Isola Ricci, Macmillan Publishing Co. 1980, 270 pp. Law, Federal Legal Publications, Inc.,1982. J Psychiatry

2.

3.

Glick ID, Clarkin KC: Handbook of Family Therapy edited by Gurman AS and Kniskern DP, Brunner-Mazel 1981, 796 pp. Hospital and Community Psychiatry 33: 490-491, June 1982. Glick ID: Inpatient Psychiatry: Diagnosis and Treatment edited by Sederer LI, Williams and Wilkins, 1983, 337 pp. New England J Medicine 309:619, 1983. Glick ID, Clarkin KC: The Strength of Family Therapy: Selected papers of Nathan W. Ackerman, Brunner/Mazel, 1982, 460 pp. J Marital and Family Therapy 329-330, July 1985. Perry S, Glick ID: Massachusetts General Hospital Handbook of General Hospital Psychiatry edited by Thomas Hackett and Ned Cassem, PSC 1987, 658 pp. NEJM 317:1609, 1987. Glick ID: The Creative Process of Psychotherapy by Arnold Rothenberg, WW Norton & Co, 1987, 210 pp. Am J Psychiatry 146:675, 1989. Glick ID: Bringing Up Baby Without Destroying Mommy and Daddy by Jerry Lewis, Brunner/Mazel, 1989, xii + 201 pp. Contemporary Psychiatry 9:96, 1990. Glick ID: Evaluating Family Mental Health by John Schwab, J Stephenson, John Ice, Plenum, 1993, 452 pp. Psychiatric Times, p. 41, November 1994. Glick ID: The Sorrow of War: A Novel of North Vietnam (1994) by Bao Ninh, New York Riverhead Books, 1996, 235 pp. Am J Psychiatry 157:12, December 2000

4.

5.

6.

8.

9.

10.

Films and Videotapes:

1. 2.

Glick ID, Marshall G: Videotape Playback in Family Therapy. 16mm, B & W, Sound 45 min., 1968 Glick ID, Marshall G: Family Therapy: An Introduction. 16 mm, B & W, Sound 45 min., 1970
26

Ira D. Glick, M.D.

Commentaries: 1. Practice Guidelines for the Treatment of Bipolar Disorders. In Abstracts of Clinical Care Guidelines, 7:5, 1995, pp 3-4, Glick ID: Introduction to the Classic Article Section. J Psychotherapy Practice Research 6:151-153, 1997.

2.

27

Ira D. Glick, M.D.

CURRICULUM VITAE - PART II

Teaching Services

University of California, San Francisco 1968-78:

1975-1978 Director of Medical Student Education, Dept. of Psychiatry:

First Year Medical Students 1969-1970 (a) Behavioral Science and Psychopathology, Seminar Leader, Winter, 2 hrs/wk. Lecture, "Psychophysiologic Disorders," given to entire class (b) Basic Clerkship 1-A. Supervisor, 2 hrs/wk, Spring

1970

Second Year Medical Students 1968-1969 1969-1970 a) b) Psychiatry 121, Basic Psychiatry. Seminar Leader, 3 hrs/wk, Spring, Fall, Winter Psychiatry 18, Behavioral Science and Psychopathology. Seminar Leader, 3 hrs/wk, Fall Quarter; 2 hrs/wk, Spring Quarter, 1969-70. Course Coordinator, Spring, 1970 Psychiatry 100, Psychopathology Course Committee, Course Coordinator and Lecturer, 6 hrs/wk, Winter, 1972 Psychiatry 101, Psychopathology Course Committee, Course Coordinator and Lecturer, 6 hrs/wk, Winter, 1972 Psychiatry 100-101, Introduction to Clinical Psychiatry: 1972-73 Course Committee and Lecturer, 6 hrs/wk, Fall-Winter 1973-74 Course Coordinator and Lecturer, 6 hrs/wk, Fall-Winter 1974-77 Course Supervisor and Lecturer, 6 hrs/wk, Winter-Spring; Lecturer

1972

c)

1972

d)

1973-1977

e)

Third Year Medical Students 1968a) Psychiatry 110, Clinical Clerkship in Psychiatry. I hour/week, 1968-present; Acting Director, Fall, 1977-78

Fourth Year Medical Students 1968-1978 1970-1975 a) b) Psychiatry 110, Clinical Clerkship in Psychiatry. 1 hour/week Behavioral Specialist Pathway, Clinical Subpathway, Individual and Family Therapy. Coordinator, 1 hour/week, Summer, Fall, Winter, Spring, 1970-75

Residents, Department of Psychiatry 1968-1978 1968-1978 1968-1978 a) b) c) Basic Psychiatry 1. Seminar Series Participant Supervisor, 1st, 2nd, 3rd, and 4th Year Psychiatry Residents Seminar on Hospital Psychiatry to Psychiatric Residents. 1 hour/week

28

Ira D. Glick, M.D.

1970-1972 1969-1970 1968-1970 1970

d) e) f) g)

Seminar, Family Dynamics and Therapy. 3 hrs/wk, Fall, '70; Spring, '71; Spring, '72 Clinical Psychiatry for Non-Psychiatrists. 2 hrs/wk, Fall-Winter Paramedical Staff. 5 hrs/wk Committee to conduct qualifying examinations for admission to candidacy for PhD degree, B. Tesher, Nursing, in the field of family therapy The Teaching-Learning Process in Psychiatry. To Psychiatric Residents, Fall-Winter, 2 hrs/wk. Coordinator, Basic Psychiatry II, to all Second Year Psychiatric Residents Core seminar, Theory & Practice of Family Therapy, as part of Basic Psychiatry II, to all second year psychiatric residents, 1974-75, 1975-76,1976-77 with David Kessler, MD Seminar on Clinical Research Design, Elective, Third Year Psychiatric Residents

1972-1973

h)

1973-1978 1974-1977

i) j)

1976-1977

k)

Cornell University Medical College - 1978-1993:

First Year Medical Students 1979 1980 1982 a) b) c) Understanding Human Behavior, Preceptor, 10 weeks, Fall Understanding Human Behavior, Lecturer and Panelist, Fall Investigative Approaches of Human Behavior, Preceptor, Spring

Third Year Medical Students 1978 1978 Other 1980-1993 1980-1981 a) b) Faculty Advisor Internship Advisor a) b) Psychological Assessment of Medicine, Preceptor, Spring Core Clerkship, Preceptor, Summer

Faculty and Staff -- Department of Psychiatry 1978 1978 1978 a) b) c) Family Therapy Supervisory Seminar for Payne Whitney Faculty, 9 weeks, Spring Family Therapy Supervisory Seminar for Westchester Division Faculty, 9 weeks, Fall Seminar on Intro to Psychiatric Research for Payne Whitney Staff, 2 weeks, Fall

Residents: Department. of Psychiatry

Research Courses:

29

Ira D. Glick, M.D.

1980-1983 1980-1986 1980-1986

a) b) c)

Introduction to Research, PGYll's, April-June Intermediate Research Course, PGY III's, 10 weeks, January-April Advanced Research Seminar, PGY IV's, 10 weeks, April-June

Psychopharmacology Courses 1982a) b) 1990-1993 1990-1993 c) d) Psychopharmacology Rounds, PGY 11, Ill & IV's, 1982-present; Coordinator 1987-89 Psychopharmacology Consultant, to Inpatient Services, 1986-88, 1991-1993 Outpatient Psychopharmacology,, PGY III's, 1990-present, weekly, all year Psychopharmacology Supervision, PGYIll's &IV's

Family Therapy Courses 1978-1993 1978-1993 1979-1993 a) b) c) Seminar on The Family Interview, PGY 11 Summer Course Family Therapy-Inpatient Introductory Course, as part of PGY11 Core Curriculum, 8 wks. Family Therapy-Outpatient, for PGY III's as part of the Core Curriculum, Intermediate Course, 8 weeks, Winter Family Therapy, for PGY IV's, as part of Continuous Case Conference, Payne Whitney Clinic, 12 weeks, Fall Seminar on Evaluation of the Family, as part of the Summer Orientation for PGY l's and II's and Psychology Interns, Westchester Division, Summer Introduction to Family Therapy, as part of Core Curriculum PGY II's, Westchester Division, 8 weeks (90 min.), Winter 9) Continuous Case Conference on Family Therapy, for the Child Psychiatry Service. Bimonthly, September to June

1985-1993

d)

1978

e)

1978-1985

1978-1980

Hospital Psychiatry Courses 1978-1993 a) b) c) d) Criteria for Selection of Inpatient Treatment Modalities, as part of PGY11 Core Curriculum. 6/hours/yearly Inpatient Psychiatry, for PGY II's, 3 weeks, Summer, (yearly). Assistant Unit Chief Clinical Rounds, PGY IV's, Payne Whitney Clinic, biweekly Psychopathology Course, Schizophrenia to PG II's

1980-1984 1991-

General Psychiatry Courses 1978-1993 1980-82 a) Psychiatric Resident Tutorial, Payne Whitney Clinic, 6/hours/yearly b) Supervisor, Long Term Psychotherapy, PGY 11's

Stanford University School of Medicine - 1993 - present:

30

Ira D. Glick M.D.

General Psychiatry Courses

1993-941994-951993-98

a) Psychopathology course, PGY II, Treatment Modules on Schizophrenia & Bipolar Disorder b) PGY IV Board Review Course, Schizophrenia Module c) Chairman's Rounds

Hospital Psychiatry Courses

19931994-98

a) Inpatient Medical Student and Resident Supervision b) Inpatient Psychiatry, Course Coordinator and Lecturer, PGY II 1. 2. 3. Overview Workup and Treatment Planning Treatment of Psychosis

Psychopharmacology Courses

1994-95 Introduction to Psychopharmacolopy, PG II, 2002 -Personality Disorder 2003 - Bipolar Disorder, Medication and Compliance Issues 1995-96-Strategies of Outpatient Psychopharmacoloov, PG III, Course Coordinator and lecturer

1. 2.

Schizophrenia Combining & Integrating Psychotherapeutic Intervention with Medication

2004

Neuroscience, PG III

Lecture, Metabolic Side Effects of Antipsychotics 2005-Introduction to Psychophatholody and Psychopharmacology, PG II, 4 quarters/year, Course

Director (with Sara Mueller, MD)

Medical School Courses

Winter, 2001-02, Medical School Clerkship, Psychotic Disorder and Neuroleptic Treatment.

Outside UCSF, Cornell University Medical College & Stanford University

1965-1966 Columbia University, College of Physicians and Surgeons. Basic Clinical Psychiatry, to Third Year Medical Students, Fall-Winter, 3 hrs/wk. Hillside Hospital. Supervision and Teaching, First and Second Year Psychiatric Residents, 15 hrs/wk, all year. U.S. Army Hospital Specialized Treatment Center. Ft. Gordon, Georgia. Basic Psychiatry I, to Medical and Paramedical Staff, I hr/wk, all year. Medical College of Georgia. Family Therapy, to Psychiatry Dept. Staff, Residents, and Medical Students, 2 hrs/wk, 20 wks/yr
31

1964-1966

1966-1968

1966-1968

Ira D. Glick, M.D.

1 970-1 978

Mt. Zion Hospital and Medical Center. Seminar in Psychopharmacology, Psychosomatic Conference, to Second and Third Year Psychiatry Residents, two 90-minute sessions yearly School of Medicine, University of Verona. Seminar on Recent Developments in American Psychiatry, to Psychiatric Residents and Faculty, January-June, six 90 minute sessions

1986

32

Ira D. Glick, M.D.

COMMITTEE SERVICE

University Of California, San Francisco, School of Medicine

Department of Psychiatry Committees: 1968-1970 1968-1970 1969 1969 1969-1970 1969-1978 1970 1971-1973 1971-1973 1972 1973 1973-1978 1973-1976 1974-1975 1974-1978 1975-1978 1976-1978 1976 1976 1976-1978 1976-1978 Chairman, Public Health and Safety Committees, Langley Porter Institute Research Committee, Clinical Research Ward, Langley Porter Institute Course Committee, Freshman Psychiatry Course, Dept. of Psychiatry Annual Graduation and Departmental Meeting, Langley Porter Institute Ad Hoc Committee on Residency Training, Langley Porter Institute Course Committee, Sophomore Psychiatry Course, Dept. of Psychiatry Ad Hoc Committee on Outpatient Psychiatric Care, Dept. of Psychiatry Residency Selection Committee, Langley Porter Institute Residency Training Committee, Langley Porter Institute Noon Conference Committee, Langley Porter Institute Building Committee, Langley Porter Institute Departmental Committee on Medical Student Education, Dept. of Psychiatry Review Committee for Appointments and Promotions of Regular Faculty, Dept. of Psychiatry Staff Affiliate Review Committee, Langley Porter Institute Committee on Academic Affairs, Dept. of Psychiatry, School of Medicine, UCSF Departmental Task Force on Revision of Medical Student Curriculum, Dept. of Psychiatry Administrative Planning Team, Langley Porter Institute Ad Hoc Committee for Alexander Simon Award, Dept. of Psychiatry Subcommittee for Basic Curriculum, Residency Training, Dept. of Psychiatry Interdisciplinary Education Committee, Dept. of Psychiatry, School of Medicine Medical Student Education Committee, Dept. of Psychiatry, School of Medicine

School of Medicine Committees 1973-1978 1974-1978 1974-1975 1974 1975-1976 Curriculum Committee Subcommittee on Evaluation Basic Clinical Course Operations Subcommittee1974; Acting Chairman, 1975 Screening and Promotions Committee Search Committee, Director of Psychiatric Nursing, 1975-76

Cornell University Medical College:

Department of Psychiatry Committees 1978-1988 1978-1980 1978-1993 1979-1983 1978-1993 1981-1983 1981-1983 1983-1988 1991-1993 1985-1988 1984-1986 1987-1988 1990-1993 1990 Inpatient Steering Committee PGY II Education Committee Family Therapy Planning Group, 1978-1993 PGY IV Education Committee Departmental Research Committee- Chairman, 1981-83; Steering Committee, 1992-1993 Computer Committee Media Committee Residency Training Committee Residency Training Committee Fellowship Selection Committee Space Committee Executive Committee Executive Committee Task Force on Vertical Services
33

Ira D. Glick, M.D.

1990-1993 1990-1993

Formulary Committee Appointments and Promotions Committee

Stanford University School Of Medicine:

Departmental Committees 1993 Executive Committee 1993 Residency Training Committe 1993 - 95 Credentials Committee, Chairman 1996 - 2005 Appointment & Promotions Chair, 1999 2005 Hospital Committees 1993 - 2000 1993 - 2000 1993 - 2000 1993 - 2000 1998 - 2000 Inpatient Management Committee Operations Improvement Committee Psychiatry Business Plan Committee Clinic Executive Committee UCSF/Stanford Merger Brown & Toland Medical Group Mental Health Executive Committee

34

Ira D. Glick, M.D.

COMMUNITY AND PUBLIC SERVICE

Presentation of paper "Psychophysiologic Factors in the Etiology of Preeclampsia," American Psychosomatic Society, April 1964. Grand Rounds, "Psychophysiologic Factors in the Etiology of Schizophrenia," to the Dept. of Psychiatry, Mt. Zion Hospital, San Francisco 1964. Grand Rounds, "Psychophysiologic Factors in the Etiology of Schizophrenia," to the Dept. of Obstetrics and Gynecology, Mt. Zion Hospital, 1964. Presentation of paper, "Mood and Behavioral Changes Associated with the Use of the Oral Contraceptive Agents: A Review of the Literature," Eighth Annual Psychiatric Research Society Meeting, 1965. Presentation of paper, "The 'Sick' Family and Schizophrenia - Cause and Effect?" to the Tenth Annual Psychiatric Research Society Meeting, Cincinnati, 1967. Institute Leader, "Family Dynamics and Treatment," Annual Meeting, Georgia Branch, National Association of Social Workers, February 1967. Invited Lecture, "The Place of Occupational Therapy in Clinical Psychiatric Treatment," Georgia Occupational Therapy Association, 1967. Institute Leader on "Family Therapy and Hospital Psychiatry," at Columbia, S.C., VA Hospital September 1967 Invited Lecture, on "The School and the Family," to the Annual Meeting of the Georgia Association of Visiting Teachers, Augusta, Georgia, November 1967. Seminar Leader on "Family Therapy," at Macon, Ga., Mental Health Clinic, Macon, Ga., November 1967. Invited Address, "The Changing Role of the Family," Unitarian Fellowship, Augusta, Ga., December 1967, Invited Lecture, "Basic Clinical Psychiatry" to Psychology Students, Paine College, Augusta, Ga., (Jan)1968. Lecture and Panel Discussion, "The Role of the Clergy in Family Counseling, at a seminar on Family Counseling, Augusta, Ga., February 1968, Address, "The Family and Southern Society," to First Mt. Moriah Baptist Church, Augusta, Ga., April 1968. Film Presentation: Videotape Playback in Family Therapy (with G. Marshall) 16mm. B & W 10 min. Presented at the 1968 annual meeting, American Psychiatric Association, Boston, Mass. May 16, 1968 Grand Rounds, "Mood and Behaviorial Changes Associated with Use of Oral Contraceptives," OBGYN, University of California, San Francisco, September 1968. Participant, panel on Training of Family Therapists, Don D. Jackson Memorial Family Conference, Asilomar, California, February 1969. Lecture on "Current Status of Family Therapy," given to Association of Family Therapists, San Francisco, 3/69. Film and Seminar Discussion on "An Introduction to Family Therapy," given at the Clinical Seminar Series, Langley Porter Neuropsychiatric Institute, Psychology Dept., March 1969.

35

Ira D. Glick, M.D.

Two-Day Seminar on Current Developments in Psychiatry given at Dept. of Psychiatry, Medical College of Georgia, May 1969. Film "Family Therapy: An Introduction," presented at the Annual Meeting, American Psychiatric Association, Miami Beach, Fla., May 1969. Discussion of paper entitled "Psychosexual Responses to Ileostomy and Colostomy" at American Psychiatric Association Meeting, Miami Beach, Fla., 1969. Film "Family Therapy: An Introduction," shown at Staff Meeting, Mental Research at Ninth Western Divisional Meeting 1969, of Westen Psychiatric Association, Seattle, August 1969. Moderator of Panel on Family Therapy: Rationale, Methods, Teaching and Research at Ninth Western Divisional Meeting 1969, of Western Psychiatric Association, Seattle, August 1969. Discussion of Paper, "The Psychiatrist as Counselor and Friend to the Family," by Herbert C. Wimberger, MD, at Ninth Western Divisional Meeting, Western Psychiatric Association, Seattle, August 1969. Abstracts Editor, Family Process, July 1964-78. Participant in CBS News Reports Program titled "The Pill," KPIX, February 1970. Participant on Panel: "Therapists and Families," American Orthopsychiatric Association 47th Annual Meeting in San Francisco, March 1970. Lecture on "Issues in Family Therapy Training," presented to Interdisciplinary Training Program Seminar, Napa State Hospital, May 1970. Moderator of Panel, "Issues in Training of Family Therapists," American Psychiatric Association Annual Meeting, May 1970. Discussion Leader, NIMH Career Teachers in Psychiatry Meeting, Boston, October, 1971 Participant In Panel, "Emotional Problems of Psychiatric Residents," American Psychiatric Association Annual Meeting, May, 1972. Presentation of paper entitled "Management of Psychoses Associated with Dialysis," American Psychiatric Association Annual Meeting, May 1972. Regional Coordinator, "The Psychiatrist as Teacher," for the National Conference on Teaching Psychiatry, one-day regional meeting held at San Francisco, May 1972. Presentation of Paper and Participant on Panel, "Stress Events & Psychiatric Illness," at the Symposium"Stress: Its Impact on Thought and Emotion," University of California at San Francisco, June 1972 Group Leader, Regional Coordinator, and Presentation at "Free University" of film on Family Therapy at the national conference, "The Psychiatrist as a Teacher." Airlie House, October 3-6, 1972. Lecture "Transference and Countertransference," to Graduate Psychiatric Nursing Students, University of California, San Francisco, November 1972. Resource Teacher in Section on "University Dept. of Psychiatry" at the First National Conference on Training in Family Therapy, Philadelphia, November 30 - December 2, 1972.

36

Ira D. Glick, M.D.

Lecture, "Depression," presented as part of a section entitled "Dilemmas in Therapy" as part of the 23rd Annual Course for Physicians in General Practice, Mt. Zion Hospital and Medical Center, February 1973. Presentation of paper, "Short vs. Long Hospitalization: A Prospective Controlled Study -- Preliminary Results of a One-Year Follow-up of Schizophrenics," Research Seminar, Dept. of Psychiatry, Mt. Zion Hospital, April 1973. Presentation of paper, "Short vs. Long Hospitalization: A Prospective Controlled Study -- Preliminary Results of a One-Year Follow-up of Schizophrenics," at the Annual Meeting, American Psychiatric Association, Honolulu, Hawaii, May, 1973. Presentation of paper, "Indications and Relative Contraindications for Family Treatment, Circa 1973," at the San Francisco Family Forum, San Francisco General Hospital, January 10, 1974. Presentation of paper, "Treatment and Outcome in Schizophrenia," at the Merger Celebration in Honor of the Merger of Langley Porter Neuropsychiatric Institute with University of California, San Francisco, February, 1974. Presentation of paper, "Indications and Contraindications for Family Therapy," at the Nathan W. Ackerman Memorial Conference, Venezuela, February, 1974. Film presentation, "Family Therapy: An Introduction:" 1971: 12 showings 1973: 8 showings 1972: 8 showings 1974: 6 showings

Discussant, Conference, "Lithium: Its Role in Manic-Depressive Illness," Chief's Conference, Dept. of Psychiatry, Mt. Zion Hospital, San Francisco, March 12, 1974. Presentation of paper, "Short Versus Long Psychiatric Hospitalization for Schizophrenia - Preliminary Results, One Year Followup," Noon Conference, Langley Porter Neuropsychiatric Institute, San Francisco, 3/74. Presentation of paper, "Mood and Behavioral Changes Associated with the Use of Oral Contraceptives," 1st World Congress of Biological Psychiatry, Buenos Aires, Argentina, September, 1974. Presentation of paper, "Short Versus Long Psychiatric Hospitalization: A Controlled Study," Dept. of Psychiatry Grand Rounds, Cornell University Medical College, New York, NY, November 1974. Presentation of paper, "Short Versus Long Psychiatric Hospitalization: A Controlled Study," SUNY, Downstate Medical Center, New York, NY, November 1974. Coordinator, "The Role of the Family in Medical Practice," Third National Workshop on Psychiatric Education, Association for Academic Psychiatry, Chicago, Illinios, November 1974. Presentation of paper, "Short Versus Long Hospitalization - A Prospective Controlled Study: One Year Followup Results,' Section on Interaction of Drugs and Nonsomatic Therapies, American College of Neuropsychopharmacology, Puerto Rico, December 1974. Presentation of paper, "Short Versus Long Hospitalization: A Prospective Controlled Study. IV-A. One Year Followup Results for Schizophrenics," Research Conference, Dept. of Psychiatry, Mt. Zion Medical Center, San Francisco, February 18, 1975. Panel Discussant, "The Treatment of Schizophrenia at Langley Porter Institute," Noon Conference, Langley Porter Institute, San Francisco, April 30, 1975. Panel Moderator, "Controlled Studies of Alternative Lengths of Hospitalization for Psychiatric Illness," presented at the 1975 Annual Meeting, American Psychiatric Association, Anaheim, California, May 1975.

37

Ira D. Glick, M.D.

Presentation of paper, "Short Versus Long Hospitalization: A Prospective Controlled Study. IV. One Year Followup Results for Schizophrenics," American Psychiatric Association Annual Meeting, Anaheim, CA, 5/75. Radio presentation, "Loxitane in Schizophrenia," CBS Radio Network, July 12 and 13, 1975. Discussant, "Conceptual Approaches to Schizophrenic Disorder," Grand Rounds, Dept. of Psychiatry, University of California, San Francisco, September 22, 1975. Discussant, "Depression in Medical Practice," Grand Rounds, Dept. of Medicine, University of California, San Francisco, September 23, 1975. Presentation of paper, "Short Versus Long Hospitalization: A Prospective Controlled Study. II. Results for Schizophrenic Inpatients," Langley Porter Institute weekly research staff conference, October 10, 1975. Panelist, "Can a Psychiatric Hospital Survive Mental Health and Marijuana?" Grand Rounds, Dept. of Psychiatry, UCSF, November 18 and 25, 1975. Seminar Leader, "Issues in Family Therapy," California Branch District Meeting American Psychiatric Association Conference, Palm Springs, November 1975. Presentation of paper, "Short VersusLong Psychiatric Hospitalization: A Controlled Study. Medication and Outcome for Schizophrenics," American College of Neuropsychopharmacology, Puerto Rico, December 1 975. Exhibit, entitled "A Teaching Package for a Preclinical Psychiatry Course," 30th All-University Faculty Conference, University of California, Santa Barbara, March 25-27, 1976. Discussant and Presentation of paper, "Short Versus Long Psychiatric Hospitalization," as part of a symposium: "A Critical Appraisal of Community Psychiatry," Kittay Scientific Foundation, NY, 3/76. Presentation of paper, "Controversial Premises of Marital and Family Therapy," (with David R. Kessler, MD) for the San Francisco Family Forum, Family Health Center, San Francisco General Hospital, April 15, 1976. Presentation and Discussion, "Short Versus Long Psychiatric Hospitalization: A Controlled Study, Two Year Results," Grand Rounds, Dept. of Psychiatry, UCSF, April 20, 1976. Panelist, "Schizophrenia -- Which Treatment and For Whom," 1976 Annual Meeting, American Psychiatric Association, Miami, May 1976. Panelist, "What Makes Medical Students So Difficult To Teach?" 1976 Annual Meeting, American Psychiatric Association, Miami, May 1976. Panelist, "Controversies in Psychiatric Education," 1976 Annual Meeting, American Psychiatric Association, Miami, May 1976. Presentation of paper, "Increasing Learning During the Psychiatric Residency," (with Leon Epstein, MD) 1976 Annual Meeting, American Psychiatric Association, Miami, May 1976. Presentation of paper, "Indications and Contraindications for Family Therapy; Changing Concepts," Psychiatry Grand Rounds, Dept. of Psychiatry, School of Medicine, U.C. Davis, September 1976. Presentation of paper, "Short Versus Long Psychiatric Hospitalization: A Controlled Study: Two Year Results," Dept. of Psychiatry, Mt. Sinai School of Medicine, New York, September 1976. Presentation of paper, "Short Versus Long Psychiatric Hospitalization: Final Results and Treatment Implications," Dept. of Psychiatry, Mt. Zion Hospital and Medical Center, San Francisco, October 1976.
38

Ira D. Glick, M.D.

Keynote Speaker, "Short-Term Intensive Psychiatric Hospital Treatment: Which Treatment and for

Whom?" National Conference on Short-Term Intensive Psychiatric Hospital Treatment, Scottsdale, AZ, 1 1 /76
Panel Moderator, "Treating the Impaired Physician: Confidentiality vs. Responsibility," presented at the 1976 Annual Meeting, Association of American Medical Colleges, San Francisco, November 1976. Examiner, American Board of Psychiatry and Neurology, Seattle, February 1977. Special Lecture, "A Teaching Package for a Preclinical Psychiatry Course," Dept. of Psychiatry, College of

Physicians and Surgeons, Columbia University, New York, February 1977.

Presentation of paper, "Short Versus Long Psychiatric Hospitalization: A Controlled Study," Grand Rounds, Dept. of Psychiatry, University of New Mexico, Albuquerque, New Mexico, March 1977. Presentation of paper, "Indications and Contraindications for Family Therapy," Grand Rounds, Veterans Administration Hospital, Albuquerque, New Mexico, March 1977. Referee, Journal of Nervous and Mental Diseases, Archives of General Psychiatry, American Journal of

Psychiatry, and Family Process. Hospital and Community Psychiatry.

Presentation of paper, "The Architectural Design of a Psychotherapeutic Milieu," 1977 Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 1977. Panelist, "New Directions in Family Research: Ritual, Real Time and Images," 1977 Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 1977. Panel Moderator, "Schizophrenia - Which Treatment and For Whom?", 1977 Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 1977. Panelist and Discussion Group Leader, at conference entitled "Families In Contemporary America: Varieties of

Form, Function and Experience," jointly sponsored by the Dept. of Psychiatry and Behavioral Sciences of the George Washington University School of Medicine and the Center for Continuing Education in Mental Health of the Psychiatric Institute Foundation, Washington, D.C., June 1977.
Television Presentation, Role of Clinical Psychiatry - on "The Hidden Universe" - ABC National Television

Documentary, June 1977.

Presentation of paper, "Short Versus Long Psychiatric Hospitalization," World Psychiatric Association, Honolulu,

August 1977.
Presentation of paper, "Indications and Contraindictions for Family Therapy," as part of an invited seminar on

Family Therapy, World Psychiatric Association, Honolulu, August 1977.

Advisory Editorial Board Member, International Journal of Family Therapy, as of September 1977. Psychiatric

Quarterly, 1980.
Discussant, "The Premenstrum: A Psychological Investigation," Grand Rounds, Dept. of Psychiatry, University of California, San Francisco, November 22, 1977. Presentation of paper, "Development of a Curriculum and of a Faculty for Medical Student Education in

Psychiatry," The Annual Meeting of the Association of Academic Psychiatry, New Orleans, January 1978.
Presentation of paper, "A New Drug Treatment for Premenstrual Psychosis," Poster Session, The Annual Meeting

of the American Psychiatric Association, Atlanta, Georgia, May 1978.

39

Ira D. Glick, M.D.

Organizer, Special Session, "Treating the Impaired Physician: Confidentiality and Responsibility," The Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 1978. Presentation of paper, "Hospitals in the 1980s: Service, Training and Research," Presented as part of the Special Session, "Hospital Treatment of Emotional Disorders: Circa, 1978, at the Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 1978. Lecture and Discussion, "Indications and Contraindications for Family Therapy: Circa, 1978," at Grand Rounds, Dept. of Psychiatry, The New York Hospital-Cornell University Medical College, May 17, 1978. Presentation of paper, "Research in Occupational Therapy," at a Conference entitled, "A Revitalization Movement within Occupational Therapy" sponsored by Metropolitan New York District, New York State Occupational Therapy Association. May 1978. Presentation and Discussion, "Family Therapy & Crisis/Loss,"Memorial Hospital, New York, November 2, 1978. Presentation and Discussion, "The Hospital Management of the Suicidal Patient," at a Symposium: "The Suicidal Patient: Identification and Treatment," sponsored by Dept. of Psychiatry, Albany Medical College, March 28, 1979, Albany, New York. Presentation and Discussion, "Psychiatric Problems in General Practice," as part of a Symposium: "Common Medical Problems in Office Practice," sponsored by the Continuing Education Committee of St. Vincent's Hospital, Santa Fe, N.M., March 30, 1979. Presentation and Discussion, "Effects of Divorce on the Family," as part of a Symposium, "Divorce and the Patient," Sponsored by Continuing Education Committee of St. Vincent's Hospital, Santa Fe, N.M., 3/79. Presentation of paper, "Short Vesus Long Psychiatric Hospitalization: A Controlled Study -- Final Results," Grand Rounds, McLean Hospital, Boston, Massachusetts, April 1979. Presentation of paper, "A New Drug Treatment for Premenstrual Exacerbation of Schizophrenia" at Harvard Medical School, Dept. of Psychiatry, Boston, Massachusetts, April 1979. Presentation of paper, "The Physician's Family: Approach to Impairment," as part of a Symposium, "The Impaired Physician: Prevention and Treatment," at the Annual Meeting, American Psychiatric Association, Chicago, May 1979. Discussant, "Psychotherapy Supervision," at the American Psychiatric Association's Annual Meeting, Chicago, May 1979. Presentation, "Short Hospital Stay is Better than Long Hospital Stay?" "Pro Position" at the 31st Institute on Hospital and Community Psychiatry, September 3-6, 1979, New Orleans. Presentation, "Future Directions in Hospital Psychiatry," keynote speech, Dept. of Psychiatry, at Alumni Teaching Day, Long Island Jewish-Hillside Medical Center, Glen Oaks, New York, September 1979. Grand Rounds, "The Family Model in an Inpatient Setting," Dept. of Psychiatry, North Shore Hospital, Manhasset, New York, October 1979. Grand Rounds, "The Family Model in an Inpatient Setting," Dept. of Psychiatry, Albert Einstein College of Medicine, New York, NY, October 1979. Grand Rounds, "Family Therapy -- Indications and Contraindications," Dept. of Psychiatry, City Hospital Center at Elmhurst, October 1979.
40

Ira D. Glick, M.D.

Grand Rounds, "Psychiatric Hospitalization for the 1980s: A Controlled Study of Short Versus Long Hospitalization, Final Results," Dept. of Psychiatry, Cornell University Medical College, April 1980. Invited Paper, "Psychiatric Aspects of Basketball," Psychiatric Annals Volume 10, Number 3:108-112, 1980. Organizer of Continuing Medical Education Seminar, titled, "Hospital Treatment: Which Treatment and How Long for Which Patients?" Cornell University Medical College, Dept. of Psychiatry, /Nod 1980. Presentation on "The Role of Psychoanalysis in Family Therapy," as part of a Continuing Medical Education Course entitled, "The Role of Psychoanalysis in Contemporary Psychiatry," at Cornell University Medical College, Spring, 1980. Discussant for Symposium, "Enhancing Treatment Compliance," at the Annual Meeting of the American Psychiatric Association, San Francisco, 1980. Presentation on "Leadership in the Hospital," as part of a Course on "Leadership," at the Annual Meeting of the American Psychiatric Association, San Francisco, 1980, Presentation on "Family Therapy and the Treatment of the Child" at the weekly Child-Adolescence Staff Meeting, Dept. of Child Psychiatry, Mt. Sinai Hospital, November 1980. Participant, on Radio Program, "Conference Call: Parents & Children, WABC, November 30, 1980, New York. Grand Rounds, "Psychiatric Hospitalization for the 80s," St. Joseph's Hospital and Medical Center, Paterson, New Jersey, February 1981. Keynote Speaker, "Illness and the Impact on Family Systems," at a Symposium entitled "Illness and the Family," sponsored by La Tortuga & Sherman Clinic, Santa Fe, March 1981. Presentation of paper, "Thinking Disorder in Depression: Longitudinal Results" (with Braff D, Griffin P), and "Outcome of Irregularly Discharged Mental Patients" (with Braff D, Johnson G), for the American Psychiatric Association Annual Meeting, New Orleans, May 1981. Consultant for Departmental Planning, Dept. of Psychiatry, Mt. Zion Hospital, San Francisco, CA , June 1981. Chapter Consultant, Family Therapy, American Psychiatric Assn. Commission on Psychiatric Therapies, 1981. Grand Rounds, "Short Vs Long Hospitalization: Final Results," State University of New York, Syracuse, NY, 9 /81. Grand Rounds, "Treating the Hospitalized Schizophrenic Patient and Family," Rockland Psychiatric Center, Orangeberg, New York, October 1981. Presentation, "Short Versus Long Hospitalization for Schizophrenia," World Psychiatric Association/APA Regional Meeting, New York City, November 1981. Chairman, Education Committee and session on the "Teaching of Psychopharmacology," Annual Meeting, American College of Neuropsychopharmacology, San Diego, December 1981. Presentation, "The Family Model in an Inpatient Setting," Family Study Group, SUNY, Downstate Medical Center, January 1982. Presentation of paper, "Duration of Hospitalization as a Variable in Outcome," (John F. Clarkin, PhD and Ira D. Glick, MD), The National Association of Private Psychiatric Hospitals, Scottsdale, Arizona, January 1982.

41

Ira D. Glick, M.D.

Panelist, "Family Therapy of Suicidal Behavior," Annual Meeting of Assn. of Suicidology, New York City, 4/82. Presentation of paper, "Thought Disorder and Depression in Psychiatric Patients," (David L. Braff, MD and Ira D. Glick, MD) for the Western Psychological Association Annual Meeting, Sacramento, CA, April 1982. Panelist, "The Widening Scope of Family Therapy," Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 1982. Presentation of paper, "Which Chronic Patients Mostly Need Readmission," (with Braff D, MD, Klar H, MD), for the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 1982. Discussant, Conference on "The Changing American Family," The 67th Annual Seymour Silverberg Lecture, Long Island Jewish-Hillside Medical Center, June 1982. Keynote Address, "Couples in the 1980s: Emerging Trends," Workshop on "Step-Parenting," and Panel Discussion - all at the Symposium, "Marital and Sexual Therapy," The Family and Couples Institute, The Dept. of Psychiatry, Tufts University School of Medicine, Boston, June 1982. Presentation of Research Project, "Inpatient Family Intervention: A Controlled Study" and Presentation of "The Family Therapy Training Program at PWC" at the 1982 Annual Meeting, American Family Therapy Association, Boston, June 1982. Invited Guest, Interviewed on topic of "Vacations & Couples," on Travel Talk, Dena Kaye, WMCA, NYC, 10/82. Invited Lecturer, "The Changing American Family: Emerging Trends and Comparison with the Japanese Family," Dept. of Psychiatry, Juntendo University, Tokyo, October 1982. Grand Rounds, "Toward the Definition and Delivery of Mental Health Care," Massachusetts Mental Health Center, Boston, October 1982. Grand Rounds, "Guidelines for Family Therapy," Dept. of Psychiatry, Medical College of Georgia, 1/83. Grand Rounds, "Guidelines for Family Therapy," Dept. of Psychiatry, Tulane University and Louisiana State University, February 1983. Presentation of paper, "Teaching Investigative Psychiatry to Psychiatric Residents, a Sequential Curriculum: Everything You Wanted to Know About Research, But Were Afraid To Ask." Free University Presentation, at the Annual Meeting of the Association for Academic Psychiatry, Tampa, March 1983. Presentation of paper, "A New Drug Treatment for Premenstrual Schizophrenia," at the Eleventh Annual Conference on Psychosomatic Obstetrics and Gynecology, Sugar Loaf, Temple University Conference Center, Philadelphia, March 1983. Visiting Scholar, Dept. of Psychiatry, School of Medicine, University of Vermont, Burlington, March 1983. Grand Rounds, "Psychiatric Hospitalization for the 1980s," Dept. of Psychiatry, School of Medicine, UCLA and Harbor Hospital, Los Angeles, April 1983. Grand Rounds, "Toward the Definition and Delivery of Mental Health Services: Who Should Pay and for What?" Dept. of Psychiatry, UCSF, San Francisco, April 1983. Invited Paper, "Treatment of Severe Premenstrual Syndrome (PMS) and Premenstrual Exacerbation of Psychiatric Disorder," Premenstrual Syndrome Workshop, co-sponsored by Center for Studies of Affective Disorder, Psychobiological Processes & Behavioral Medicine Section, Clinical Research Branch, and the Intramural Research Program, NIMH, April 1983.
42

Ira D. Glick, M.D.

Presentation, "Treatment of Dual Doctor Couples," as part of an APA Issue Workshop, "Dual Doctor Couples" at the Annual Meeting of the American Psychiatric Association, New York, May 1983. Co-Chair and Presentation, "Overview" for Component Presentation, "Obstacles to Quality Clinical Systems,"
presented by APA Committee on Administrative Psychiatry, at the Annual Meeting of the American Psychiatric Association, New York, May 1983.

Presentation and Co-Moderator, APA Issue Workshop, "Family Therapy Training in Residency Programs," at the Annual Meeting of the American Psychiatric Association, New York, May 1983. Presentation, "The Basics of Family Treatment" (with Henry Grunebaum, MD), as part of "Psychiatry
Update," at the Annual Meeting of the American Psychiatric Association, New York, May 1983.

Presentation, "Review of Length of Stay Research," as part of a course, "Inpatient Treatment Programs:
Programs: Acute and Long-Term," at the Annual Meeting of the American Psychiatric Association, NY, 5/83.

Presentation of paper, "The Importance of Thought Disorder in Depressives" (with David Braff, MD), at the Annual
Meeting of the American Psychiatric Association, New York, May 1983.

Presentation of paper, "Inpatient Family Intervention: A Controlled Study," at the Annual Meeting of the American
Psychiatric Association, New York, May 1983.

Presentation of Research Project, "Inpatient Family Interventions: A Controlled Study" and Presentation of "The
Family Therapy Training Program at PWC" at the 1983 Annual Meeting, American Family Therapy Association, San Francisco, California, June 1983.

Grand Rounds, "Psychiatric Hospitalization for the 1980s," Bergen Pines County Hospital, Paramus, NJ. 6/83. Presentation, "Inpatient Family Intervention: A Controlled Study," at the Annual Meeting of the American
Psychological Association, Anaheim, California, August 1983.

Grand Rounds, "When Should the Chronic Patient be Hospitalized," Dept. of Psychiatry, St. Luke's/Roosevelt
Hospital Center, New York, September 1983.

Distinguished Lecturer, "Doing Research Without Pain," University of Medicine and Dentistry of NJ, 101/83. Lecture, "Diagnosis and Treatment of Depression," as part of a course, "Recent Advances in Medicine," Temple
University School of Medicine, Philadelphia, November 1983.

Co-Chairman, ACNP Training Session, "Issues in Clinical Psychobiologic-Psychopharmacologic Research Training," Annual Meeting of the American College of Neuropsychopharmacology, San Juan, 1983, Grand Rounds, "Toward the Definition of and Delivery of Mental Health Services - Who Should Pay and for
What?" The New York Hospital-Cornell University Medical College, January 1984.

Grand Rounds, "The Changing Role of the Hospital in Treatment of the Chronic Patient," Roosevelt Hospital, New York, February 1984. Invited Lecturer, "Focus on Family Psychotherapy Advances" and "Practical Office Psychotherapy," Winter
Update, Dept. of Psychiatry, University of South Dakota, February 1984.

Free University Presentation, "Teaching Integration of Psychiatric Models to Residents," at the Annual Meeting of the Association of Academic Psychiatrists, Tampa, March 1984.

43

Ira D. Glick, M.D.

Grand Rounds, "Diagnosis and Treatment of Depression" at Grand Rounds, in Dept. of Psychiatry in 5 settings,
1983-84.

Grand Rounds, "Toward the Definition of and Delivery of Mental Health Services: Why Don't Patients Receive Appropriate Care?" Dept. of Psychiatry, Mt. Sinai, April 1984. Invited Lecture, "Towards the Definition of and Delivery of Mental Health Services: Why Don't Patients Receive Appropriate Care?" Dept. of Psychiatry," The University of New Mexico, April 1984. Grand Rounds, "Toward the Definition of and Delivery of Mental Health Services," Dept. of Psychiatry, College of
Physicians and Surgeons of Columbia University, April 1984.

Grand Rounds, "Psychiatric Hospitalization for the 1980s," Dept. of Psychiatry, New York Medical College, Valhalla, New York and Metropolitan Hospital, New York City, May 1984.
At the Annual Meeting of the American Psychiatric Association, Los Angeles, May 1984:

Presentation, "Treatment of the Premenstrual Syndromes," as part of a Symposium, "Premenstrual Syndrome: Current Findings and Future Directions." Faculty, "Short-Term Psychosocial Inpatient Treatment," as part of a Course, "Short-Term
Psychiatric Treatment."

Leader of Discussion Group, "Delivering State-of-the-Art Multimodality Treatment." Co-Chair and Presentation, "New Demographic Trends in American Marriage," (with Oliver
Bjorksten, MD and Thomas Stewart, PhD), as part of a Symposium, "New Clinical Concepts in Marital Therapy."

Chairman and Presentation, "Inpatient Family Intervention: A Controlled Study, Preliminary

Results," (with J. Clarkin, PhD, G. Haas, PhD, J. Spencer, MD, et al), as part of a Symposium, "Results of Family Treatment: Second Generation Studies."

Grand Rounds, "Is There Any Future for Long-Term Hospitalization?" Silver Hill Foundation, New Canaan, CT,
June 1984.

Grand Rounds, "Which Chronic Patients Most Need Readmission?" Norristown State Hospital, 9/94. Visiting Lecturer, "Why Don't Patients Receive Appropriate Psychiatric Treatment?" Dept. of Psychiatry, University
of Chicago School of Medicine, September 1984.

Invited Lecturer, "Creativity and Madness," Annual Meeting, Louisiana Psychiatric Society, New Orleans, 9/84. Invited Lecturer, "Guidelines for Family Therapy," Departments of Psychiatry, Tulane University and Louisiana State University, October 1984. Presentation, "The Family Model and the Treatment of Affective Disorders," at Albert Einstein Medical Center,
Northern Division, Philadelphia, October 24, 1984.

Grand Rounds, "Indications and Contraindications," Dept. of Psychiatry, Bronx Lebanon Hospital Center, 11194, Departmental Colloquia, "Why Don't Patients Receive Appropriate Psychiatric Treatment?" Dept. of Psychiatry,
University of Pennsylvania, December 1984.

Guest Speaker, "Trends in Marriage & Marital Therapy," South Jersey Psychiatric Society, Cherry Hill, N J, 12/84.
44

Ira D. Glick, M.D.

Co-Chair, ACNP Study Group, "Psychotropic Drug and Psychotherapy Interaction Research," Annual Meeting of the American College of Neuropsychopharmacology, San Juan, 1984. Co-Chairman, ACNP Training Session, "Proposed Curriculum for Teaching Psychopharmacology," Annual Meeting of the American College of Neuropsychopharmacology, San Juan 1984. Grand Rounds, "Guidelines for Marital and Family Therapy," Detroit Psychiatric Institute and Lafayette Clinic, Detroit, January 1985. Continuing Education Workshop, "Family Therapy - Working with Couples," Dept. of Continuing Education, Harvard Medical School at New York City, January 1985. Grand Rounds, "Why Don't Patient Receive Appropriate Psychiatric Treatment?" Dept, of Psychiatry, University of Utah, Salt Lake City, February 1985. Grand Rounds, "Diagnosis and Treatment of Depression," Coney Island Hospital, New York, February 1985. Grand Rounds, "Inpatient Family Intervention: A Controlled Study - Preliminary Results," University of California, San Francisco, February 1985. Grand Rounds, "New Concepts About Inpatient Family Intervention for Psychiatric Disorders," Peninsula Hospital, Hillsdale, California and San Mateo Hospital, San Mateo, California, March 1985. Grand Rounds, "New Concepts in Family Intervention in Chronic Mental Illness," Harlem Valley Psychiatric Center, Wingdale, New York, March 1985. Grand Rounds, "Psychiatric Hospitalization for the 1980s: A Controlled Study of Short-Term Versus Long-Term Hospitalization," Duke University Medical Center, Durham, North Carolina, March 1985. Invited Faculty, "The 'Shrinking' of Inpatient Psychiatry: What To Do About Limited Hospital Stays" and Workshop, "Family Work on an Inpatient Unit," both as part of course at Harvard Medical School, Dept. of Continuing Education, Boston, March 1985. Grand Rounds, "Recent Trends in Marriage and the Family: Effects on Therapy," Tufts-New England Medical Center, Boston, April 1985. Grand Rounds, "The 'Shrinking' of Hospital Psychiatry," Dept. of Psychiatry and the Behavioral Sciences, USC School of Medicine, Los Angeles, April 1985. Grand Rounds, "Inpatient Family Intervention: A Controlled Study," The Medical College of Pennsylvania, Philadelphia, April 1985. Grand Rounds, "The Family and Its Role in Diagnosis and Treatment of Depressive Disorder," Georgetown University School of Medicine, Washington, D.C., April 1985. Grand Rounds, "Psychoeducation in a Hospital Setting," Silver Hill Hospital, Silver Hill, Connecticut, 5/85. Grand Rounds, "Guidelines for Marital and Family Therapy: Circa 1985," Dept. of Psychiatry, Stanford Medical School, Palo Alto, California, May 1985. At the Annual Meeting of the American Psychiatric Association, Dallas, May 1985: Workshop, Presentation of "A Model Psychoharmacology Curriculum," (with David S. Janowsky, MD, Richard I. Shader, MD and Carl Salzman, MD)
45

Ira D. Glick, M.D.

Presentation, "The Family and Antidepressant Noncompliance" (with John Clarkin, PhD and Gretchen Haas, PhD) as part of a Symposium, "Resistance to Antidepressants: Psychosocial Factors" Presentation, "Quality Treatment and Practitioner Competence" as part of a Symposium, "Evaluation of Knowledge and Practice in Psychiatry - Joint Session with the Association for Academic Psychiatry" Study Group, "Residents with Marital Distress: The New Epidemic?" Chairman and Presentation, "Inpatient Family Intervention: A Controlled Study," (with John Clarkin, PhD, Gretchen Haas, PhD, James H. Spencer, MD, Alfred Lewis, MD and Joanne Newman, M.S.W.) as part of a symposium "Results of Family Therapy Outcome Studies" Faculty, "Short Term Psychosocial Inpatient Treatment," as part of a Course, "Short-Term Psychiatric Treatment" Workshop, "Family Therapy, Severe Psychiatric Problems and the Psychiatric Hospital: Critical Issues at the Interface," as part of a series of workshops, "Family Therapy: The Master Therapists," sponsored by Dept. of Psychiatry, University of Connecticut School of Medicine, 6/85. Grand Rounds, "Diagnosis and Treatment of Depression," Dept. of Psychiatry, Bowman Gray School of Medicine, Winston-Salem, North Carolina, August 1985. Invited Address, "Survival for the Physician and the Family in the 1980s," Capital Medical Society, Tallahassee, Florida, August 1985. Grand Rounds, "Indications and Contraindications for Family Therapy," Dept. of Psychiatry, Emory University, Atlanta, September, 1985. Invited Presentation, "The Shrinking Of Hospital Psychiatry And What To Do About It," Annual Meeting, Hospital Corporation of America, Orlando, December 1985. ACNP Poster Presentation, "Inpatient Family Intervention: The Patient, the Family and Compliance with Drug Treatment for Affective Disorders," December 1985. Presentation of paper, "Inpatient Family Intervention: A Controlled Study" at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May, 1986. Invited Lecture, "The Family and Recent Developments in Psychiatry," Family Institute of Milan, Italy, 3/86. Visiting Professor, "Family Therapy: Indications and Contraindications," Dept. of Psychiatry, School of Medicine and Surgery, University of Naples, Italy, May, 1986. Grand Rounds, "The Patient, the Family and Psychiatric Hospitalization," Dept. of Psychiatry, Jefferson Medical College, Philadelphia, October, 1986. Grand Rounds, "Psychiatric Hospitalization for the 1980's," Dept. of Psychiatry, Hahnemann University, Philadelphia, October, 1986. Grand Rounds, "Treating the Family of the Hospitalized Patient, Is it Worth It?" North Shore University Hospital, New York, October, 1986. Grand Rounds, "Combination Therapy: A Study of Inpatient Family Intervention," Westwood Lodge Hospital and Pembroke Hospital, Boston, October, 1986.
46

Ira D. Glick, M.D.

Grand Rounds, "Receiving Effective Psychiatric Treatment," Albert Einstein Medical Center, PA, 11/86. Grand Rounds, "Working With The Family - Is It Worth It? A Controlled Clinical Trial of Inpatient Family Intervention", Dept. of Psychiatry, Cornell University Medical College and Payne Whitney Clinic, The New York Hospital, November, 1986. Grand Rounds, "New Developments in the Treatment of Schizophrenia: Combining Drug and Family Therapy," Dept. of Psychiatry, Lincoln Hospital, New York, November, 1986. Grand Rounds, "Psychosocial Interaction in the Treatment of Schizophrenia," Dept. of Psychiatry, Coney Island Hospital, Brooklyn, November, 1986. At the Annual Meeting of the American College of Neuropsychopharmacology, Washington, D.C., 1986: Co-Chair, ACNP Training Session, "Teaching Psychopharmacology in the 1990's" Chair, Presentation of Paper, "The Teaching of Psychopharmacology in the United States" ACNP Poster Presentation, "The Patient, the Family, and Compliance with Drug Treatment for Affective Disorders" At the Annual Meeting of the American Psychiatric Association, Chicago, Illinois, May, 1987: Presentation, "Inpatient Family Intervention for Affective Disorders" as part of a Symposium, "Depression and Families: Recent Advances" Presentation, "Inpatient Family Intervention for Psychotic Disorders" as part of a Symposium, "Advances in Family Psychiatry" Presentation, "Study Design Influences Generalizability of Result" as part of a Symposium, "Long- Term Treatment Strategies in Schizophrenia" In Japan, lectures and other activities during sabbatical year, 1987: 1) 2) 3) 4) 5) 6) 7) 8) 9) New Directions in Family Therapy, School of Medicine, Kanazawa University, January. Indications and Contraindications for Family Therapy, Kochi Medical School, Kochi City,Shikoko The Psychoeducational Approach, Psychoanalytic Seminar, Keio University & Hospital Indications and Contraindications for Family Therapy, Tokyo Community Counseling Service The Family on the Move: Family Function and Problems, International School of the Sacred Heart, Tokyo, April. Diagnosis and Therapy of Depression, Dept. of Psychiatry, Tokai University, April. Psychoeducational Treatment in Psychiatry, Okayama Prefectorial Mental Hospital, April. Indications and Contraindications for Family Therapy, Psychiatric Research Institute of Tokyo Hasagawa Hospital - April-June a. New Concepts in Treatment of Schizophrenia b. Psychoeducational Treatment in a Hospital Setting c. Diagnosis and Therapy of Depression The Changing American Family, Continuing Education Course, Japan NIMH Indications and Contraindications for Family Therapy, Dept. of Psychiatry, School of Medicine, Fukuoka University Recent Trends in Treatment of Mental Patients, Dept. of Social Administration, Tokyo Metropolitan Hospital Indications and Contraindications for Family Therapy, Tokyo Family Therapy Association

10) 11) 12) 13)

47

Ira D. Glick, M.D.

14) 15) 16) 17) 18) 19) 20)

The Changing American Family, Emerging Trends and Comparisons with the Japanese Family, U.S. Information Service Seminar, Sapporo, Hokkaido Combination Therapy in Modern Psychiatry, Keio Medical School A Model Psychopharmacology Curriculum, Nihon University, Tokyo The Changing American Family, Emerging Trends and Comparisons with the Japanese Family, U.S. Information Service Seminar, Tokyo Featured Guest, The Changing American Family, Japanese-American Cultural Program, NHK - Educational TV The Changing American Family, Emerging Trends and Comparisons with the Japanese Family, U.S. Information Service Seminar, Nagoya A Study of the Quality of Psychiatric Care - Preliminary Results, Staff Conference, Japan NIMH

Research Conference, "A Controlled Study of Transitional Day Care for Non-Chronically III Patients," Dept. of

Psychiatry, Cornell University Medical College and Payne Whitney Clinic, The New York Hospital, 9/87.
Grand Rounds, "Working with the Family of a Hospitalized Patient - Is It Worth It?" Dept. of Psychiatry, Brookdale

Hospital, Brooklyn, New York, September, 1987.

Clinical Conference, Grady Memorial Hospital and Emory Medical School, Atlanta, Georgia, October, 1987. Invited Lecture, "Recent Advances in Psychiatry: The Family and Family Therapy," Prasat Neurological Hospital,

Bangkok, November, 1987.

Invited Lecture, "Recent Advances in the Treatment of the Psychoses," Dept. of Neurology & Psychiatry, Pra Mongkutklao Army Hospital, Bangkok, November, 1987.

The Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 12/87:
Study Group - Drug & Psychosocial Therapy in Schizophrenia and Affective Disorders, Co-Chair with

Nina Schooler, PhD

Presentation of Paper - Inpatient Family Intervention: Final Results for Schizophrenia and

Affective Disorder
Grand Rounds, "New Therapies in Depression: Combining Drugs & Psychotherapy," Pacific Presbyterian Medical

Center, San Francisco, January, 1988.

Guest Consultant, Biological Psychiatry Colloquium, "Clinical Management of a Treatment Resistant Patient with a

Bipolar Compulsive Disorder," Pacific Presbyterian Medical Center, San Francisco, January, 1988.
Grand Rounds, "Inpatient Family Interventions for Psychotic Disorders," South Beach Psychiatric Center, Staten

Island, New York, February, 1988.

Grand Rounds, "Inpatient Family Intervention: A Randomized Clinical Trial," Dept. of Psychiatry, Emory University

School of Medicine, Atlanta, Georgia, February, 1988.

Presentation, "How to Teach Family Therapy and (Even, Sometimes) Succeed," (with Alan Manevitz, MD), Annual

Meeting of the Association for Academic Psychiatry, Free University Section, Tampa, Florida,3/88.
Presentation & Workshop, "The Interface of Psychodynamic Psychotherapy and Psychophamacology" 10th Annual Menninger Foundation Winter Conference, Park City, Utah, March, 1988:

The Annual Meeting of the American Psychiatric Association, Montreal, Canada, May, 1988:
48

Ira D. Glick, M.D.

Presentation, "The Family and Schizophrenia" as part of a Symposium, "Psychosocial Treatment of Schizophrenia'' with James Spencer, MD, Gretchen Haas, PhD, John Clarkin, PhD, et al Presentation, "Inpatient Family Intervention: Follow-up Results" as part of a Symposium, "Psychotherapy: Process and Outcome" with James Spencer, MD, Gretchen Haas, PhD, John Clarkin, PhD, Alfred Lewis, MD Presentation, "Predictors of Early Stabilization in Schizophrenia" as part of a Symposium, "Long-term Treatment Issues in Schizophrenia" with Nina Schooler, PhD, Sam Keith, MD, Alan Balleck, MD, et al The Annual Meeting of the Association for Clinical Psychosocial Research, Montreal, Canada, May, 1988: Presentation, "Family Therapy Manuals: Treatment in Search of a Manual or Manuals in Search of a Treatment" as part of a Symposium on Psychotherapy Manuals, with John Clarkin, PhD and Gretchen Haas, PhD. The Annual Meeting of the American Family Therapy Association, Montreal, Canada, June, 1988: Presentation, "Inpatient Family Intervention: Final Results for Schizophrenia and Affective Disorder" Plenary Session, "NIMH Update" The Regional Symposium of the World Psychiatric Association, Washington, D.C., October 1988: Presentation: "Developing an Effective Treatment Equation" Presentation: "The Family Model and Schizophrenia" Participant on Panel: "Mental Health and the News Media," The Fourth Annual Rosalynn Carter Symposium on Mental health Policy, Atlanta, October 1988. Keynote Speaker, "National Priorities in Mental Health Research," First Annual Kansas Scientific Symposium, Kansas City, October 1988. Grand Rounds, "Family Therapy: Indications and Contraindications," Carrier Clinic, Princeton, NJ, 11/88. Presentation: "The National Institute of Mental Health Public Academic Liaison Initiative," National Association of Social Workers 1988 Annual Conference, Philadelphia, Pennsylvania, November 1988. Presentation: "Fostering Collaborative Research that Impacts the Adminstration of Public Mental Health Programs: The Federal Perspective." American Public Health Association, Boston, MA, November 1988. The American College of Neuropharmacology (ACNP) 27th Annual Meeting, San Juan, Puerto Rico, 12/88: Presentation of paper for the TSS Collaborative Study Group, "Depressive Symptomatology, Negative Symptoms and Extrapyramidal Symptoms (EPS) in Acute Treatment Response and Short Term Outcome," as part of a symposium, Acute Treatment Response and Short Term Outcome in Schizophrenia" Poster with the IFI Research Group, "Working with the Family to Improve Medication Compliance" Keynote Remarks, "The NIMH Program for 1989 and its Implications for Training." Annual Meeting of AADRPT, San Diego, California, January 1989. Keynote Address, "NIMH Prospects and Promises," California Coalition for Mental Health, Los Angeles, California, January 1989.
49

Ira D. Glick, M.D.

Presentation of paper, "The Programs of the NIMH and Their Implications for Training," 1989 Annual Meeting of the Association for Academic Psychiatry, Atlanta, Georgia, March 1989. Ground Rounds, "Among Doctors, Patients, and Family: Achieving Effective Treatment for Serious Mental Illness," Chope Hospital, San Mateo, California, April 1989. Poster Presentation, "Depressive Symptomatology, Negative Symptoms and Extrapyramidal Symptoms (EMPS) in Acute Treatment Response and Short Term Outcome," International Congress on Schizophrenia Research, San Diego, California, April 1989. At the Annual Meeting of the American Psychiatric Association, San Francisco, California, May 1989: Workshop, Presentation of "The Family and DSM-IV: A Progress Report from the Group for the Advancement of Psychiatry" (with LC Wynne MD, L Combrinck-Graham MD, and AL Price MD) Workshop Chairperson, Presentation of "Public/Academic Liaison: Can It Work?" (with SC Shulz MD. JD Burke MD, D Jones MSW, and GM Simpson MD) Presentation, "Inpatient Family Intervention: Process Results" (with JF Clarkin PhD, JH Spencer MD, GL Haas PhD, and AB Lewis MD) as part of a Paper Session, "Family Therapy Strategies" Co-author, "Sex Differences in Schizophrenia Outcome," (with GL Haas PhD, JF Clarkin PhD, and JH Spencer MD) as part of a Paper Session, "Schizophrenia Treatment Outcomes: New Consideration" Co-author, "Social and Family Factors Predict Early Stabilization," (with NR Schooler PhD, JB Severe MS, SJ Keith MD. AS Bellack MD, WA Hargreaves PhD, JM Kane MD, and PT Ninan MD) as part of a Symposium, "Long-term Treatment Issues in Schizophrenia" Presentation, "State/University Collaboration: The Public-Academic Liaison," National Conference on Mental Health Statistics, San Diego, California, June 1989 At the Eleventh Annual Meeting of the American Family Therapy Association, Colorado Springs, CO, 6/89 Chair, Interest Group, "Medications, Hospitalization and Family Systems" Presentation, "The Family and Treatment of Depression" Presentation, "NIMH Update" Grand Rounds, "Family Intervention for Affective Disorders," Dept. of Psychiatry, Louisiana State University Medical Center, New Orleans, October 1989. Invited Speaker, "The National Plan for Research to Improve Care of the Severely Mentally III," at a conference, "Privatization of Mental Health Care: A National Perspective," Center for Health and Human Resources Policy, JFK School of Government, Harvard University, Boston, Massachusetts, October 1989. At the 1989 Institute on Hospital and Community Psychiatry of the American Psychiatric Association, Philadelphia, October 1989: Lecture, "Update from the NIMH" Workshop, "Follow-up Studies of Hospitalized Psychiatric Patients: Triumphs, Tragedies, and Surprises" (with Harding, CM)

50

Ira D. Glick, M.D.

Symposia, "Family Intervention and Psychiatric Hospitalization" (with Sholevar, GP) Poster, "Improving Treatments for the Severely Mentally III - Implications of the Italian Psychiatric Reform" Grand Rounds, "The Effectiveness of Treatment for Major Depressive Disorder One year Later," Jefferson Medical College, Philadelphia, November 1989. Workshop, "Fundamentals of Mental Illness Research," National Mental Health Association Scientific Symposium, Washington, November 1989. At the 1990 Annual Meeting of the ACNP, Maui, December 1989. Study Group, "Public/Academic Liaison to Generate Psychpharmacology Research: Can it Work?" (Co-chair with Schulz S) Open Session, "New Initiatives of the NIMH - the PAL Initiative" Grand Rounds, "Working with the Family of the Hospitalized Patient: Is It Worth It Over the Long Run?" Holliswood Hospital, Queens NY, December 1989. Presentation of Paper, "A Cross National Followup Study of the Treatment of Major Depressive Disorder," Annual Meeting Psychiatric Research Society, Park City, Utah, March 1990. Grand Rounds, "Increasing the Effectiveness of Psychiatric Care: What Happens to Patients and Their Families After Hospitalization", Dept. of Psychiatry, University of North Carolina, Chapel Hill, April 1990. At the 1990 Annual Meeting of the American Psychiatric Association, New York, May 1990: Vestermark Award Session, "Overview of the Model Curriculum and a Follow Up Evaluation of its Usefulness," as part of the session, "The Teaching and Learning of Psychopharmacology in the 1990's: How to Jump in a Rapidly Moving Train" A Workshop, "National Plan Research on Severely Mentally III" (with Burke, J) Presentation, "Cross-National Study of Major Depressive Disorders." as part of Symposium, "Cultural Aspects of Depression in Asia and America" Research Colloquia, "Drug and Family Treatment for Major Affective Disorder," Dept. of Psychiatry, University of Pennsylvania School of Medicine, May 1990. Brief Presentation, "Making Inpatient Family Intervention Work," American Family Therapy Association, Philadelphia, June 1990. Invited Presentation, "Implications of the Italian Reform for the Delivery of Mental Health Services in the U.S. and Canada," sponsored by British Columbia Mental Health Society, Vancouver, July, 1990 At the 7th Annual Scientific Symposium, National Mental Health Association, "New Findings & Practical Applications Of Mental Health Research" Houston, Texas, 1990: Workshop, "Fundamentals of Mental Illness Research" Workshop, "Increasing the Effectiveness of Psychiatric Treatment."

51

Ira D. Glick, M.D.

Professional Symposium Series, "Psychoeducation for Patients and Families: What and How," Portsmouth Pavilion, Portsmouth, New Hampshire, September, 1991. Grand Rounds, "Effectiveness for the Patient and Their Families of Psychiatric Care: A Cross-National Study of the Process of Treatment and Outcome of Major Depressive Disorder," Brookside Hospital, Nashua, New Hampshire, September, 1991. Grand Rounds: "The Family and Affective Disorder: A Followup Study." Butler Hospital, Brown University School of Medicine, Providence, November 1990. Grand Rounds: "Effectiveness of Inpatient Psychiatric Care: A Two Year Followup Study of Major Affective Disorder." Manhattan Psychiatric Center, New York, December 1990. Grand Rounds, "Does Treatment Help? The Process of Hospital Treatment and Outcomes for Major Depressive Disorder." Dept. of Psychiatry, The New York Hospital-Cornell University Medical College, NY, 1/91. Presentation, "A Model Curriculum in Psychopharmacology." Annual Meeting of the Association for Academic Psychiatry, Free University Section, Tampa, Florida, March, 1991, Grand Rounds, "Increasing Effectiveness of Psychiatric Care: What Happens to Patients and Their Families After They Leave the Hospital." Dept. of Psychiatry, The New York Hospital-Cornell Medical College-Westchester Division, NY, March 1991. Grand Rounds, "The Changing American Couple and Indications for Marital Therapy." State University of New York Health Science Center at Brooklyn, New York, April, 1991. At the Annual Meeting of the American Psychiatric Association, New Orleans May 1991: Presentation: "Family Outcome of Hospitalization for Mood Disorders" with Lorenzo Burti, MD, Kuninao Minakawa, MD, Michael Sacks, MD, Katsua Maehara, MD Invited Lecture: "The Integration of Psychopharmacology with Psychosocial Therapies for Treatment of Psychoses" sponsored by The Bipolar Foundation, Buenos Aires, Argentina, July 1991. Invited Lecture: "Psychoeducation as the Tool to Integrate Psychopharmacology with Psychosocial Therapies for Schizophrenia and Bipolar Disorder." sponsored by The Uruguayian Psychiatric Society, Montevideo, Uruguay, July 1991. Invited Lecture: "Effectiveness in Psychiatric Care: A Followup Study of Major Affective Disorder." Dept. of Psychiatry, LSU, New Orleans, October 1991. Clinical Research Award Address: "Effectiveness in Psychiatric Care: II. Outcome for the Family After Hospital Treatment for Major Affective Disorder." Annual Meeting of the American Academy of Clinical Psychiatrists, New Orleans, October 1991. At the Annual Meeting of the American College of Neuropsychopharmacology, Puerto Rico, December 1991: Study Group, "Maximizing the Effectiveness of Medication for Schizophrenia and Affective Disorder," Study Group organizer and Co-chair as well as Presenter (with four others) Presentation, "Effectiveness of Psychiatric Care, A Followup Study of Psychopharmacologic Practices in Treatment of Major Affective Disorder." As part of a Symposium on Transcultural Psychopharmacolopv organized by T. Rai and N. Sartorius

52

Ira D. Glick, M.D.

Poster, "Increasing the Effectiveness of Psychiatric Care: Achieving Effective Medication Management" (with three others) Grand Rounds, ''The Changing American Couple and Indications for Marital Therapy." Coney Island
Hospital, Brooklyn, New York, January, 1992 At the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 1992:

Debate: Resolved: For Most Psychiatric Inpatients, a Ten Day Hospitalization is as Effective as a Longer Stay (with M. Herz, MD) Paper: Increasing the Effectiveness of Treatment for Mood Disorder, as part of a symposium, The Family and Mood Disorder. New Research Poster: "Psychoeducation For Mood Disorder" with Lorenzo Burti, MD, Keigo Okonogi, MD and Michael Sacks, MD. Poster: "Achieving Effective Medication Management" with Lorenzo Burti, MD, Koji Suzuki, MD and Michael Sacks, MD, NCDEU Annual Meeting, Boca Raton, Florida, June 1992. International Seminar: "Revamping of the Uruguayan Mental Health System: New Patterns of Care, Methods of
Diagnosis and Treatment for Severe Mental Disorders" sponsored by the Uruguayan Psychiatric Association, World Association for Psychosocial Rehabilitation and the Republican National Bank, Director and Lecturer, Uruguay, June 1992 with John P. Docherty, MD.

Grand Rounds: "Alternative Treatments of Bipolar Disorder." Bronx State Psychiatric Cenmter. NY9192. Grand Rounds: "Effectiveness in Psychiatric Care: A Follow-up Study of Hospitalized Patients with Major Affective
Disorder." St. Vincent's Hospital and Medical Center. New York. September, 1992.

Grand Rounds, "Alternative Treatments of Bipolar Disorder." Bronx State Psychiatric Center, NY,9/92. Invited Plenary Lectures: At the Fall Meeting, Louisiana Psychiatric Association, Destin, Florida, 1992:
a) "Theoretical Background and Literature Underlying Psychopharmacotherapy and Marital/Family Therapy Combinations" "The New Algorithms for Combining Marital/Family Therapy with Drug and Other Psychotherapies"

b)

Invited Lecture, "The Role of Psychotherapy in Combination with Pharmacotherapy," as part of a symposium, "Bipolar Disorder: Current Progress and Future Directions in Diagnosis and Management," sponsored by Stanford University School of Medicine, San Francisco, October, 1992. Workshop, "The Millenium Has Arrived: Suggestions for a New Model of (and Research Questions about) Hospital
Treatment of Psychiatric Disorders," Institute on H&CP, Toronto, October, 1992.

Grand Rounds, "Combining Medication and Psychosocial Strategies for the Treatment of the Major Psychoses."
Stanford University Medical Center, Stanford, CA, November, 1992.

Grand Rounds, "Effectiveness in Psychiatric Care: What Happens to the Patient and Family After Hospitalization."
Creedmoor Psychiatric Center, New York, December, 1992.

At the Annual Meeting of the American College of Neropharmacology (ACNP), Puerto Rico, December 1992:
53

Ira D. Glick, M.D.

Paper, Treatment Strategies in Schizophrenia, (with 12 co-authors) Invited Lecture: "Combining Treatments to Improve Outcomes: A Followup Study of Major Affective Disorders in Italy, Japan and the United States." Bronx District Branch of the American Psychiatric Association, New York, March, 1993. At the Annual Meeting of the American Psychiatric Association, San Francisco, May, 1993: Invited Speaker for the Annual Review of Psychiatry Series, the Combined Treatments Symposium, Combining Medications with Family Psychotherapy (with Scott Goldsmith and John Clarkin) Workshop, Medication and the Italian Reform (with L. Mosher, G. Palermo and A. Bartolomeis) Lecture: "Increasing Effectiveness of Psychiatric Inpatient Care." Medical Staff, Dept. of Psychiatry, Stanford University Hospital, September, 1993. Grand Rounds, "Effectiveness in Psychiatric Care." Dept. of Psychiatry, Bronx-Lebanon Hospital Center, Bronx, NY, November 1993. At the Annual Meeting of the American College of Neuropharmacology (ACNP), Hawaii, December 1993: Paper, Promising New Medications for Schizophrenia not Available in the U.S.A., (with five co-authors) as part of the European College of Neuropsychopharmacology panel, Are You Missing Anything? Recent Psychotropics Available in Europe, But Not in U.S.A. (Chair, Stuec Montgomery) Poster, Promising Psychopharmacologic Medications not Available in the U.S.A. (with five co-authors) Lecture: "Medication Combined With Couples Treatment" as part of a symposium, "Clinical Pharmaco logy: An Update", Stanford University School of Medicine, January, 1994. Grand Rounds: "The Role of the Psychiatric Hospital in the 1990's," Langley Porter Psychiatric Institute, UCSF, San Francisco, March 1994. Grand Rounds: "New Strategies for the Treatment of Acute and Chronic Schizophrenic." California Medical Facility, Vacaville, CA. April 1994. Grand Rounds: "Atypical Antipsychotic Medications," Sacred Heart General Hospital, Eugene OR, April 1994 Invited Presentation: "A Cross Cultural Study of Treatment of Mood Disorders in Italy, Japan and the United States," The Northern California Psychiatric Society 1994 Annual Meeting, Olympic Valley, CA, April, 1994. Lecture: "New Strategies for Treatment of Acute and Chronic Schizophrenia" as part of a symposium, New Approaches to Treating Schizophrenia. Stanford University School of Medicine, May 1994. Paper: Psychiatric Aspects of Basketball Annual Meeting, International Society of Sports Psychiatry, Philadelphia, May 1994. Poster: Efficacious and Safe Psychotropics Not Available in the US., 1994 Annual Meeting, Society of Biological Psychiatry, Philadelphia, May 1994. Training Seminar: The Legal - Psychiatric Interface, for San Francisco, Santa Clara & San Mateo judges and other legal mental health professionals, San Jose, CA, August, 1994.

54

Ira D. Glick, M.D.

Keynote Address, "Combining Medication with Psychosocial and Rehabilitation Strategies in the '90s": sponsored by the Department of Psychiatry, University of Saskatchewan and the Department of Psychiatry, University of Alberta Hospitals, presented at Edmonton, Saskatchewan, and at Kingston,Canada, October, 1994. Grand Rounds, "Combining Medications and Psychotherapy in the 1990's: Researching Clinical Issues". California
Pacific Medical Center, San Francisco, October, 1994.

Grand Rounds, "Changing Models of Psychiatric Care: Psychiatric Hospitalization for the 90's." Chope Hospital & San Mateo Health Services Agency, San Mateo, CA, November, 1994. Poster: "Current European Clinical Trials of Anti-Dementia Drugs," (with Shwartz GE, Montgomery S, Klein F) at the 1994 Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December, 1994. Grand Rounds, "Combining Psychotherapy and Drugs in the 1990's." Department of Psychiatry, University of Arizona Health Sciences Center, Tucson, January, 1995. Lecture: "Combining Psychotherapy & Pharmacotherapy" as part of the 1995 Annual Meeting of the American College of Psychiatrists, Acapulco, Mexico, February, 1995. Grand Rounds, "Diagnosis and Treatment of Psychotic Disorders Related to Parturition" Department of Ob/Gyn,
Stanford University School of Medicine, March, 1995. At the Biannual International Congress on Schizophrenia Research (ICSR), Warm Springs, VA, May, 1995

Poster: Lithium Augmentation Fails to Reduce Symptoms in Poorly Responsive Schizophrenic Outpatients, (withSchultz SC, TSS Collaborative Study Group). Poster: Promising Psychopharmacologic Medications Not Available in the USA, Glick, ID, (with Lecrubier Y, Montgomery S, Vinar 0, Klein DF). Clinical Update: "The Forces Forming Character," at the 1995 Annual Meeting of the Northern California
Psychiatric Society,Pacific Grove, CA, April,1995.

Keynote: "Combining Family Therapy with Medication for the Treatment of Axis I Disorders." as part of seminar,
Effective Approaches: Working With Children, Adolescents and Their Families. Tender Lion Family Program, Family Service Agency of San Francisco, April 1995.

Grand Rounds: "New Strategies for Treating Schizophrenia," Eden Hospital, Castro Valley, CA, May, 1995. Poster: "New Psychopharmacologic Strategies for Treatment," (with Braff D, Janowsky D) at the 1995 Annual
Meeting of the Society for Biological Psychiatry, Miami, FL, May, 1995.

Grand Rounds: "The Effectiveness of Family Therapy for inpatient Psychiatric Patients," Department of
Psychiatry, School of Medicine, UC Davis, and Sacramento County Mental Health, Sacramento, November, 1995.

Grand Rounds: "Psychiatric Hospitalization for the 90's," Napa State Hospital, Napa, CA, December,1995.
At the Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Puerto Rico, December 1995.

Mentor: Travel Awardee. Poster: New Treatment Strategies, (with Braff D, Janowsky D). Poster: Treatment Outcomes of First Episode & Chronic Multiepisode Schizophrenia, (with Lieberman J,
et al).

Study Group: A Psychopharmacologic Jam Session: A Dialogue on Tricks of the Trade, (with Janowsky
D, Klein D, Schatzberg A)

55

Ira D. Glick, M.D.

Lecture: "Family Therapies: Efficacy, Indications and Therapy Outcomes." Annual Meeting of the American Psychopathological Association, New York, March, 1996. Lecture: "Pharmacologic Treatment of Schizophrenia," at the 1st Stanford Review of Psychopharmacology Course, San Francisco, March, 1996. Grand Rounds: "A Model Curriculum in Psychopharmcology for the 21st Century," San Mateo County General Hospital, San Mateo, March, 1996. Grand Rounds: "Sertindole and New Antipsychotic Therapies for Schizophrenia," Atascadero State Hospital, Atascadero, CA, April, 1996. Grand Rounds: "New Treatments and New Pharmacologic Strategies for Schizophrenia," Sutter Center for Psychiatry, Sacramento, CA, April, 1996. Lecture: "Advancing the Treatment of Mania." Departments of Psychiatry, University of California, Irvine and University of Southern California, Los Angeles, CA, June, 1996. At the Annual Meeting of the American Family Therapy Academy, San Francisco, June 1996. Poster: "Inpatient Family Intervention: Final Results from a Controlled, Random-Assignment Study," (with three others). Roundtable: "The Family Model and Psychiatric Illness." Grand Rounds: "Combing Medication with Family Intervention for Axis I Disorders," Hackensack Hospital Medical Center, Hackensack, NJ, September, 1996. International Congress: Schizophrenia: New Frontiers, Association for Research on Schizophrenia, Milan, October, 1996. Keynote: "Family Associations and Family Therapy: From Conflict to Collaboration." Workshop: "Psychoeducational Treatment of Schizophrenia: The Inpatient Family Intervention Study Experience" Grand Rounds: "Treatment Strategies in Schizophrenia: Final Results," Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, Stanford, CA, November, 1996. Grand Rounds: "New Drugs and New Strategies in Schizophrenia," Menlo Park Veterans Administration Hospital and Palo Alto Veterans Administration Hospital, Menlo Park and Palo Alto, CA, November, 1996. Grand Rounds: "Combining Medication with Psychotherapeutic Intervention, " Dept of Psychiatry, University of Miami School of Medicine, Miami, December, 1996. Grand Rounds: "Atypical Antipsychotics & New Treatments/New Strategies for Schizophrenia" Kaiser Hospital, San Francisco, CA, November, 1996 Central Missouri Psychiatric Society, St. Louis, MO, November, 1996 Boone County Medical Society, MO, November, 1996 Fulton State Hospital, Fulton, MO, November, 1996. Coutesville V-A Medical Center, Coutesville, PA, December, 1996 Institute of Pennsylvania, Philadelphia, PA, December, 1996 Arizona Alliance for the Mentally III, Phoenix, AZ, January, 1997 Good Samaritan Regional Medical Center, Phoenix, AZ, January, 1997 Porter Hospital, Denver, CO, January, 1997 University of Colorado Health Sciences Center, Denver, CO, January, 1997 First Hospital, Vallejo, CA, February, 1997 Mercy Memorial Hospital, Ardmore, OK, March, 1997 St Mary's Hospital, Colorado West Mental Health Meeting, Grand Junction, CO, April, 1997 Lakeview Veterans Administration Hospital, Chicago, IL, June, 1997 California Psychiatric Society South Coast Chapter, Santa Cruz, CA, July, 1997 County of Santa Cruz Community Mental Health Services, Santa Cruz, CA, July, 1997 Fulton State Hospital, Fulton, MO, August, 1997 Department of Psychiatry, School of Medicine, University of Missouri, Columbia, MO, August, 1997
56

Ira D. Glick, M.D.

Flower Hospital, Toledo, OH, September, 1997. International Health Care, Salt Lake City, UT, September, 1997. Napa State Hospital, Napa, CA , 1997. Sacred Heart Medical Center, Spokane, WA, October, 1997. John George Psychiatric Pavilion, San Leandro, CA, November, 1997. Tampa General Hospital, Tampa, FL, February, 1998. Florida Hospital, Orlando, FL, February, 1998. Peninsula Hospital, Burlingame, CA, January, 1999. At the Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Puerto Rico, December, 1996. Study Group: "A Psychopharmacologic Jam Session:Tricks of the Trade," moderator and participant. Poster: "New Psychotropic Drugs for Axis I Disorders: Recently Arrived, In Development, and Never Arrived" (with Belanoff J, Golden W). Grand Rounds: "Inpatient Family Intervention: A Controlled Study," National University of Taiwan, Taipai, Taiwan, December, 1996. Grand Rounds: "Combining Medication with Family Intervention for Axis I Disorders," Texas Tech Health Sciences Center, Amarillo, TX, January,, 1997. Medical Students' Forum: "Working With Families of Seriously III Patients," Texas Tech Health Sciences Center, Amarillo, TX, January, 1997. Grand Rounds: "Combined Therapy for Treatment of Axis I Disorders," First Hospital Vallejo, Vallejo, CA, February, 1997. Research Seminar: "Treatment Strategies in Schizophrenia: Final Results," Department of Psychiatry, College of Medicine, University of Iowa, Iowa City, IA, March, 1997. Grand Rounds: "Combining Medicine in Psychosocial Intervention," Department of Psychiatry, College of Medicine, University of Iowa, Iowa City, IA, March, 1997. Keynote: "New Developments in Antipsychotics," Western Colorado Psychiatric Meeting, Colorado Springs, CO, April, 1997. International Congress on Schizophrenia Research, Colorado Springs, CO, April 1997. Poster: New Psychotropic Drugs for Schizophrenia (with Belanoff J). Grand Rounds: "Diagnosis and Treatment of Schizophrenia," St. Vincents Hospital, New York, NY, April 1997. Invited Seminar: "New Treatments for Agitation and Aggression in Axis I Disorders," University of Medicine and Dentistry of New Jersey, Piscataway, NJ, April, 1997. Lecture: "Current Concepts in the Treatment of Schizophrenia," Conference: Understanding and Treating Schizophrenia: Progressing into the Next Century, Ann Arbor, MI, April, 1997. At the Annual Meeting of the American Psychiatric Association, San Diego, CA, May, 1997: Paper: "New Strategies and New Treatments for Schizophrenia," (with Belanoff J and DeBattista C). Paper: "The Professional Athlete as Role Model." Poster: "The Teaching of Psychopharmacology in the 1990's," (with Klein D, Doraiswamy M, Lydiard B). NCDEU Annual Meeting, Boca Raton, FL, June, 1997. Lecture: "Combining New Antipsychotics with Psychosocial Intervention in the 1990's," St. Lawrence Hospital, E. Lansing, MI, September, 1997. Lecture: "Combining New Antipsychotics with Psychosocial Intervention in the 1990's," as part of the program, Contemporary Issues in Psychiatry. Huran Valley Center, Yipsilanti, MI, September, 1997.

57

Ira D. Glick, M.D.

Lecture: "New Treatment Approaches for Psychosis in the Elderly," McComb Hospital, Detroit, September, 1997. Grand Rounds: "New Treatments for Schizophrenia," Department of Psychiatry and Behavioral Sciences,
University of Washington, Seattle, WA, October, 1997.

Grand Rounds: "New Treatments for Schizophrenia,"Department of Psychiatry, School of Medicine, Indiana
University, Indianapolis, IN, November, 1997. At the 36th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Waikoloa, HI, December, 1997. Poster: "The Teaching of Psychopharmacology in the 1990's," (with ASCP Committee)). Poster: "Extrapyramidal Symptom Profile of Sertindole," (with L. Ramirez) Continuing Education Update on Schizophrenia, for Neuroscience Regional Research Managers, Eli Lilly Co., at Stanford University School of Medicine, February, 1998. Expert Breakout Session (Schizophrenia). Second Stanford Psychopharmacology Review Course. Stanford, CA, March, 1998.

Lecture: "New Treatments and New Strategies for Schizophrenia: New Data," West Coast College of Biological
Psychiatry, Palo Alto, California, 1998.

Lecture: "Progress in Psychoses: Improving Treatment and Evaluation, Enhancing Cognition," Continuing Medical
Education Seminar, Los Angeles, April, 1998.

Grand Rounds: "Combining Medication with Psychotherapy," Weber County Mental Health Center, Ogden, Utah,
April, 1998.

Grand Rounds: "New Treatments and New Strategies for Schizophrenia," University of California at Irvine, Irvine,
California, April 1998.

Grand Rounds: "New Treatments and New Strategies for Schizophrenia," Department of Psychiatry and
Behavioral Sciences, Stanford University School of Medicine, Stanford, California, May 1998.

Grand Rounds: "Combining Medication and Psychotherapy for Psychiatric Disorder," North Shore University
Hospital, Great Neck, New York, May 1998.

Grand Rounds: "Combining Medication with Psychotherapy," Department of Psychiatry, Wright State University
School of Medicine, Dayton, Ohio, May, 1998.

Grand Rounds: "The Patient, the Family and Medication," Palo Alto and Menlo Park Veterans Administration,
California, June , 1998. At the Annual Meeting of the American Psychiatric Association, Toronto, May, 1998: Industry Symposium: " New Atypical Antipsychotics: Data versus Clinical Experience," Chair and lecturer: Lecture 1: "History of Somatic Therapy for Schizophrenia" Lecture 2: "Combining Medication with New Antipsychotics"

Grand Rounds: "An Overlooked Serotonin Dopamine Blocker; Loxapine Revisited," Atascadero Forensic Center, Atascadero, California, September, 1998, Grand Rounds: "New Atypical Antipsychotics," Department of Psychiatry, Louisianna State University, New
Orleans, October, 1998.

Lecture: "Schizophrenia: Receptor Profiles & Efficacy," at the Continuing Education Seminar,
Psychopharmacology 1998 Clinical and Research Update, sponsored by Department of Psychiatry, Stanford University and West Coast College of Biological Psychiatry, San Francisco, California, October , 1998.

58

Ira D. Glick, M.D.

Invited Lecturer: "Clinical Efficacy of Antipsychotics," at the World Psychiatric Association and the Mexican
Psychiatric Association, Guadalajara, Jalisco, Mexico, October, 1998.

Invited Lecturer: "Combining Medication Therapy with Family Interventions," Bipolar Dirsorder Minifellowship, Stanford Univrsity School of Medicine, Palo Alto, California, November,1998 Grand Rounds: "Combining Medication with New Antipsychotics," Herrick Hospital, Berkeley, California,
November, 1998.

Invited Lecturer: "A Model Currriculum in Psychopharmacology," Payne Whitney Clinic and Cornell University
Medical College, New York, December, 1998. At the Annual Meeting of the American College of Neuropsychopharmacology, Puerto Rico, December, 1998: Study Group: A Psychopharmacological Jam Session: A Dialogue on Psychosis, (Moderator and Participant) Poster: "New Psychotropic Drugs for Axis I Disorders; Recently Arrived, in Development and Never Arrived," (with JK Belanoff and JS Ballon). Poster: "The Teaching of Psychopharmacology in the 1990's: The First Year Experience with the Model Curriculum," (with PM Doraiswamy, J Halper, DS Janowsky, DF Klein, RB Lydiard, J Osterheld, DW Preven, P Ross, NG Ward and S Zisook).

Grand Rounds: "Combining Medication and Psychotherapy for Axis I Disorders," Dept Psychiatry, College of
Physicians and Surgeons and New York State Psychiatric Institute, New York, December, 1998.

Grand Rounds: "Combining Medications with Psychosocial Intervention for Axis I Disorders," Department of
Psychiatry and Behavioral Sciences, Baylor College of Mediche, Houston, Texas, January,1999.

Grand Rounds: "Combining Medications with Psychosocial Intervention for Axis I Disorders," Department of
Psychiatry, University of Texas at Houston, March, 1999.

Symposium: " Teaching Biological Psychiatry to Residents, West Coast College of Biological Psychiatry, Tucson,
April, 1999. At the Biannual International Congress on Schizophrenia Research, Santa Fe, April, 1999: Poster: "The Efficacy Spectrum for New Antipsychotics in Clinical Practice with S Marder, P Vasudevan. Poster: "Comparisons of the Effects of the Newer Atypical Antipsychotics in the Treatment of Schizophrenia," with J Davis.

Grand Rounds: "Combining Drugs and Ps;ychotherapy for Axis I Disorders." Department of Psychiatry, University
of Mississippi Medical Center, Jackson, May, 1999. At the Annual Meeting of the American Psychiatric Association, Washington DC, May, 1999: Paper Presentaton: "A Model Psychopharmacology Curriculum (with DF Klein and B Lydiard, et al) Paper Presentation: "Keeping the Athlete Functioning," (with J Horsfall).

Invited Lectures: "The New Atypical Antipsychotics - Efficacy and Outcomes," delivered in May, 1999 at
Departments of Psychiatry in Japan at: St Marianna University, Tokyo Hiroshima University, Hiroshima Kyorin University, Tokyo Fukushima Medical University (joint sponsorship with the Fukushima Medical Society), Fukushima

Invited Lecture: "Psychopharmacology in Psychiatry." Department of Psychiatry, University Hospital Utrecht, The
Netherlands, August 1999.

Grand Rounds: "New Treatments for Psychoses." The Netherlands, August, 1999.
Vincent van Gogh Hospital, Venray Delta Hospital, Poortugal

Workshop: Annual Meeting of the Association for Academic Psychiatry, New Orleans, October, 1999.
59

Ira D. Glick, M.D.

A Followup Evaluation of a Model Curriculum in Psychopharmacology, 1999

Workshops: Northwest Medical Health Institute and Oregon Psychiatric Association, Gleneden Beach, Oregon,
November, 1999. New Treatments for Psychosis in the Year 2000 Combining Medication with Psychotherapy for Axis I Disorders

Grand Rounds: "Combining Medication with Psychotherapy for Axis I Disorders." Santa Barbara County CMHC,
Santa Barbara, November, 1999.

Grand Rounds: "New Short and Long-term Strategies for Schizophrenia, Bipolar Disorder and Depressive
Disorder." Department of Medicine, Stanford University School of Medicine, December, 1999.

Grand Rounds: "Teaching Psychopharmacology in the New Millennium." Department of Psychiatry, University of
Hawaii at Manoa, December, 1999.

Study Group Presentation: "Clozapine Treatment Resistance: What Does it Mean? New Methodological Issues in
the Study of Treatment Refractory Schizophrenia," at the Annual Meeting of the ACNP, Acapulco, Mexico, December, 1999.

Invited Lecture: "New Treatments and New Strategies for Psychosis for the Millennium," 2000 Annual Meeting of
the Philippine Psychiatric Association, Hilo, Philippines, January, 2000.

Grand Rounds: "Combining Medical and Psychosocial Interventions for Schizophrenia." Grand Rounds
Presentation at Nihon University and Keio University, Tokyo, Japan, February, 2000.

Workshop: Organizer and Moderator, "Introduction to Neuropsychopharmacology: Pathophysiology to Clinical

Practice." A Workshop for the Neurobiology Unit, Roche Bioscience. Palo Alto, CA, February, 2000. Lectures: Overview of New Medication Strategies for Axis I Disorders Schizophrenia Clinical Trials Design (with Alan Schatzberg)

Invited Lecture: "Long Term Maintenance: Risperidol versus Haldol." In the symposium, "Psychosis: New
Perspectives and Strategies," Monte Carlo, March, 2000.

Korea: April, 2000

Grand Rounds: "Indications for New Antipsychotics," Seoul National University, Seoul. Invited Lecture: "New Treatments for Bipolar Disorders," Annual Meeting, Korean Psychopharmacology Association. "New Antipsychotics for Bipolar Disorder," Samsung Hospital, Seoul. Regional Symposium, Kyong-Ju, "New Antipsychotics for Bipolar Disorder." Regional Symposium, Kwang-Ju, "New Antipsychotics for Bipolar Disorder."

At the 2000 Annual Meeting of the American Psychiatric Association, Chicago, May, 2000. Industry-supported Symposium: New Antipsychotics: From Practice to Theory.
- Co-chair and Paper, "The Efficacy Spectrum for Atypicals in Clinical Practice."

Symposium: Psychopharmacological Approaches to the Athletic and Exercise Population.

- Paper, "Diagnosis and Psychiatric Treatment of Athletes."

Media Session: - Cultural Identity on the Tex Mex Border: Impact on Relationships Past and Present, discussion of movie, Lone Star, Chair and Presenter Co-Chair, Forum, "The Future of Psychopharmacology: Generativity and Mentoring" at the NCDEU Annual
Meeting, Boca Raton, May, 2000.

Grand Rounds: "Combining Medication with Psychotherapeutic Intervention for Axis I Disorders." Department of
Psychiatry, University of California at San Diego, June, 2000.

Grand Rounds: "Atypical Antipsychotics." Alameda Center for Behavioral Healthcare, June, 2000.
60

Ira D. Glick, M.D.

Sabbatical, New Zealand and Australia, July-August, 2000 New Zealand

Grand Rounds, "New Treatments for Psychosis," Dept Psychiatry, School of Medicine, Otago University, Dunedin, July, 2000. Australia (August, 2000) All "grand rounds" presentations or as "invited lecturer" for community mental health practitioners and students on 1) atypical antipsychotics, 2) combining medication with psychotherapy and/or 3) the teaching and learning of pharmacotherapy.

Brisbane
Royal Brisbane Hospital Princess Alexandra Hospital Prince Charles Hospital Ipswich Hospital and Wolsten Park Hospital

Sydney
Royal North Shore Hospital Macquarie Hospital Hornsby Hospital and Manley Hospital Cumberland Hospital Nepean Hospital St. Vincents Hospital

Melbourne
Royal Melbourne Hospital St. Vincents Hospital Alford Hospital Teleconference: Hallarat, Bendigo, Hobart, Warrnambool and Trarigan Hospitals EPPIC Mental Health SKY Unit Round Table with Professors of Psychiatry, Victoria Plenary Lecture: New Trends in Treating Psychosis regional symposium

Adelaide
Royal Adelaide Hospital, Glenside Campus Lecture, Southern Australian Psychiatrists

Perth
Graylands Hospital Lectures, Psychiatrists both Southern and Northern regions Queen Elizabeth Hospital

Grand Rounds: "New Drugs for Brain Disorders." Department of Pharmacology and Toxicology, College of
Pharmacy, University of Texas, Austin, September 2000.

Grand Rounds: "Combining Medication and Psychotherapy." Department of Psychiatry, University of Texas, San
Antonio, September 2000.

Invited Speaker: "New Drugs for the Treatment of Psychoses," Central California Psychiatric Society, Fresno,
September 2000.

Workshop: "The Nuts and Bolts of Psychiatric Course Planning in the New Millennium." 2000 Annual Meeting of
the Association of Academic Psychiatry, Vancouver, October, 2000 (with Rona Hu).

Grand Rounds: "The New Atypical Antipsychotics." Western State Psychiatric Hospital, Seattle, November, 2000. Invited Lecturers: US Psychiatric and Mental Health Congress, San Diego, November 2000
"Combining Medication and Psychotherapeutic Intervention" "Diagnosis and Psychiatric Treatment of the Elite Athlete"

61

Ira D. Glick, M.D.

Grand Rounds: "Cutting Edge Inpatient Pharmacotherapy." San Mateo Community Mental Health Service. San Mateo, November 2000. Postgraduate Education Seminar, for Lilly Pharmaceutical Co. (Japan). "Treatment of Psychosis in the New Millennium," Dec. 2000. At the 2000 Annual Meeting of the ACNP, Puerto Rico, December, 2000 Study Group: Comparing Antipsychotics: What Do We Really Know? Chair and Presenter; (with Rajiv Tandon, Moderator). Poster, A Model Psychopharmacology Curriculum (with the ASCP Committee) Poster, The Efficacy and Extrapyramidal Side Effects of the Atypical Antipsychotics (with J. Davis). Grand Rounds: "New Antipsychotics Controversies and Questions." Palo Alto Veterans Administration, Palo Alto, January 2001. Invited Lecture: "Psychosis and Atypical Antipsychotics," at the conference "Psychopharmacology in the Year 2001," sponsored by the American Society of Clinical Psychopharmacology, Maui, February 2001. Grand Rounds: "New Treatments for Psychosis." Maui Community Mental Health Center, Maui, February 2001. Preceptor: "Update on Schizophrenia." Pfizer Preceptorship, Stanford, CA, February 2001. Invited Lectures: Japan, March 2001 "Combining Medication with Psychosocial Intervention for Treatment of Schizophrenia," at 1) Department of Psychiatry for School of Medicine, Hiroshima University, 2) at Kita-Kyusyu University, Kyushu, and 3) at the National Center of Neurology and Psychiatry (NCNP), Tokyo. "Atypical Antipsychotics," for the Department of Psychiatry, School of Medicine, Chiba University, Chiba. Grand Rounds: "Long-term Treatment of Schizophrenia in the Community." Santa Maria County Mental Health Center, Santa Maria, CA, April 2001. Lecture: "Treatment of Geriatric Psychosis." St Johns Medical Center, Oxnard, CA, April 2001. Grand Rounds: "Atypical Antipsychotics." Santa Barbara College Hospital, Santa Barbara, CA, April 2001. Invited Lecture: 'Diagnosis and Management of Treatment-Resistant Schizophrenia," at the symposium, "Psychiatric Care in Community Residential Setting," sponsored by the Los Angeles County of Mental Health and the Southern California Psychiatric Society, Los Angeles, CA, April 2001. At the 2001 Annual Meeting of the American Psychiatric Association, New Orleans, May, 2001. Chair, Industry Symposium, A New Era for Managing Psychosis: Rebuilding Lives for Patients and Families. Paper, "Consumer Organizations May Improve Medication Compliance." Poster, "The Efficacy and Extrapyramidal Side Effects of the Atypical Antipsychotics," with Davis, J. Poster, "Ziprasidone's Benefits Versus Olanzapine on Weight and Insulin Resistance." Presentation, A Model Curriculum in Psychopharmacology, at the workshop, "Teaching Psychopharmacology to Residents Using Evidence-based Algorithms." NCDEU 2001 Annual Meeting, Phoenix, May, 2001 Poster, "The Efficacy and Extrapyramidal Side Effects of the Atypical Antipsychotics." Co-Chair, Workshop, "Mentoring Throughout the Professional Life Cycle: Challenges and Lessons" (with A. Gelenberg) 7th World Congress of Biological Psychiatry, Berlin, Germany, July 2001 Poster, "Ziprasidone vs Olanzapine: Weight, Lipids, Insulin."
62

Ira D. Glick, M.D.

Grand Rounds: "New Antipsychotics: Ziprasidone." Kaiser, Santa Teresa, San Jose, August 2001. CME Lecture: "Schizophrenia: New Treatment Dimensions," at the program, "Psychopharmacology Clinical and Research Update," sponsored by the West Coast College of Biological Psychiatry, San Francisco, CA, October 2001. Grand Rounds: "New Antipsychotics: Current Controversies." Menlo Park Veteran's Administration Hospital, Menlo Park, December, 2001. At the 2001 Annual Meeting of the American College of Neuropsychopharmacology, Hawaii, December 2001. Chair, Special session, "Teaching Neuropsychopharmacology," and presentation, "The Teaching of Psychopharmaclogy: Who Does It? With What Materials?) Poster, "Improving the Teaching of Psychopharmacology: Circa 2001," (with D Janowsky and S Zisook). Poster, "The Efficacy of Atypical Antipsychotics Compared to Typical Antipsychotics: A Meta-Analysis Revisited," (with N Chen and J Davis). Lectures: "Current Controversies Around the New Atypical Antipsychotics," at the Nevada Adult Mental Health Center, and the Psychiatry Dept, Nevada Dept of Corrections, Reno, Nevada, Dec. 2001. Grand Rounds: "Advancements in the Management of Schizophrenia." Spokane Community Mental Health Center, January, 2002. Grand Rounds: "Schizophrenia: The New Atypical Antipsychotics." Dept of Psychiatry, Oregon Health Sciences University, Portland, Oregon, January, 2002. Grand Rounds: "New Data and New Indications for the Atypical Antipsychotics in Both Psychotic and Nonpsychotic Disorders." Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, March, 2002. Invited Lecture: "The Use of New Antipsychotic Agents to Treat Bipolar Disorder," as part of a CME course on treating Bipolar Disorder. Department of Psychiatry, UC Davis, Sacramento, CA, March, 2002. Grand Rounds: "Clinical Management of Psychosis: The Short- and the Long-term." UCLA Neuropsychiatric Institute, Los Angeles, CA, April, 2002. Grand Rounds: "Fiscal Pharmacology of the Atypical Antipsychotics." Napa State Hospital, Napa CA, April, 2002. CME Lecture: "Stabilizing the Dopamine-Serotonin System: A New Era in the Treatment of Psychosis." San Diego, CA June, 2002, Grand Rounds: "The Efficacy of Atypical Antipsychotics: A Meta-analysis Revisited." Manhattan State Hospital, New York, New York, June 2002. Sabbatical, Japan, July 2002 Plenary Lectures: "The New Atypicals: New Data and Controversies" at the symposium "Challenges and Opportunities in the Management of Schizophrenia, "Osaka and Tokyo, July, 2002. Grand Rounds: "The New Atypicals: Challenges and Opportunities," 1) Kyoto University, 2) Sapporo Medical School, 3) Tokushima Medical School and 4) Okayama International Hospital. CME Lecture: "Borderline Personality Disorder, Medication and the Family." Conference, on Borderline Personality Disorder, Research and Treatment, Stanford University Medical Center, September, 2002.

63

Ira D. Glick, M.D.

Grand Rounds: "The New Atypicals." Northwest Behavioral Healthcare, Department of Mental Health, Northfield, Ohio, September, 2002. CME Lecture: "Novel Antipsychotics: What We've Learned; What We Need to Know." Case Western Reserve University School of Medicine, Cleveland, September, 2002. CME Lecture: "New Steps in the Evolution of Antipsychotics: The Role of Partial Agonists," Sponsored by Bristol-Myers Squibb and Otsuka Pharmaceutical: San Diego, June, 2002; San Francisco, September, 2002; New York City, September, 2002; Seattle, March, 2003; Phoenix, April, 2003; Long Island, May, 2003. Grand Rounds: "The New Atypicals." Metropolitan State Hospital, Los Angeles, Sept 2002. Grand Rounds: "The New Atypicals." San Joaquin Community Mental Health Center, Fresno, September 2002. Lecture: "Mental Illness and the Workplace." Section on Labor Law, Annual Meeting of the State Bar of California, Monterey, October 2002. Grand Rounds: "The New Atypicals." San Francisco Veterans Administration Hospital, San Francisco, October 2002. Grand Rounds: "Update on the Atypical Antipsychotics." Department of Psychiatry, University of California at San Diego, San Diego, October 2002. Grand Rounds: "Aripiprazole and the New Antipsychotics." Mood Disorders Program, UCSF, San Francisco, November 2002. CME Lecture: "The New Antipsychotics: Are There Differences?" First West Coast ASCP Psychopharmacology Symposium, San Francisco, November, 2002. Lecture: "Aripiprazole Efficacy and Safety." Continuing Education Meeting, BMS, Laguna Nigel, CA November 2002. Grand Rounds: "Second Generation Antipsychotics: New Data and New Dilemmas." Napa State Hospital, Napa, CA, December 2002. At the 2002 Annual Meeting of the American College of Neuropsychopharmacology, Puerto Rico, December 2002: Chair, Second Annual Session on "Teaching Neuropsychopharmacology," and presentation of paper "The ASCP Model Psychopharmacology Currticulum: New Scope and New Audiences." Poster: "Cocomitant Psychotropic Medication Use in a Two-Year Study Comparing Clozapine and Olanzapine for the Prevention of Suicidal Behavior." Poster: "A Meta-analysis of the Efficacy of Second-Generation Antipsychotics," (with John Davis) National Teleconference: "Improving Outcome in Schizophrenia." Psychlink, Dallas, TX, January 2003. Grand Rounds: "Update on Mood Disorders." Carlisle Hospital, Carlisle, PA, January 2003. Public Lecture: "The Changing American Family: New Roles, Opportunities and Challenges for Men, Women and Children." Dickinson College, Carlisle, PA, January 2003. Lecture: "The New Atypicals and Treatment of Psychoses at the 2003 Biannual CME Conference." University of Wisconsin School of Medicine and Madison Institute of Medicine, Madison, WI, March 2003.
64

Ira D. Glick, M.D.

Plenary Lectures: Annual Meeting Central California Psychiatric Society, Monterey, CA , March 2003. "Combined Treatment of Axis I Disorders" "The New Atypicals" Invited Lecture: "Recent Advances in Treatment of Schizophrenia." Stanford University School of Medicine Seventh Psychopharmacology Course, Update in Psychopharmacoloqy Clinical Case Conference, Stanford, March, 2003. Poster: "The Efficacy of Atypical Antipscychotics Compared to Typical Antipscychotics: A Meta-Analysis." (with N Chen and J Davis). International Congress of Schizophrenia Research, Colorado Springs, CO April, 2003. Presentation: "Effectiveness of Aripiprazole." Regional Advisory Council Bristol Myers-Squibb, Phoenix, AZ, April, 2003. Grand Rounds: "New Atypicals: New Medications and New Controversies." LSUHSC, Shreveport, LA Baton Rouge CMHC, Baton Rouge, LA, April 2003 Grand Rounds: "Atypicals: New Drugs New Controversies." St. Peter Regional Treatment Center, St. Peter, MN, May 2003. Invited Lecture: "Combining Medication with Psychotherapy." St. Luke's Hospital, Dept of Psychiatry, Racine, WI Rogers Memorial Hospital, Dept of Psychiatry, Milwaukee, MN, May 2003. At the 2003 Annual Meeting of the American Psychiatric Association, San Francisco, May, 2003. Lecture, "Clinical Considerations in the Management of First-Episode and Acute Exacerbation of Schizophrenia," as part of the industry-supported symposium, Managing the Spectrum of Psychotic Disorders. Discussion, as part of an Issue Workshop: Psychiatric Perspectives on the Execution Process: A Continuing Conundrum, with HJ Osofsky, RK Bailey, AM Freedman, AL Halpern, DM Mancuso .Lecture: "Overview of the Efficacy of 2 nd and 1 st Generation Antipsychotics," as part of an APA symposium , Meta-Analyses of the Efficacy of 2nd VS 1st-Generation Antipsychotics, chaired by ID Glick and JM Davis. Discussion, Efficacy of Atypicals in Acute Care Settings, as part of an industry-supported symposium, Best Practices in Antipsychotic Use. Plenary Speaker: "Update on Care and Treatment of Schizophrenia."Southeast Regional Committee, National Alliance for the Mentally III, Pennsylvania Chapter, Norristown State Hospital, Norristown, PA, June 2003. Grand Rounds: "Atypicals: New Drugs and New Controversies," June 2003. Milwaukee Veterans Administration Milwaukee County Mental Health Clinic Winnebago Mental Health Clinic Colloquium: "Recent Trends in the Development of Novel Antipsychotics." Atascadero State Hospital, CA, July 2003. Grand Rounds: "Combining Medication with Psychotherapy to Improve Compliance." Santa Clara Valley Mental Health Center, August 2003. Invited Lecture: "A Meta-analysis of Antipsychotic Medications Are the Second-generation Agents Better than the First-generation Agents?" 1) Westchester Medical Center and 2) Rockland State Hospital, August, 2003.
65

Ira D. Glick, M.D.

Lecture Tour: "First vs Second Generation Antipsychotics: Efficacy and Use of Polypharmacy Strategies." Asahiyama, Tottari, Osaka, Fukuoka and Saga, Japan, September, 2003. Grand Rounds: The New Atypical Antipsychotics, Phoenix, October 2003, Good Samaritan Hospital Phoenix V.A. Hospital CME: "Management of Treatment Refractory Schizophrenia," UC Davis and Sacramento County, September 2003. Grand Rounds: "Use of Atypicals in Special Populations," at the Medical College of Georgia and at Augusta VA Psychiatric Hospital, Augusta, GA, October, 2003. Grand Rounds: "New Treatments for Psychosis," at the Mayo Clinic, at the University of Minnesota Medical School and at Minneapolis VA Medical Center, October, 2003. Grand Rounds: "New Treatment for Treatment Resistant Schizophrenia," Kirby Forensic Psychiatric Center, New York City, November, 2003. At the Annual Meeting of the American College of Neuropsychopharmacology, Puerto Rico, December 2003: Study Group Co-Chair, "New Comparative Studies of Antipsychotics: Evidence from Controlled Trials versus Clinical Practice" and presentation on Efficacy of Antipsychotics. Chair, Third Annual Session on "Teaching of Neuropsychopharmacology." Poster: "Maintenance Therapy with Haloperidol Decanoate or Quetiapine." Poster: "Issues Which May Determine Outcome of Antipsychotic Trials: Populations, Sponsorship, Design, etc." Poster: "Update on Psychopharmacology Curriculums: Is There Any Relationship of Teaching to Clinical Practice?" Grand Rounds: "A Meta-analyses of the Efficacy of Antipsychotics," Harvard-Longwood Grand Rounds Services and Caritas St. Elizabeth's Hospital Series, Boston, January 2004. Invited Lectures, New Data, Treatments and Controversies about Schizophrenia and Psychosis, India, February, 2004. Goa Psychiatric Society g. Bombay Kolcatta Gowati Dehli Kochin-Kerola " Grand Rounds: "Combining Psychotherapy with Medication: Is It Helpful?" Kern Medical Center, Bakersfield, CA, April, 2004. Invited Lecture: "Antipsychotics for Bipolar Disorder: Monotherapy an Adjunct?" Central California Psychiatric Society, Bakersfield, April, 2004. At the Annual Meeting of the American Psychiatric Association, New York, May, 2004: Issue Workshop participant : "Evidence-based treatment for schizophrenia in a correctional setting." Symposium discussant : "Personality disorders in the workplace." Master Educator Clinical Co nsultation: "Combining and integrating medication and psychotherapy for schizophrenia and other Axis I disorders."

66

Ira D. Glick, M.D.

Grand Rounds: "Practical Management of Psychoses at South Nevada Adult Mental Health Center," Las
Vegas, May, 2004.

At the Annual Meeting of NCDEU, Phoenix, June 2004 Poster: "Maintenance Therapy with Haloperidol Decanoate and Quetiapine: A Controlled Random
Assignment Study."

Lecture: "Families in the Treatment of Personality Disorders and Issues of Compliance." As part of the symposium Personality Disorders: Research & Treatment An Update. Stanford University Medical
Center, June, 2004.

Lecture: "Terrorism, Changing Family Roles and Functions and Women's Wellness: Part II." Women's
Wellness Rounds, Stanford University School of Medicine, June, 2004.

Grand Rounds: "What Does Psychotherapy Add to Medication Alone for Axis I Disorders." Dept Psychiatry &
Behavioral Sciences, Stanford Univ School of Medicine, Sept, 2004

Grand Rounds: "Combining Medications and Psychotherapy." Dept of Psychiatry, University of Iowa School of
Medicine, September, 2004.

Grand Rounds: "Antipsychotic Use in Special Populations." Dept of Psychiatry, UCSF University Medical
Center, Fresno, CA, October, 2004.

Lecture: "New Treatments for Schizophrenia." Univ of Oklahoma Health Sciences Center, Oklahoma City,
October, 2004

Grand Rounds: "New Treatments for Psychosis." Fulton State Hospital, Fulton, MO, Oct, 2004. Grand Rounds: "New Treatments for Psychosis." Dept of Psychiatry, University of Missouri, Columbia, MO,
Oct, 2004.

Grand Rounds: "New Treatments for Schizophrenia." Dept of Psychiatry, Univ of Kansas School of Medicine,
Wichita, KA, October, 2004.

Lecture: "New Treatments of Schizophrenia." North West Missouri State Hospital, Kansas City, KA, October,
2004.

CME Program: "A Workshop: Interpreting Mental Health Scales and Their Practical Application to Your
Practice." 2004 US Psychiatric and Mental Health Congress, October, 2004.

Chair Lecture: "Assessment Scales: How Are They Useful?" At the Annual Meeting of the American College of Neuropsychopharmacology, Puerto Rico, December, 2004: Poster: "New Developments in Teaching of Psychopharmacology," with Sid Zisook. Poster: "Second Generation Atypicals vs. First Generation Decanoate," with Stephen Marder. Poster: "Analysis of Industry vs Investigator Initiated Trials," with John Davis. Chair: Fourth Annual ACNP "Teaching of Psychopharmacology" session. Lecture: "Combination Drug Strategies in Schizophrenia." As part of the symposium Stanford Psychopharmacology: Course and Clinical Update. Stanford University Medical Center, March, 2005. Lecture: "Metabolic Issues of Atypical Antipsychotics." Dominican Santa Cruz Hospital, March, 2005. Consultant: "Antipsychotic Drugs." Smith Barney Citigroup 2005 Healthcare Conference, Washington, D.C.,
March, 2005 (with John Kane, M.D. and Les Citrone, M.D.).
67

Ira D. Glick, M.D.

At the 2005 Annual Meeting of the American Psychiatric Association, Atlanta, GA, May, 2005. Debate, Resolved: Seccond Generation Antipsychotics are Uniformly Superior in Safety and Efficacy to First Generation Antipsychotics. Moderator: Richard E. D'Alli, MD Affirmative: Ira D Glick, MD, John M Davis, MD Negative: Rajiv Tandon, MD, William T Carpenter, Jr., MD Chair, Symposium, "Use of Concomitant or Adjunctive Medications in Schizophrenia," Paper presentation, "Efficacy of Concomitant Medications for Stabilized Patients with Schizophrenia," (with J Davis). Paper presentation, "The Challenge of Teaching Psychopharmacology in the New Millennium: The Role of Curriculum (with S Zisook) as part of Symposium "Teaching Psychopharmacology in the 21 st Century." Chair, Symposium, "Inpatient Psychiatry: Crisis and Response." Paper presentation, "Inpatient Psychiatry at the Turn of the Century" (with G Carter & R Tandon). Lecture: "Careers in Geriatric Psychopharmacology:" Collaboration with Big Pharma," at the Eleventh Annual Summer Research Institute in Geriatric Psychiatry, Stanford University, July 2005 Grand Rounds: "Update on Schizophrenia and Bipolar Disorder." Sacred Heart Hospital, Spokane, WA, October, 2005. Grand Rounds: "Update on Schizophrenia and Bipolar Disorder." American Lake VA, Tacoma, WA, October, 2005, CME Lecture: "Overcoming the Issues of Noncompliance in Schizophrenia," at the 2005 U.S. Psychiatric & Mental Health Congress, Las Vegas, October, 2005. Grand Rounds: "New Atypicals." Shasta Community Mental Health, Redding, October 2005. At the 2006 Annual Meeting of the American College of Neuropsychopharmacology Hawaii, December, 2005: Chair: Fifth Annual "Teaching Neuropsycopharmacology" session: The Neglected Constituencies: Can T eaching About Psychopharmacology Change Attitudes and Practices? Paper: "The Challenge of Teaching at the Academic-Industry Interface" (with Terence Ketter). Invited Lecture: "New Treatments in Schizophrenia," Psychopharmacology Update for Visiting Clinical Research Psychiatrists from Spain, Stanford University School of Medicine, January, 2006.

68

Ira D. Glick, M.D.

Photography
Training
Tutorial - Mitch Heickin - 2001

Published Photos 1995 Museo de San Isledefonso, Mexico City, in the New England J Medicine, Sept 7, 1995, p. 633.
2001 2002 2003 2004

Golden Gate Morning, in the New England J Medicine, Aug. 30, 2001, pg. 655. Midnight, Fort Mason, in the New England J Medicine, Aug. 1, 2002, pg. 313. Nocturne, in the New England J Medicine, July 24, 2003, pg 381 South American Psychiatric Hospital Series, cover Neuropsychopharmacology, Sept, Oct, Nov,
2004

Prizes
1997 Third Place, Color, at the annual meeting of the Art Association of the APA (American Psychiatric Association), for Toroko Gorge, Taiwan. 1999 Second Place, Black and White, at the annual meeting of the Art Association of the APA (American Psychiatric Association), for Castel del Monte, Italy 2000 First Place, Color, at the annual meeting of the Art Association of the APA (American Psychiatric Association), for Argentinian Tango, (Argentina). 2004 Honorable Mention, Color, at the annual meeting of the Art Association of The American Psychiatric Association, for Golden Gate Morning.

Shows
2001-2 Group Show, Presidio Nocturnes, at the Presidio Alliance, San Francisco, Dec-Jan, 2002 2002 Group Show, Ft Mason and Environs (an exhibition that explores the night landscape and features over a dozen established and emerging Bay Area photographers), at the San Francisco Fort Mason Center, Nov. 2002.

69